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Abstract 
The evolution of mesoporous silica particles at the nanoscale in the past two decades has 
directed them towards several fields of application including catalysis, sensing and 
biomedicine. Exceptional interest has been attracted by mesoporous silica nanoparticles 
(MSNs) as bioimaging devices and drug delivery systems for targeted cancer treatment. This 
class of porous materials has been established as multifunctional drug delivery nanocarriers 
since it offers advantageous properties compared to other drug delivery systems such as 
polyplexes, liposomes, and dense metal or metal oxide nanoparticles. MSNs with high 
colloidal stability feature a well-defined and tunable porosity at the nanometer scale, high 
loading capacity, and versatile functional groups for post-synthetic modification such as the 
attachment of targeting ligands to specifically enter different types of cells. Nevertheless, 
researchers still face several challenges to improve the biological performance of the drug 
delivery vehicles based of mesoporous silica. Control over the cargo release from the porous 
host material, prevention of fast degradation in biological fluids, avoidance of cytotoxic 
effects, specific cell targeting, and escape from endosomal entrapment are highly desirable 
features in view of successful applications. These requirements for efficient drug delivery are 
part of recent research. 
In this work, the effective tailoring of mesoporous silica nanoparticle (MSN) design is 
described to further develop their great potential as multifunctional drug delivery 
nanocarriers. The requirements for an efficient stimuli-responsive and thus controllable 
release of cargo molecules into cancer cells and the design principles for smart and 
autonomous nanocarrier systems are discussed. The in vitro and in vivo performance of the 
silica host material can be improved by further modification such as the incorporation of 
functional groups or magnetic cores and through a stabilization of the silica framework. For 
an efficient and specific disease treatment on the cellular level, different strategies were 
employed to achieve control over the endosomal escape of endocytosed MSNs. The coating 
of the nanoparticles with different organic shells improves their biocompatibility, it can be 
utilized for the effective encapsulation of cancer therapeutics, and it facilitates attachment of 
targeting ligands for specific cellular recognition. Several of these key prerequisites for 
efficient drug delivery nanocarriers based on MSNs are discussed in the present work. 
The first part of this work focuses on a novel high temperature liquid phase “calcination” 
method with high boiling solvents including trioctylphosphine oxide (TOPO), tri-n-
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octylamine (TOA), and squalene for template removal and strengthening of the silica network 
in colloidal MSNs. The standard calcination procedure in air is not suitable for these nano-
sized silica particles as it results in strong agglomeration, thus preventing their use in colloidal 
suspensions. The highest efficiency of this novel approach was obtained by thermal treatment 
in TOPO at 275 °C. Here, an increasing degree of silica condensation and the retention of the 
high colloidal stability of the MSNs could be observed. The ability to remove the template 
and thus saving a preparation step represents an additional advantage of the present 
calcination method. The resulting MSNs retained the ordered mesostructure, its high porosity, 
and the large surface area of the original mesoporous nanoparticles, while showing a much 
greater degree of silica condensation and improved stability than before the treatment. The 
concept of “liquid calcination” represents a powerful and general approach for the preparation 
of stable colloidal porous nanoparticles. 
The combination of spatially controlled drug delivery and magnetic resonance imaging (MRI) 
can be achieved by magnetic nanocomposites based on MSNs. The incorporation of a 
superparamagnetic core into mesoporous silica provided improved properties regarding 
targeted drug delivery and bioimaging applications. Thus, manganese ferrite nanoparticles 
(~10 nm) doped with Zn
2+
 were synthesized via thermal decomposition of the iron precursor 
[Fe(acac)3] in the presence of manganese chloride and zinc chloride in octylether. Oleic acid 
and oleylamine served as structure directing agents to result in single nanometer-sized 
crystals. These nanocrystals exhibited an extremely high magnetization (~200 emu/g). 
Different functionalized mesoporous silica onion-like shells were generated around the 
magnetic cores via a delayed co-condensation approach. This new synthetic strategy was 
based on a sol-gel approach in the presence of the template cetyltrimethylammonium chloride 
(CTAC) in basic milieu (triethanolamine, TEA). The magnetic nanocomposites enabled 
physically directed movement by applying an external magnetic field. Moreover, the 
functional silica shells offer multiple modification sites for tailor-made properties of a smart 
drug delivery system. 
In a joint project with Prof. G. Bein, Prof. Rädler and coworkers, a novel nanoscale, injectable 
drug-delivery system was designed. These nanocarriers combined heparin, which prevents 
blood clotting, with multifunctional core-shell colloidal mesoporous silica nanoparticles. An 
EDC amidation reaction resulted in covalent binding of the highly negatively charged 
polysaccharide exclusively to the external surface of amino-functionalized MSNs The 
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anticoagulant and biocompatible properties of heparin together with the highly porous 
features of the nanoparticles may lead to an efficient multifunctional drug-delivery system 
that can itself act as an anticoagulant and allows for incorporation of biologically active 
molecules as deliverable cargo. 
Stimuli-responsive drug release from MSNs may result in a more targeted release of the 
drugs, and can be achieved by a change in biological environment, such as altered levels of 
disease-specific enzymes. Specifically, matrix metalloproteinase 9 (MMP-9) is known to be 
overexpressed during advanced stages of cancer, while minimally expressed in healthy tissue. 
Additionally, increased MMP-9 expression has been associated with a poor survival rate of 
lung cancer patients. Here, a novel synthesis of MSNs containing MMP-9 cleavable peptide 
linkers in combination with avidin caps was successfully established in cooperation with 
members of the Comprehensive Pneumology Center (CPC, Helmholtz Institute). The bulky 
avidin allowed for efficient sealing of the mesopores. These multifunctional MSNs showed no 
release of the diverse cargo molecules when MMP-9 was absent, but stimuli-responsive drug 
release in the presence of MMP-9 enzyme could be observed. Dose-dependent release was 
shown for model cargo, calcein-AM, as well as for the chemotherapeutic drug cisplatin. 
Functionalized MSNs were found to be non-toxic up to high concentrations, with avidin 
functionalization having a protective effect regarding toxicity of these particles. Notably, 
MSNs that contained non-toxic doses of cisplatin together with the proteasome inhibitor 
bortezomib resulted in an increased cell death, indicating that these particles can also be used 
for combination treatments, thus indicating another possible advantage of this nanoparticle 
platform. 
Another strategy for internal cellular triggered drug release based on pH-responsive 
gatekeepers was investigated in collaboration with the groups of Prof. Bräuchle and Prof. 
Carell. In this study, the enzyme carbonic anhydrase was attached to the external surface of 
MSNs via linkage to sulfonamide derivatives. By changing the pH to slightly acidic values 
(5.5), the efficient sealing of the mesoporous channels with these bulky bio-macromolecules 
became reversible. Consequently, loaded cargo molecules could be released. In vitro studies 
showed a controlled intracellular release of the fluorescent model drug DAPI after 
endocytosis and acidification of the endosomal compartment. 
Mesoporous nanoparticles for drug delivery would benefit significantly from further 
improvements in targeting efficiency and endosomal release. We present a system based on 
colloidal MSNs with targeting-ligands and a red-light photosensitizer. Furthermore, these 
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nanocarriers were equipped with a supported lipid bilayer (SLB) as a removable cargo 
encapsulation. Upon photoactivation of these multifunctional drug delivery vehicles, a 
successful cargo delivery to the cytosol was observed. This nanoparticle system provides 
spatial and temporal control of the release of drugs into the cytosol of cancer cells. Our 
system presents a general platform since it can be loaded with different model drugs and 
adapted for targeting multiple cell types. 
Multifunctional mesoporous silica nanocarriers feature excellent cellular uptake behavior due 
to their nanometer-scaled size. Nevertheless, after endocytosis of the MSNs, the endosomal 
entrapment is known to be a major bottleneck for efficient cytosolic cargo release. In a joint 
project with Prof. Bräuchle and coworkers, PAMAM dendron-coated MSNs exhibiting high 
buffering capacity were investigated. These adopted buffering properties prevented 
acidification of the endosomal compartment, ultimately causing endosomal escape via the 
proton-sponge effect. In vitro studies showed a time-dependent release of immobilized 
fluorescent dye (DAPI) and anticancer drug (colchicine) from the mesopores. Furthermore, 
targeting specificity to KB cancer cells was achieved by folate receptor-mediated endocytosis 
and could be observed by fluorescence live-cell imaging. 
In summary, different requirements that are of key importance for a controlled and targeted 
drug delivery have been investigated. Multifunctional mesoporous silica nanoparticles with 
precisely tailored properties are viewed as a promising and flexible platform for numerous 
biomedical applications such as targeted drug delivery and bioimaging. In this work, we could 
show that multifunctional MSNs are suitable for applications as versatile drug delivery 
vehicles. A co-delivery of different chemotherapeutics for an enhanced combination treatment 
of cancer cells could also be achieved. We established different successful approaches for the 
endosomal escape of the multifunctional MSNs via internal and external stimuli. In the future, 
the combination of many or all of these essential features into one multifunctional nanocarrier 
is anticipated to result in powerful drug delivery systems. 
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1 Introduction 
This chapter is based on the following perspective article: 
Christian Argyo, Veronika Weiss, Christoph Bräuchle, and Thomas Bein, Chemistry of 
Materials 2014, 26, 435 – 451. 
1.1 Multifunctional Mesoporous Silica Nanoparticles 
Multifunctional mesoporous silica nanoparticles (MSNs, size typically < 500 nm) have 
attracted substantial attention in recent years due to their advantageous structural properties, 
such as a high internal surface area and pore volume, tunable pore sizes, colloidal stability, 
and the possibility to specifically functionalize the inner pore system and/or the external 
particle surface. These highly attractive features make MSNs a promising and widely 
applicable platform for diverse biomedical applications including bioimaging for 
diagnostics,
[1-2]
 biosensing,
[3-4]
 biocatalysis,
[5-7]
 bone repair and scaffold engineering,
[8-10]
 and 
drug delivery.
[11-13]
 Caruso and coworkers established another interesting approach using 
mesoporous silica particles as a template to create submicron-sized polymer capsules for 
anticancer drug delivery.
[14-16]
 Periodically ordered mesoporous silica, created by combining 
surfactant micellar aggregates with reactive silica precursors, was discovered about 20 years 
ago by researchers at Mobil.
[17-18]
 In particular, inorganic-organic (hybrid) core-shell 
nanoparticles based on mesoporous silica have received great attention as drug delivery 
vehicles, where the decoration of the inner or outer surface of the particles with organic 
molecules can impart important features for successful drug delivery. MSNs have first been 
proposed around 2001 as nanocarriers for transporting therapeutics.
[19]
 Inspired by this simple 
concept (at that time still lacking control over cargo uptake or release), many efforts were 
made in recent years to create multifunctional stimuli-responsive nanocarrier systems 
consisting of MSNs as host materials.
[20]
 This is based on the excellent material properties of 
MSNs such as good biocompatibility, high loading capacity and efficient encapsulation of 
cargo molecules in their mesopores. Additional benefits include the possibility to design 
stimuli-responsive mechanisms with spatio-temporal control of release of the cargo, and the 
efficient attachment of organic surface functionalities including hydrophilic polymers, gate 
keepers, and targeting ligands, respectively.
[21-27]
 
1.1. Multifunctional Mesoporous Silica Nanoparticles 
 
2 
 
The delivery of anti-cancer therapeutics into cancer cells by employing nanoparticle carriers 
has made significant progress in recent years. Here, the intention is to overcome common 
issues of conventional systemic drug supply such as poor solubility, limited stability, rapid 
metabolization and excretion of the drug, undesired side effects, and to overcome the lack of 
selectivity towards specific cells types.
[28-30]
 The encapsulation of therapeutics within 
nanocarriers that selectively target certain cell types or tissues represents a promising strategy 
to address these problems. 
Here, recent research in the field of multifunctional MSNs intended for drug delivery 
applications is discussed. MSNs can be designed as a multifunctional platform for different 
stimuli-responsive trigger systems for a specific drug release. Moreover, different strategies 
for achieving controlled endosomal escape will be discussed. Coating the nanoparticles with 
different organic shells improves biocompatibility, facilitates attachment of targeting ligands 
for specific cellular recognition, and can be utilized for the effective encapsulation of cancer 
therapeutics. Investigation of in vitro behavior of colloidal particles, often fluorescently 
marked to track the particles in cells, with live-cell imaging serves to evaluate targeting 
specificity and efficient delivery. The implementation of the above strategies and features into 
one multifunctional drug delivery vehicle provides a promising basis for wide-ranging 
applications in cancer therapy and diagnosis. These key prerequisites for efficient drug 
delivery nanocarriers based on MSNs are schematically presented in Scheme 1.1. They will 
be discussed in more detail in the following sections. 
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Scheme 1.1: Schematic illustration of a multifunctional mesoporous silica nanoparticle (MSN) containing 
the necessary features for a stimuli-responsive controlled release of the loaded cargo into the cytosol of a 
targeted cell (SPION: superparamagnetic iron oxide nanoparticle, QD: quantum dot, PEG: poly(ethylene 
glycol), Au-NP: gold nanoparticle, RGD: Arg-Gly-Asp amino acid sequence, EGF: epidermial growth 
factor, PEI: poly(ethylene imine), H5WYG: endosomolytic peptide). 
1.2 Multifunctional Drug Delivery Vehicles Based on MSNs 
1.2.1 Inorganic Silica Core as a Host System 
MSNs acting as host systems for therapeutics provide high loading capacity within the porous 
system and protection of the guest molecules from degradation and from detection by the 
immune system. Furthermore, the nanocarrier systems can be utilized for the transport of 
hydrophobic molecules through biological media, thus increasing the therapeutic effect at the 
desired location. The synthesis of ordered mesoporous silica materials has been extensively 
studied in recent years,
[31-34]
 including sol-gel processes to create MCM-41
[35]
 and SBA-15,
[36]
 
amongst various different structure types.
[37-39]
 Fine-tuning of the reaction parameters such as 
concentrations, pH value, chemical nature of the surfactants, temperature and time allows for 
a precise adjustment of size, morphology and pore structure of the mesoporous silica. The 
scope of conventional mesoporous materials such as MCM-41 for applications in drug 
delivery is limited due to their relatively large particle sizes in the micrometer range. Cellular 
uptake studies of nanoparticles showed that particle sizes less than 120 nm are preferred for 
endocytic uptake.
[40]
 Thus, efforts have been made to obtain spherical mesoporous silica 
nanoparticles MSNs in that size range.
[41-45]
 For example, a standard synthesis route following 
addition of surfactant template, silica source, and organotrialkoxysilanes to a highly basic 
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aqueous solution (2 M NaOH, pH 12.3) at elevated temperatures to create MCM-41-like 
nanoparticles, is used by many research groups.
[46-51]
 Another versatile approach for obtaining 
stable suspensions of MSNs in high yields was developed in our group. Here, triethanolamine 
is exploited as base and as complexing ligand for the silica precursor and is used to tune the 
particle size (to about 80 nm).
[21, 52]
 Their worm-like pore structure with pores growing from 
the center to the periphery suggests a seed-growth mechanism (Figure 1.1c). Delivery of large 
cargo molecules, such as enzymes or oligonucleotides, leads to a growing interest in the 
synthesis of MSNs with large pores (10 – 20 nm, Figure 1.1d) and is part of recent 
research.
[53-54]
 
 
Figure 1.1: Transmission electron micrographs of a) MCM-41-type nanoparticles,
[55]
 b) micron-sized 
SBA-15 material,
[56]
 c) colloidal MSNs with worm-like pore structure, and d) monodispersed MSNs with 
large pores (> 15 nm).
[53]
 
In order to gain access to the pores, the templating surfactant molecules have to be removed. 
This can be achieved either by calcination or with extraction methods. To overcome 
impediments such as reduction in pore size, particle agglomeration, removal of organic 
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moieties, or low degree of condensation of the silica network, Cauda et al. established a new 
approach that combines the advantages of both aforementioned methods for template removal 
(cf. chapter 3).
[57]
 Here, a liquid-phase high temperature “calcination” of MSNs is performed 
in a high-boiling organic solvent leading to a higher degree of silica condensation while 
maintaining the colloidal nature of the nanoparticles. 
Functionalization. In order to exploit the whole potential of MSNs for drug delivery 
applications, it is desirable to add functionality to the silica scaffold. Molecular functionality 
attached to the surfaces of inorganic silica can dramatically change the properties of the 
obtained material, which is important in host-guest interactions with the cargo. The 
incorporation of organic moieties at specific locations is intended to fine-tune surface and 
materials properties and is a subject of current research.
[58-59]
 The spatially selective 
modification of the internal pore system and the external particle surface with organic and 
inorganic moieties is often an essential requirement for these materials to operate as 
multifunctional drug carriers exhibiting the required features. External surface 
functionalization is particularly important for colloidal and chemical stability as well as for 
interactions with the environment, such as modifying the particles for specific cell targeting or 
attaching large molecules for pore gating and improving biocompatibility.
[60-64]
 On the other 
hand, internal organic moieties can supply enhanced interaction or covalent binding sites for 
cargo molecules, such as drugs or proteins, which allows for control over diffusional 
transport, delivery kinetics, and stability of the therapeutic molecules.
[65-67]
 
In general, there are several approaches to achieve functionalization of silica materials. The 
most important functionalization strategies are via post-synthetic grafting and via co-
condensation, besides the synthesis of periodic mesoporous organosilicas (PMO) and 
employment of metal organic reagents.
[35, 68-70]
 In order to gain control over the location of the 
functional groups in silica nanoparticles, Bein and co-workers established a site-selective 
delayed co-condensation approach.
[22, 71]
 Here, bi-functional MSNs with a selective 
functionalization of the interior and an orthogonal functionality at the external particle surface 
in different onion-like shells can thus be prepared (Figure 1.2). This strategy opens new 
possibilities for the design of numerous highly functionalized porous nanoparticles with 
applications in controlled drug delivery. 
1.2. Multifunctional Drug Delivery Vehicles Based on MSNs 
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Figure 1.2: Site-selective delayed co-condensation approach for creating bi-functional MSNs. In a first 
step a mixture of organosilane (green) and tetraethyl orthosilicate (TEOS) in an aqueous solution 
containing template and catalyst creates a functionalized nanoparticle core. Subsequently, the 
nanoparticle growth is completed by addition of pure TEOS (blue) resulting in an unfunctionalized silica 
shell around the core. Finally, the addition of another organotriethoxysilane (RTES, R represents any 
organic moiety, red) and TEOS forms an external skin with different functionality. 
1.2.2 Modification of MSNs with a Functional Shell 
The potential to design biocompatible external surfaces of nanoparticles providing tunable 
interactions with the biological environment by attachment of molecular or macromolecular 
moieties for biomedical applications has been recently demonstrated.
[25-26, 72]
 Surface 
modification with organic and inorganic species can introduce a large variety of 
functionalities for controlling diffusion and release of cargo molecules and cell surface 
recognition, among others. The combination of the properties of such an external functional 
shell and the advantageous structural properties of the mesoporous silica core can create 
multifunctional drug carriers, making the delivery process highly controllable. 
Gating. One of the important functionalities in this context is triggered release of the cargo 
through specially designed gating concepts. In general, gatekeepers can be classified into 
three different types (cf. Figure 1.3). Pore gating systems can either consist of bulky 
molecular groups or nanoparticles, such as proteins, superparamagnetic iron oxide 
nanoparticles (SPIONs), or gold nanoparticles (Au-NPs) which block the pore entrances for 
efficient sealing of the interior mesoporous environment.
[25, 73-74]
 These macromolecular 
structures are either degradable or covalently linked to the silica particle surface via linkers 
that are cleavable upon exposure to certain stimuli.
[75-76]
 Very good pore sealing can also be 
achieved by a complete coating of the MSNs. For instance, polymers, oligonucleotides, or 
supported lipid bilayers (SLB) have been shown to prevent premature cargo release.
[24, 27, 77-84]
 
Often phase transitions or competitive displacement reactions lead to opening of the pores and 
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efficient cargo delivery.
[85-86]
 The third strategy for controlled cargo release involves 
attachment of the cargo molecules in the porous system of the silica nanocarriers. 
Coordinative or covalent bonds can be cleaved by certain stimuli such as competitive 
molecules reducing agents or competitive molecules reducing agents to activate cargo 
release.
[87-89]
 Zink and coworkers have presented different nanocarriers with on-demand 
controllable release mechanisms, including nanoimpellers consisting of azobenzene groups 
that have been described to trigger UV-light-activated release of a cell membrane-
impermeable dye.
[90]
 
 
Figure 1.3: Strategies of controlled release can be classified into three different types, molecular/particle 
pore gating (a,b), surface coating (c,d), and internal pore modification (e,f). a) Mesoporous silica nanorods 
capped with superparamagnetic iron oxide nanoparticles (SPIONs) containing redox-responsive cleavable 
disulfide linkers;
[73]
 b) temperature-dependent programmable molecular valve system consisting of avidin 
caps being opened by melting the DNA linkers;
[91]
 c) temperature-dependent phase transition of PNIPAM-
coating on MSNs;
[92]
 d) disulfide-linked polymeric network at the outlet of mesoporous silica allowing 
redox-responsive controlled release of the cargo;
[93]
 e) schematic release mechanism for a pH-responsive 
system based on coordination bonding in mesopores;
[94]
 and f) light-activated cis/trans isomerization of 
azobenzene groups inside mesopores expels the cargo.
[90]
 
Biocompatibility and stability. For applications of MSNs as nanocarriers, biocompatibility 
and low toxicity are required. A modification of the nanoparticle surface with functional 
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shells, such as polymer coatings, charged groups, or a supported lipid bilayer (SLB) was 
found to decrease particle aggregation and improve stability in biological media. For instance, 
functionalization of the particle surface with phosphonate groups was shown to improve the 
stability and dispersibility of MSNs in aqueous media.
[95-96]
 This modification helped to 
prevent interparticle aggregation, and redispersion after a drying process was highly 
improved.
[1]
 In general, MSNs provide good biocompatibility, but the high surface area and a 
low degree of condensation of the silica framework can promote a high rate of dissolution.
[97-
98]
 Bare, non-functionalized MSNs featuring silanol groups at their surface dissolve fairly 
rapidly in simulated body fluid (SBF) under physiological conditions and produce soluble 
silicic acid species (which are found to be nontoxic).
[99]
 The rate of silica dissolution is 
dependent on particle size, functionalization, degree of silica condensation, and pore 
morphology. A surface functionalization can prevent fast degradation and provide prolonged 
stability of MSNs in biological media. For example, a hydrophilic polymer shell such as 
poly(ethylene glycol) (PEG) or a SLB on colloidal MSNs improves stability in water, 
maintains monodispersity, and can minimize nonspecific adsorption of proteins on the 
nanoparticle surface.
[20, 79, 96]
 Such a polymer coating provides a protective shell for the silica 
surface, which is important when prolonged circulation time in an organism is required for 
effective drug delivery. PEGylation can hinder capture by organs of the reticuloendothelial 
system (RES) and consequently slow down biodegradation.
[100]
 
Hemocompatibility is another important attribute of MSNs. Surface functionalization of bare 
MSNs can reduce or even completely prevent thrombogenic effects and non-specific protein 
adsorption on MSN surfaces.
[101]
 For example, heparin-coated core-shell MSNs have recently 
been described (cf. chapter 5).
[102]
 Heparin is a highly sulfated, anionic polysaccharide, known 
for its anticoagulant properties. This novel nanoscale system combines the efficiency of 
heparin in preventing blood-clotting with multifunctional core-shell MSNs featuring excellent 
structural properties and colloidal stability. In general, MSNs with organic shells offer 
multifunctionality and improved biocompatibility and hemocompatibility and are expected to 
have potential as blood-stream-injectable drug-delivery systems offering new options for 
cancer therapy. For illustration, a typical sequence of cytosolic delivery of therapeutics to 
cancer cells with mesoporous silica nanocarriers is depicted in Scheme 1.2. 
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Scheme 1.2: Schematic representation of different stages of a targeted cellular uptake of a multifunctional 
MSN and controlled release of the cargo into the cytoplasm of cancer cells. 1) Active docking to cell 
surface receptor of a nanocarrier via targeting ligands; 2) process of ligand/receptor-mediated 
endocytosis; 3) MSN entrapped in endosome; 4) intracellular transport and acidification of endosome; 5) 
triggered endosomal escape of nanocarrier, thus obtaining access to the cytoplasm; 6) controlled delivery 
of the cargo inside the cell. 
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1.3 Drug Delivery and Bioimaging Applications 
1.3.1 Targeting and Cellular Uptake 
Targeting. Insufficient target selectivity of drugs can cause unwanted side effects and reduce 
therapeutic efficacy. Especially in anticancer chemotherapy, limited selectivity of cytostatins 
and cytotoxins towards tumor cells is responsible for many undesired side effects. The 
efficacy of the treatment can be affected when nonspecific toxicity to normal cells prevents an 
effective dose that is necessary to eradicate malignant cells.
[103-104]
 Extensive studies showed 
that passive targeting of nanocarriers in tumor tissue could be observed.
[105-106]
 Well-stabilized 
nanoparticles with optimal size and appropriate antifouling surface can remain in blood 
vessels long enough to accumulate at the tumor site. Passive targeting relies on the enhanced 
permeability and retention (EPR) effect. This effect is described as the tendency of particles 
of certain sizes, such as liposomes, nanoparticles, and macromolecular drugs, to preferentially 
accumulate in tumor tissue. Tumor vasculature typically exhibits an increased permeability 
and is lacking of effective lymphatic drainage.
[107]
 Enhanced passive bioaccumulation via the 
EPR effect could be achieved by modifying the MSN surface with positively charged 
groups.
[108]
 However, the EPR effect is not universal for all types of tumor cells and a lack of 
cell-specific interactions might decrease therapeutic efficacy and induce multiple drug 
resistance (MDR).
[84, 107, 109]
 
In contrast, employing targeting ligands like folic acid or macromolecules like the epidermal 
growth factor (EGF) in order to exploit the overexpression of certain receptors on tumor cell 
surfaces can promote specific and active nanocarrier binding and cellular uptake. Active 
targeting can be achieved by covalent attachment of targeting molecules (ligands) to the 
particle surface. The main challenge for targeted nanocarriers is to achieve high targeting 
specificity and drug delivery efficiency simultaneously, while avoiding nonspecific binding 
and activation of immunogenic effects. A recent advance has been reported by Brinker and 
coworkers, who combined a porous, inorganic MCM-41-type silica core coated with a 
supported lipid bilayer to prevent cargo leakage with a short targeting peptide (SP94).
[84]
 This 
small peptide was identified by phage display to bind efficiently to hepatocellular carcinoma 
cells. The complementary receptor is still unknown. In this study, a ligand recruitment 
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procedure was described leading to efficient receptor-mediated endocytosis of the 
nanocarriers. 
The small molecule folic acid (FA) has been widely investigated as targeting ligand and has 
shown a notable enhancement in uptake efficiency of MSN nanocarriers (citations see 
Table 1.3-1). Often long spacers, e.g. PEG chains, are used for the covalent attachment of the 
targeting ligands to the external surface of the MSNs. This linkage provides high flexibility to 
obtain efficient binding of the targeting ligands to the cell membrane receptors. Ligands such 
as FA, mannose, hyaluronic acid, and EGF (amongst others) used as targeting devices are 
abundantly present in organisms. Moreover, the associated receptors are widely present on 
many eukaryotic cells. This implies concerns about the achievable targeting specificity. In 
those cases the significant overexpression of receptors on cancer cells has been exploited. 
Extensive efforts have been made to create actively targeted nanocarrier vehicles using 
ligands for specific recognition of the cell-surface receptors as well as antibodies and DNA 
aptamers. Important examples are summarized in Table 1.1. Studies on antibodies attached to 
the nanoparticle surface either via electrostatic interactions or covalent linkage showed highly 
specific binding with high affinity to antigens overexpressed on different cancer cell lines.
[110-
111]
 MSN bioconjugates with DNA-aptamers were also investigated and showed specific 
binding to nucleolin, a cell membrane protein overexpressed on breast cancer cells.
[112]
 
However, concerns may arise about the stability of these systems in body fluids due to 
potential degradation of the targeting ligands by extracellular nucleases or proteases, which 
may reduce targeting efficiency of antibody- and aptamer-aided delivery concepts. 
  
1.3.1. Targeting and Cellular Uptake 
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Table 1.1: Diverse targeting ligands used for active and specific cell recognition of nanocarriers based on 
MSNs. 
Targeting Ligand Cell Membrane Receptor Targeted Cell Line Ref. 
Folic acid (FA) Folate receptor (FR-α) HeLa, KB 
[27, 79, 113-121]
 
RGD motifs Integrins HeLa, MCF-7, U87-MG, HT-29, SCC-7 
[122-124]
 
Antibody ME1 Mesothelin MM 
[110]
 
Antibody ab2428 ErbB 2 MCF-7 
[111]
 
Antibody Herceptin HER2/neu BT-474 
[125]
 
Aptamer AS 1411 Nucleolin MCF-7, MDA-MB-231 
[112]
 
Mannose Mannose receptor MDA-MB-231 
[126]
 
Galactose Galactose receptor 
HCT-116, Capan-1, 
MDA-MB-231 
[127]
 
Hyaluronic acid 
CD44 (RHAMM, CD168, 
HARE) 
MDA-MB-231 
[128]
 
Anisamide Sigma-receptor ASPC-1 
[129]
 
EGF EGF-R HuH-7 
[27]
 
SP94 Unknown Hep3B 
[84]
 
FA, TEM-7, CD31 
FR-α, TEM-7 antibody, 
CD31 antibody 
MCF-7, HUVEC 
[130]
 
 
Endocytosis. In general MSNs are internalized into the cells via endocytosis.
[12]
 The 
endocytic pathway is the most common uptake mechanism of cells for many different 
nanoparticles and macromolecules. Endocytosis is a very complex process by which cells 
absorb such particles by engulfing them with a lipid bilayer forming vesicles. Therefore a part 
of the cell membrane is used for creating an endosome.
[131]
 Size and morphology of the silica 
nanoparticles and functional groups on the external particle surface influence the ability of 
MSNs to be internalized via endocytosis.
[132-137]
 Utilizing such modifications of the MSNs can 
aid in specific cellular uptake in a precisely controlled manner. In a study of Slowing et al.,
[63]
 
endocytosis of aminopropyl-functionalized MSNs was shown to be affected by caveolar 
inhibition suggesting a cellular uptake via a caveolae-mediated mechanism. Endocytosis of 
MSNs can be investigated via flow cytometry, transmission electron microscopy, confocal 
microscopy and other techniques.
[138]
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1.3.2 Endosomal Escape 
Recent studies have demonstrated that MSNs are able to undergo smooth cell internalization, 
but endosomal escape has been identified as a bottleneck for the efficient delivery of 
macromolecular substances or nanoparticles.
[72]
 The entrapment in the endosomes could lead 
to degradation of the nanocarriers and their cargo molecules by specific digestive enzymes 
when fusion with a lysosome occurs. Thus, an important step in achieving an appropriate 
therapeutic effect is to facilitate the endosomal escape and to ensure cytosolic delivery of the 
therapeutics. Many anticancer therapeutics such as doxorubicin (DOX) feature cell membrane 
permeability and consequently a trigger for endosomal escape is not required. These 
permeable drugs only require means of preventing premature release from the nanocarrier to 
avoid global distribution in the organism and targeted transport into cancer tissue to achieve a 
sufficiently high local drug concentration. Nevertheless, a large number of molecular and 
macromolecular therapeutics are either hydrophobic or membrane-impermeable. Therefore 
the multifunctional nanocarrier vehicles should provide an efficient endosomal escape 
mechanism for the local delivery of the drug molecules into the cytoplasm, thus gaining 
access to the targeted cell compartments or to the nucleus. Excellent strategies for achieving 
endosomal escape are provided by nature. Evolution created bacteria and viruses, which are 
able to penetrate membranes via different mechanisms to escape the endosomal pathway and 
to reach their target sites. Thus, it would be desirable to transfer these very efficient natural 
mechanisms to the drug delivery vehicles. Different mechanisms such as pore formation in 
the endosomal membrane, pH-buffering effects of protonable groups (“proton sponge”) or 
fusion into the lipid bilayer of endosomes have been proposed to facilitate the endosomal 
escape.
[139]
 In addition, photochemical methods to rupture the endosomal membrane have 
been introduced to MSNs.
[27, 72, 140]
 
In a study by Sauer et al.,
[72]
 MSNs were taken up into cells and transported within 
endosomes, but no release of the cargo into the cytoplasm could be detected during 
incubation. In order to overcome the barrier of endosomal entrapment, photoinduced 
endosomal release via excitation of a photosensitizer was employed. Photochemical 
internalization (PCI) using photosensitizers (PS) that generate reactive oxygen species upon 
photoactivation is a powerful tool to overcome trapping by the endosomal membrane.
[141]
 
Initial approaches of combining PS with mesoporous silica as a drug carrier did not provide a 
covalent bond of the PS to the particles. This could lead to uncontrolled spreading of the 
compounds and toxic effects on the cells. To achieve a more spatially controlled activity of 
1.3.2. Endosomal Escape 
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nanodevices operating with PS, it is desirable to bind the PS directly to the surface of the 
mesoporous particles. Thus, a mesoporous core–shell system with covalently surface-linked 
photosensitizer was designed that provides an on-board trigger for light-activated endosomal 
membrane rupture.
[140]
 The nanocarriers can be loaded with model drugs in a broad size-range 
and are encapsulated by a SLB. The controlled release mechanism in living cells operates in a 
two-step cascaded manner, where the SLB is disintegrated by singlet oxygen in a first step 
and, secondly, the endosomal membrane is ruptured causing efficient cytosolic drug release. 
This nanodevice for drug delivery is capable of stimuli-responsive and localized endosomal 
escape and drug release without the systemic cell toxicity exhibited by common (dissolved) 
PS. In order to create a general photoactivatable drug delivery platform being applicable in 
biological environments, such as cancer tissue, further improvements have to be 
accomplished. Strategies for red-light activation have already been investigated (cf. chapter 
6).
[27, 127]
 The activation of the photosensitizer with light of low energy reduces the 
phototoxicity and significantly increases the depth of tissue penetration, which will be crucial 
when activation in vivo is required. 
Another promising endosomal release strategy is based on the proton sponge effect, in which 
osmotic swelling and membrane rupture of endosomes is initiated by macromolecules with 
high buffering capacities (cf. chapter 9).
[142]
 This mechanism does not require an external 
stimulus and custom-made nanocarriers can activate an ”automatic” pathway for endosomal 
escape. Several cationic lipids and polymers, such as poly(ethylene imine) (PEI), possess 
substantial buffering capacity below the physiological pH which is a potential trigger to 
escape the endosomal entrapment.
[143-144]
 The cationic polymers or particles enter the cell via 
endocytosis, subsequently being entrapped in the endosome. Upon intracellular trafficking to 
late endosomes or lysosomes, the compartment is acidified from an initial physiological pH 
value of 7.4 to 5.5.
[145]
 Thus, the overall protonation level for PEI increases drastically.
[146]
 
The accumulation of positive charge inside the endosome is coupled with a passive influx of 
chloride anions through ion channels to maintain electroneutrality. The large increase of ion 
concentration within the endosome in turn results in an inflow of water molecules, which 
causes osmotic swelling and subsequent membrane rupture. Employment of the proton 
sponge effect would provide an elegant solution for the problem of endosomal entrapment of 
MSNs. However, the exact mechanism is not fully understood. It is still an open question 
whether there has to be a high-capacity buffering agent present that is subsequently 
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protonated and highly charged, or if an already highly charged surface of particles is also 
sufficient to cause counter-ion influx, endosome swelling and rupture. Lin and coworkers 
reported on MSNs with negatively charged surface functionalization achieving endosomal 
escape via the proton sponge effect.
[63]
 More negatively charged nanoparticles would escape 
more easily from endosomes of cancer cells owing to their high buffering capacity. The zeta 
potential of the silica nanoparticles seems to have a great impact on the ability of particles to 
escape the endolysosomal pathway. However, such highly negatively charged nanoparticles 
exhibit unfavorable cellular uptake behavior due to electrostatic repulsion with the negatively 
charged cell membrane. Nanocarriers providing protonable groups at mildly acidic conditions 
should result in much more efficient cellular uptake and subsequent drug release to the 
cytosol. In general, the proton sponge effect is a promising intrinsic endosomal escape 
pathway that should be further investigated. 
As an alternative mechanism, endosomolytic peptides can be utilized to achieve endosomal 
release.
[147]
 The lipid bilayer-enclosed MSNs established by Brinker and coworkers were 
decorated with such an endosomolytic peptide (H5WYG) (Figure 1.4).
[84]
 This peptide 
sequence is a subunit of the glycoprotein hemagglutinin of the influenza virus A, and 
undergoes a conformational change upon protonation. H5WYG peptides were often employed 
in combination with nanocarriers, but experimental evidence for the exact molecular 
mechanism was not provided so far.
[148-150]
 Different endosomal escape pathways were 
believed to take place, such as the proton sponge effect (protonation of the histidine residues 
of the peptide) or fusion of the endosomal membrane with the SLB. Further investigations are 
needed to evaluate the exact mechanism, which could lead to full exploitation of this 
endosomal escape pathway. 
 
Figure 1.4: “Protocell” consisting of MSN-supported lipid bilayers with targeting peptides (SP94) and 
endosomolytic peptides (H5WYG) attached to the outer periphery of the nanoconstructs.
[83]
 
1.3.3. Controlled Release of Cargo 
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In general, endosomal entrapment was found to be a bottleneck in efficient cytosolic delivery 
of non-permeable drug molecules and further efforts have to be made to overcome this 
entrapment. Complete understanding of the diverse escape mechanisms is highly desirable. 
Internalized multifunctional MSNs with an integrated trigger could rapidly escape from 
endolysosomal vesicles into the cytoplasm and resist the lysosomal degradation and thus 
protect the loaded drugs from bioerosion. 
1.3.3 Controlled Release of Cargo 
Extensive in vitro studies have been performed to gain insights regarding the feasibility of 
MSNs as drug nanocarriers. Cargo release in a controlled manner is highly desirable, since 
side effects can be drastically reduced by locating delivery to single cells or target tissue and 
since the optimal amount of drug can be liberated. MSNs serving as drug delivery vehicles 
can be functionalized on the external particle surface with stimuli-responsive molecules, 
nanoparticles, polymers, and proteins acting as caps and gatekeepers for such a controlled 
release of various cargos. Delivery of antitumor drugs and other pharmaceutical cargos such 
as enzymes or oligonucleotides requires effective protection from undesired degradation in 
harsh environments, such as the stomach and intestines. On the other hand, when injected into 
the blood stream such a drug delivery device should offer perfect enclosure of the cargo to 
prevent undesired premature release and systemic distribution before reaching the targeted 
tissue or cells. 
The most common pore sealing strategies can be classified into three different types of gate 
keepers, i.e. molecular/particle pore gating, coating of the external particle surface, and 
internal pore binding. Reported in vial and in vitro studies and the diverse opening 
mechanisms based on external or internal stimuli are presented in Table 1.2 and Table 1.3, 
respectively. 
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Table 1.2: Controlled cargo release mechanisms triggered by external stimuli. 
Stimulus Gating system Opening mechanism Cargo 
Release 
experiments 
Ref. 
External 
UV-Vis light 
(λ = 240 – 
639 nm) 
Molecular pore gating 
Thymidine dimers Cleavage Dye In vial [151] 
Cylcodextrin (CD) Dethreading Dye In vial [152] 
Cucurbit[6]uril Photothermal dethreading Dye In vial [153] 
Nitroveratryl 
carbamate 
Cleavage Anticancer drug In vial [154] 
Coating 
Polymer shell Photolysis, dethreading Dye In vial, in vitro 
[155-
156] 
Supported lipid 
bilayer (SLB) 
Photolysis Dye, therapeutic In vitro 
[27, 140, 
157] 
Internal pore modification 
Coordinative bonds Cleavage Dye In vial [87] 
IR-light (λ = 
808 nm) 
Coating 
Aptamer DNA shell 
Photothermal 
dehybridization 
Anticancer drug In vitro [78] 
Pore modification 
Coordinative bonds Photothermal cleavage Anticancer drug In vitro [89] 
Magnetic field + 
absorber 
Molecular/Particle pore gating 
DNA Thermal cleavage Dye In vial [158] 
SPIONs 
Heat-shock induced 
cleavage of disulfide 
linker 
Dye In vitro [73] 
Au-NPs 
Cleavage of boroester 
linker 
Dye In vial [159] 
Coating 
PEI/NIPAM Thermal phase transition Dye , enzyme In vial [160] 
Temperature 
Molecular/Particle pore gating 
Biotin-Avidin Cleavage of DNA linker Dye In vial [91] 
Au-NPs Cleavage DNA linker Dye In vial [161] 
Coating 
Paraffin Melting Dye, anticancer drug In vitro [162] 
Polymer Phase transition 
Dye, antibiotic, 
anticancer drug 
In vial, in vitro 
[85, 92, 
163] 
Molecules 
Molecular pore gating 
DNA Competitive displacement Dye In vial, in vitro 
[86, 164-
165] 
Glycoprotein 
Cleavage of boroester 
linker 
Dye, antifungal drug In vitro [166] 
18-crown-6 Competitive displacement 
Antiinflammatory 
drug 
In vial [167] 
SLB Lysis Dye, colchicine In vitro [24] 
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Table 1.3: Controlled cargo release mechanisms triggered by internal stimuli. 
Stimulus Gating system Opening mechanism Cargo 
Release 
experiments 
Ref. 
Internal 
pH (acidic) 
Molecular/Particle pore gating 
SPIONs 
Cleavage of boroester 
linker 
Antiinflammatory 
drug 
In vitro [76] 
Au-NPs 
Cleavage of boroester 
linker 
Dye In vial [159, 168] 
CD Dethreading Dye, anticancer drug In vial, in vitro [169-172] 
[2]pseudorotaxane Dethreading Dye In vial [173] 
Curcubit[6]uril Dethreading Dye In vial [174-175] 
Coating 
Saccharides 
Cleavage of boroester 
linker 
Dye In vial [176] 
Layered double 
hydroxides (LDH) 
Dissolution Dye In vial [177] 
Polymer Phase transition 
Anticancer drug, 
insulin, dye 
In vial, in vitro 
[67, 77, 85, 
154, 178-
181] 
Coordination polymer Cleavage Anticancer drug In vitro [182] 
Chitosan Phase transition 
Anti-inflammatory 
drug, Anticancer 
drug 
In vial, in vitro 
[48, 111, 
183] 
Internal pore modification 
Coordinative bonds Cleavage Anticancer drug In vial, in vitro [89, 94] 
Acetal linkage Cleavage Peptide In vitro [184] 
Electrostatic 
interactions 
Cleavage Anticancer drug In vitro [185] 
Template Extraction Anticancer drug In vitro, in vivo [186] 
Hydrazone linkage Cleavage 
Anti-inflammatory 
drug 
In vitro [187] 
pH (basic) 
Molecular pore gating 
β-Lactoglobulin Phase transition 
Dye, anti-
inflammatory drug 
In vial [188] 
Lysozyme Detaching Dye In vitro [189] 
Sulfophenyl 
isothiocyanate 
Cleavage 
Anti-inflammatory 
drug 
In vial [26] 
Enzymes 
Molecular pore gating 
Azopyridine derivatives Cleavage Dye, anticancer drug In vitro [190] 
Cucurbit[7]uril Competitive displacement Dye In vial [191] 
[2]pseudorotaxane Cleavage of ester linker Dye In vial [192] 
Biotin-Avidin Enzymatic digestion Dye In vial [25] 
Coating 
Hyaluronic acid Cleavage Dye, anticancer drug In vitro [128] 
Ethylene glycol ester Cleavage Dye, anticancer drug In vitro [193] 
Peptides Cleavage Dye In vial [194] 
Starch derivatives Enzymatic digestion Dye, anticancer drug In vitro [75] 
Lactose derivatives Enzymatic digestion Dye In vial [195] 
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Reducing 
agent 
Molecular pore gating 
CD 
Cleavage of disulfide 
linker 
Dye In vial [172] 
ssDNA 
Cleavage of disulfide 
linker 
Anticancer drug, 
ssDNA 
In vitro [196] 
Coating 
Collagen 
Cleavage of disulfide 
linker 
Dye In vial [197] 
Polymer 
Cleavage of disulfide 
linker 
Dye In vial, in vitro 
[93, 156, 
181] 
Internal pore modification 
Disulfide linkage Cleavage Enzyme, cysteine In vial, In vitro [72, 88] 
Molecules 
Molecular pore gating 
ATP aptamer Competitive displacement Dye In vial, in vitro [198-200] 
Insulin derivatives Competitive displacement Insulin, cAMP In vial [201] 
Au-NPs 
Dehybridization of DNA 
linker 
Dye In vial [74] 
Coating 
Enzyme multilayers Phase transition Insulin In vial [202] 
 
A broad spectrum of triggers for specific cargo release has been described. External triggers, 
such as light, external magnetic fields, and temperature, require activation of the release 
mechanism from the outside.
[152, 160, 162]
 These systems provide perfect control over temporal 
and spatial release of the drugs into the targeted tissue or cells, but tissue penetration in in 
vivo studies can limit performance. Temperature changes have been investigated to release 
encapsulated molecules.
[162-163]
 Light can also be used to activate various opening 
mechanisms.
[151, 153]
 Recently, Bein, Bräuchle and co-workers could demonstrate an improved 
system consisting of MSNs coated with a supported lipid bilayer (SLB) and equipped with a 
covalently attached photosensitizer (PS).
[27]
 The SLB was shown to seal the pores and to 
prevent premature release of the loaded cargo. Upon photoactivation of the PS with red light, 
generation of reactive oxygen species initiated cargo release due to rupture of the SLB (cf. 
chapter 6). Photosensitizers are promising components of nanocarrier systems for efficient 
drug delivery because they can simultaneously serve as a means for endosomal escape and for 
triggering controlled release in combination with SLB-coated MSNs. Changes in pH, 
enzymatic reactions, and reducing agents are internal triggers that can provide intrinsic and 
autonomous release of the loaded cargo molecules from the mesoporous host system. Many 
mechanisms for controlled closure and release have been developed in recent years, often 
with a view on utilizing such biologically relevant changes in the cell environment 
encountered by the particles upon endocytosis. Thus, pH changes have been used to open 
gates at the pores of the mesoporous nanoparticles and changes in redox potential could be 
used to cleave disulfide bridges. pH-responsive nanocarriers have been designed to achieve a 
1.3.4. Biological and Pharmaceutical Activity 
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site-selective controlled release, because tumor and inflammatory tissues are more acidic than 
normal tissue and blood. Importantly, the acidification of endosomes inside targeted cells can 
be utilized to trigger pH-responsive intracellular release of the cargo molecules.
[111, 182, 187]
 
Zink and coworkers have described a pH-responsive dethreading of bulky β–cycodextrin 
molecules upon protonation of a complementary stalk located at the pore entrances, and the 
resulting efficient DOX release in vitro. In the context of oral administration, nanocarrier 
systems have been designed with acid-stable gatekeepers to be able to pass the stomach 
without premature release. After passing the acidic environment, pH-responsive caps can be 
cleaved in the basic milieu of the intestines to efficiently release the loaded 
pharmaceuticals.
[26, 188-189]
 Enzyme-responsive controlled release can be highly efficient once 
the nanocarriers have entered the cancer tissue or the cytosol of targeted cells. Many 
intracellular and extracellular enzymes are overexpressed in cancer tissue and exhibit 
increased activity, resulting in preferential cargo release at those locations.
[190-194]
 
Summarizing, molecular and particle-based pore gating or coatings, removable by either 
intracellular or external triggers, can provide exquisite control over the location and time of 
cargo release during drug delivery. 
1.3.4 Biological and Pharmaceutical Activity 
On-demand cargo release from the mesopores of silica nanoparticles has been proven to be 
feasible. To understand the biological and pharmaceutical activity of the MSN drug delivery 
systems in vitro and in vivo, it is useful to investigate the response of cells, such as knock-
down of certain genes, stimuli-responsive labeling of cell compartments, destruction of the 
microtubule network, or apoptosis of cancer cells.
[24, 140, 203-204]
 Dependent on the charge of the 
cargo, the surface of the nanocarriers has to be tuned and the release systems need to be 
adjusted to the scope of the application. Diverse model systems have been devised to learn 
more about the complex processes during cellular uptake of MSNs and subsequent drug 
release. Here, the focus is not to give insight to the challenges of preclinical studies, but to 
provide information about the mode of operation of multifunctional MSNs in the biological 
environment. For instance, attaching fluorescent dyes to the MSNs provides the possibility to 
directly observe the behavior of the nanocarriers and the cells. Common dyes include 
rhodamine or fluorescein derivatives, as well as ATTO or ALEXA dyes.
[72, 118, 135, 205]
 
Fluorescent cargo and/or labeling of cell compartments also aids to examine the intracellular 
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processes. Drug loading of small anti-cancer therapeutics can be achieved by simple 
immersion of the particles into a concentrated solution of the desired drug, followed by 
sealing with the gating mechanism under study. Efficient loading was shown by Bein and co-
workers upon adsorbing colchicine, propidium iodide, phalloidin, chromobodies, calcein or a 
rhodamine derivative into MSNs, which were subsequently sealed by a supported lipid 
bilayer.
[24, 27, 140]
 Doxorubicin (DOX) is a commonly used anti-cancer therapeutic due to its 
efficient induction of apoptosis in cancer cells, and it is fluorescent thus enabling direct 
microscopic observation.
[206]
 Several DOX-containing systems have been investigated, 
ranging from Fe3O4@mSiO2 nanocapsules
[207]
 to hollow MSNs,
[208-210]
 mesoporous silica-
coated gold nanorods,
[78]
 and to MSNs including targeting functionalities like aptamers.
[112]
 
Our groups (Bein, Bräuchle and coworkers) could show an efficient release behavior of 
calcein in HeLa cells over time driven by photoactivation of an on-board photosensitizer 
(AlPcS2a, cf. chapter 6). 
In vitro methods can verify the encapsulation of a large amount of drug molecules in MSN 
carriers, which increases their efficiency. This was proven in a study of Tian and co-
workers.
[203]
 They demonstrated a significant increase of early and late apoptosis of 
paclitaxel-loaded MSNs on MCF-7 cells compared to free drug molecules. Gene transfection 
or oligonucleotide delivery with MSNs has not been studied to a large extent yet, and in most 
reported cases the oligonucleotides are only adsorbed on the external surface of the MSNs or 
incorporated in a polymer shell of coated MSNs.
[211]
 Milligan and co-workers used so called 
“protocells” for GFP and IL-10 gene delivery in vitro and in vivo, but no proof of gene 
adsorption inside the pores was provided.
[82, 211]
 Tamanoi and co-workers attached siRNA to 
the external surface of coated MSNs with the aid of PEI and observed gene silencing of 
EGFP.
[212]
 Attachment of the oligonucleotides exclusively on the external particle surface 
could cause concerns about premature degradation via abundantly available ribonucleases. 
Therefore, controlled loading of siRNA into large pores of MSNs is a highly desirable 
approach that is expected to provide efficient protection from bioerosion. In addition to 
extensive in vitro investigations, the first in vivo application of MSNs was reported in 
2008.
[213]
 Recently Nel and co-workers presented a successful proof of principle aimed to 
overcome DOX resistance in a mouse xenograft model with PEI-PEG functionalized 
MSNs.
[214]
 Unfortunately, heterogeneity in the tumor microenvironment, such as differences 
in the vascularity, possibly influences the efficacy of drug delivery in vivo. Further research is 
necessary to evaluate the MSN distribution in tumor models, particularly with targeting 
ligands to ensure the capability of the delivery systems to efficiently reach all cells within the 
1.3.4. Biological and Pharmaceutical Activity 
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tumor tissue. Nevertheless, these early experiments provide strong evidence that MSNs are 
promising candidates for improved cancer therapy and that they are able to reduce side effects 
for healthy tissues.
[47, 215]
 Furthermore, very promising results for siRNA delivery were 
obtained by Min and co-workers.
[204]
 They showed successful delivery of GFP 
downregulating siRNA in a tumor xenograft mouse model (Figure 1.5). The reduction of GFP 
fluorescence could be observed with optical imaging in vivo (Figure 1.5a/b) and more clearly 
in tissue sections (Figure 1.5c). Although the results demonstrate the feasibility of this 
approach, the system is still lacking control over pore sealing and a release mechanism. 
 
Figure 1.5: Knockdown of GFP genes with siRNA-loaded, PEGylated (P), and 
carboxytetramethylrhodamine-labeled (T) MSN with a pore diameter of 23 nm (P-T-MSN23) in vivo. a,b) 
In vivo optical images before (a) and after removal of tumors (b) and quantitative analysis of GFP-
expressing tumors. c) Optical microscopic images of a tissue section after 4′,6-diamidino-2-phenylindole 
(DAPI) staining show considerable reduction in GFP expression in the siGFP–P-T-MSN23-treated tumor, 
compared with tissue treated with P-T-MSN23.
[204]
 
In addition to possible cancer therapeutics and gene delivery there are also studies for 
inhibitor delivery and delivery of cytokines.
[148, 216]
 A detailed overview on in vivo bio-safety 
evaluations and diagnostic/therapeutic applications of MSNs has recently been provided by 
Shi and co-workers.
[217]
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1.3.5 Imaging 
The imaging possibilities for MSNs and their combinations with other materials range from 
optical microscopy to magnetic resonance imaging, and to ultrasonic imaging, near infrared 
imaging and other techniques. Here, we will focus on optical microscopy and its applicability 
to gain real-time observation of MSNs in cell cultures and tissues. Other imaging techniques 
and the preparation methods for functionalized hybrid nanoparticles, such as silica 
nanoparticles containing magnetic cores, have been extensively discussed elsewhere.
[2, 217-219]
 
In this context MSNs are used as a platform for incorporation of nanocrystals or doping with 
active ions including iron oxide nanocrystals, quantum dots, gold nanoparticles, and 
manganese or gandolinium ions. These multifunctional nanocarriers gain high interest in 
theranostic applications. There are different possibilities to fluorescently label MSNs. 
Depending on the desired type of labeling (removable or not), fluorescent dye molecules can 
be attached to the inner and outer particle surface by covalent linkage via post-synthetic 
grafting, incorporation into the silica framework, or pH-/redox-sensitive linkage. Diffusion of 
dye molecules or nanoparticles like quantum dots inside the pores has been investigated as 
well.
[220]
 In that case, an efficient enclosure of the fluorescent cargo in the mesopores can be 
achieved by supported lipid bilayers or other bulky molecules used as valves. Diffusion 
dynamics of fluorescent molecules in porous silica materials were intensively studied with 
fluorescence microscopy. Bräuchle and co-workers could image single dye molecules
[221-223]
 
as well as the anticancer agent DOX
[224]
 moving inside mesoporous channels of silica 
materials. Such studies are crucial for understanding diffusion processes and confirm the need 
for defined surface modifications for controlling adsorption and desorption processes of the 
cargo molecules in the mesoporous system. Functionalization of the mesoporous interior with 
amino-groups in order to achieve positively charged surfaces resulted in preferential and 
increased uptake of negatively charged siRNA constructs.
[225]
 Issues of cargo loading efficacy 
may arise due to electrostatic repulsion when negatively charged molecules like double 
stranded DNA should be absorbed into nanocontainers featuring negative surface charge.
[226]
 
On the other hand, electrostatic interactions may not be too strong, otherwise they can cause 
entrapment in the porous system and consequently cargo release is inhibited. The stability of 
the cargo to be transported is a key factor in particle design, especially if the goal is to 
efficiently deliver sensitive cargos like siRNA. Fluorescent donor-acceptor pairs offer the 
possibility to investigate the stability of oligonucleotides inside the pores by measuring the 
Förster resonance energy transfer (FRET).
[225-226]
 Thus, the stability of oligonucleotides in 
specifically functionalized mesopores after adsorption was demonstrated. Since nanocarriers 
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provide protection against diverse biological attacks, incorporation of oligonucleotides into 
the mesopores of silica materials is very promising for future experiments in gene delivery, 
especially because previous efforts in delivery so far have focused on oligonucleotides 
attached to the external particle surface, as already discussed in chapter 3.4.
[211-212]
 FRET is 
also a useful method to monitor the release of payload from the pores of MSNs in real-time. 
For that purpose Lee and co-workers attached a FRET donor-acceptor pair of coumarin and 
fluorescein isothiocyanate (FITC) to the cap system β-cyclodextrin located at the pore 
entrances of MSNs. After light activation, cleavage of the gatekeepers occurred and 
subsequently the FRET-signal vanished due to great distance of the donor-acceptor pair.
[227]
 
Optical imaging is also the most widely used technique to study the feasibility of custom-
made drug nanocarriers based on MSNs. The direct release and distribution of cargo inside 
cells can be monitored via fluorescence microscopy. Furthermore, precise investigations of 
uptake behavior and cellular internalization mechanisms of MSNs in single cells can be 
realized. Methods that were developed to evaluate the uptake behavior of viruses and single 
polymeric gene carriers (polyplexes) were extensively exploited by Bräuchle and co-
workers.
[228-231]
 Subsequently, the internalization of epidermal growth factor receptor (EGFR) 
targeted MSNs into living cells was also investigated. Detailed information on the 
internalization pathway, the behavior of the MSNs inside the cells, and information on 
unexpected interactions between the particles and the cell can be gathered by life-cell imaging 
and consequently possible challenges can be monitored. Similar to the behavior of polyplexes 
it was observed that porous silica nanoparticles exhibit three phases of motion during their 
internalization (Figure 1.6). The particle motion was measured on a sensitive fluorescence 
wide field microscope and analyzed with single particle tracking methods. In the first phase 
the particles attach to the cell membrane and consequently show a slow directed movement, 
provoked by movement of the subjacent actin cytoskeleton mediated by the EGF receptor and 
linker proteins. With the transition to phase II the particles are internalized into the cells. 
Phase II consists either of normal, anomalous and confined diffusion or a combination of all 
three. Normal diffusion is often hindered in the cytoplasm by the local microenviroment 
(cytoskeleton, organelles, large molecules etc.). Phase III shows much faster, active transport 
of the particles entrapped inside endosomes along the microtubule network via motor proteins 
with velocities up to 2 µm/s. 
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Figure 1.6: Internalization of epidermal growth factor receptor (EGFR)-MSNs with supported lipid 
bilayer.
[27]
 (a) Trajectory of an MSN during uptake into a HuH7 cells. The particle was tracked 4 minutes 
after addition of the particles on top of the cells, for 5 minutes and 50 seconds at a temporal resolution of 
150 ms/frame. Three phases are typically observed during the internalization process.
[229]
 The starting 
point of the trajectory is indicated with an arrow. The overlying color boxes indicate the three phases. 
Yellow: phase I – slow active transport; green: phase II – anomalous and confined diffusion; red: phase 
III – active transport with back and forth movement. (b) Instantaneous velocities of the trajectory shown 
in (a), and (c)-(e) the mean square displacement (MSD) plots of the three phases obtained from several 
trajectories. The corresponding plots from the trajectory are indicated in blue. The analysis of the 
trajectories was performed with the help of the viro-tracker developed by Godinez et al.
[232]
 to localize the 
xy-coordinates and with the help of the transport-program developed by Arcizet et al.
[233]
 to calculate 
MSD plots. 
Optical microscopy also provides the capability to image in vivo. However, attenuation of 
photon propagation and a poor signal to noise ratio due to auto-fluorescence of the tissue can 
cause difficulties and should be considered in the selection of the type of dye and its 
concentration. Nevertheless, the high loading capability of MSNs makes them promising 
candidates to overcome this problem. Thus, Lo and co-workers could study the spatial 
distribution of MSNs with positive surface charge and loaded with indocyanine green (ICG) 
via near infrared microscopy inside anesthetized rats.
[234]
 In that case the biodistribution of the 
optical MSN probe was evaluated in comparison to FITC-labeled MSNs. FITC seems to be 
not appropriate for in vivo optical imaging, since tissue penetration depth of the fluorescent 
signal of this dye is too small and consequently not detectable. NIR fluorescent dyes can be 
clearly detected after intravenous injection for evaluating particle accumulation inside the 
liver and kidney, and partially in lungs, spleen and heart. Further verification of the 
biodistribution in the dissected organs can be seen in Figure 1.7. Optical microscopy utilizing 
NIR fluorescent dyes offers the possibility to investigate long-term biodistribution of 
nanocarrier systems, since it is a non-invasive method and animal models do not need to be 
sacrificed. As can be seen in this experiment, bare MSNs seem to face the problem to be 
cleared through the reticuloendothelial system (RES), such as spleen or liver, and 
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subsequently the EPR effect is decreased.
[99, 105, 234]
 Further modifications of the particle 
surface including PEGylation of the MSNs have to be done to avoid the activation of the 
immune system.
[235]
 
 
Figure 1.7: I) Comparison of FITC-tagged MSN with ICG-tagged MSN (50-100 nm) (a)/(b) 
Biodistribution of MSN-NH2-FITC in an anesthetized rat before and after (90 min) i.v. injection. The 
experimental conditions were set at 492 nm (excitation) and 518 nm (emission) and (a) a longer shutter 
time (60 s) for a visible imaging and (b) 30 s shutter time. (c) Biodistribution of MSN-TA-ICG in an 
anesthetized rat before and after i.v. injection for 90 min. MSN-TA-ICG sample showed less interference 
of autofluorescence in a shorter shutter period (30 s). (d) MSN-TA-ICG in nude mice after i.v. injection 
for 3 h. II) Dissected organs from a rat sacrificed after i.v. injection of MSN-TA-ICG for 3 h. (a) 
representative white-light and (b) fluorescent images. III) In vivo biodistribution of silicon percentage in 
various organs of rat after i.v. injection of MSN-TA-ICG for 6 h.
[234]
 
1.4 Future Perspectives 
Colloidal MSNs have attracted great attention as potential drug delivery systems for cancer 
cell targeting, and as bioimaging devices. In addition to their biocompatibility and 
biodegradability, they can be selectively modified at their inner and outer surface. Guest 
molecules can be efficiently encapsulated in their tunable pore system. Furthermore, it is 
possible to functionalize their outer surface with targeting ligands, biomimetic and other pore 
gating molecules, fluorescent dyes, and biocompatible polymers. Compared to most other 
prominent organic carriers, such as liposomes and polyplexes, MSNs offer several advantages 
including high loading capacity, high stability, and the ability to protect the guest molecules 
from various biochemical attacks causing degradation of the bioactive cargo molecules. 
Extensive in vitro studies on the controlled release of therapeutics and the evaluation of 
cytotoxicity have proven the feasibility of multifunctional MSNs for a sustainable and 
efficient drug delivery to cancer cells. Today’s challenge is the investigation of 
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pharmacokinetics and pharmacodynamics of mesoporous silica nanoconstructs for in vivo 
diagnostic and therapeutic applications. Issues and opportunities have been recently reviewed 
by several groups.
[32, 217, 236-237]
 The biological effects of MSNs at different levels ranging 
from molecules, cells, and blood to tissue and organs, involving cytotoxicity, 
biodegradability, blood compatibility, biodistribution and excretion are currently under 
investigation. Oral administration and injection into the blood stream of such nanocarriers 
require specific properties for long-term stability during circulation in the organism, specific 
targeting of the desired location, and controllable release of the loaded drugs to obtain the 
desired therapeutic outcome. Controlling all these requirements is important to avoid side 
effects harming healthy tissue. Researchers are still faced with many challenges, especially in 
vivo applicable stimuli-responsive release mechanisms, targeting specificity, and bio-safety 
issues, which need to be fully understood to achieve efficient and safe drug delivery. A 
complete understanding of the mechanisms for intracellular uptake, trafficking, and the fate of 
multifunctional MSNs in the body would be highly desirable. Up to now only a few in vivo 
studies of the pharmacokinetics of multifunctional MSNs including biodistribution, 
biodegradation, and excretion and clearance have been performed and additional work in this 
area is clearly needed.
[99, 238-241]
 Additional functional groups, such as PEG chains, on the 
external surface of MSNs seem to be important for achieving the EPR effect and were shown 
to decrease the clearance through the RES.
[99, 105]
 Selected strategies and model systems are 
needed to gain insights to such complex processes before reaching the stage of clinical trials. 
Comprehensive reviews address the state of the art for preclinical studies.
[217, 237]
 Here, model 
systems for investigations on the way to clinical trials are discussed including chorioallantoic 
membrane, zebrafish embryo and mouse, amongst others.
[242-244]
 Pharmacokinetics of 
nanomaterials is closely related to in vivo toxicity, biocompatibility and retention. The issue 
of potential toxicity to cells or organisms caused by nanocarriers seems to be strongly 
influenced by several particle properties including size, morphology and surface 
functionality.
[64]
 Studies on the dissolution of silica nanoparticles concerning retention and 
clearance in the body showed that the silica was adsorbed or excreted in the urine in the form 
of silicic acid or organic silica species.
[99]
 For future applications of multifunctional MSNs as 
drug delivery devices and to pave the way to clinical trials, these nanocarriers could be 
designed with two very different operating modes in mind. One approach would pursue the 
design of autonomous drug delivery vehicles, which can perform their tasks as a response to 
stimuli already present in the organism, including receptors on cell and tissue surfaces, 
changes of pH and redox potential in endosomes (for opening gate functions), the presence of 
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enzymes, and autonomous endosomal escape. Reversible opening and closing methods should 
also be developed further, because it was shown that MSNs can also be exocytosed from 
cells.
[245]
 Successful re-sealing of the MSNs could efficiently hinder further drug release after 
leaving the cell or tissue to prevent unintended distribution of the drug. The other approach 
would rely on the use of external triggers (in combination with internal stimuli) to spatially 
control the drug release behavior, for example to focus the release to a certain area of tissue or 
a certain time period. Light activation with red or near infrared light, two-photon activation 
(to enhance tissue penetration), ultrasound, and local heating by different means such as RF 
absorption all present intriguing opportunities for future research. External stimuli for 
endosomal escape and controlled cargo release are also excellent tools for mechanistic studies 
in cell cultures, because they allow control over time and location of the initial release. 
Finally, recent studies focus on the ultimate combination of diagnostic and therapeutic 
capabilities in the multifunctional mesoporous nanoparticles, such that the nanocarrier uses 
diagnostic information to control or tune its therapeutic actions. One such approach could be 
the detection of the presence of multiple receptors indicating specific target tissue, where the 
logical combination of this information leads to release of drug only at this location, another 
one the detection of several enzymes that together constitute the signature of a target tissue. 
The future is bright for multifunctional mesoporous nanoparticles in diagnostics and therapy. 
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2 Characterization 
The synthesis and functionalization of MSNs can be characterized by various techniques. 
Structural and morphological parameters are obtained by X-ray diffraction, nitrogen 
physisorption measurements and transmission electron microscopy (TEM). By means of 
dynamic light scattering (DLS) the size of the MSNs and their agglomeration behavior can be 
investigated. Furthermore, zeta potential was used to characterize the charge of the particle 
surface. Vibrational spectroscopy (IR- and Raman spectroscopy) elucidates the properties of 
chemical bonding in materials. The complementary selection rules for either IR- or Raman-
active vibrations make these two approaches versatile tools for the analysis of the synthesized 
samples. Additionally, nuclear magnetic resonance spectroscopy of liquids and solid state 
NMR shows chemical bonding in the samples. Thermogravimetric analysis (TGA) was used 
to evaluate the amount of functional organic compounds attached to the MSNs. Fluorescence 
spectroscopy was performed to gain information about the time-based release of fluorescent 
model drugs such as fluorescein from the mesoporous nanocarriers. 
2.1 Dynamic Light Scattering (DLS) 
Dynamic light scattering (DLS) measurements provide information about the size of particles 
suspended in a liquid.
[1-2]
 This technique is valuable for the analysis of nano-sized particles 
typically having a diameter between 1 – 1000 nm. The size of particles is correlated with the 
Brownian motion which is the random movement of particles in a liquid caused by constant 
collisions with the surrounding solvent molecules. The smaller the particles, the more 
effective these collisions are, causing rapid movement. Slow Brownian motion is observed for 
large particles. The velocity of the Brownian motion is related to the translational diffusion 
coefficient D, from which the particle size can be calculated following the Stokes-Einstein 
equation (2.1). 
     (2.1) 
Stokes-Einstein equation: d(H) is the hydrodynamic diameter, D is the translational diffusion coefficient, k 
is the Boltzmann’s constant, T is the temperature, η is the viscosity. 
𝑑 𝐻 =
𝑘𝑇
3𝜋𝐷
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DLS measures the hydrodynamic diameter d(H), which is related to the diffusion properties of 
a particle in a liquid. The translational diffusion coefficient D depends on several parameters, 
including the ionic strength of the suspension, the texture of the particle surface, and the shape 
of the particles. Upon illumination of the particles by laser light, the intensity fluctuations in 
the scattered light are analyzed during DLS measurements. These intensity fluctuations occur 
by constructive and destructive interferences of the scattered light being detected. The size of 
the particles will determine the rate of occurrence of these intensity fluctuations. The particle 
size distribution which is obtained by DLS measurements is based on intensity. This intensity-
derived size distribution is suitable for small particles (size smaller than one-tenth of the 
wavelength of the illuminating light) in a suspension featuring monodispersity, and is well 
described by Rayleigh scattering. The Rayleigh approximation (2.2) presents the relation 
between the light scattering intensity I and the particle diameter d. 
     (2.2) 
Rayleigh approximation: I is the intensity of scattered light and d is the particle diameter. 
The scattering intensity is proportional to d
6
. Thus, large particles and agglomerations would 
dominate the intensity size distribution even if only present in small amounts. For particles 
that have a size similar to the wavelength of the laser, and broad particle size distributions or a 
suspension containing different particle size populations, Mie theory has to be applied. Here, 
a conversion to volume size distribution or number size distribution is more accurate, taking 
into account the refractive index of the sample. Volume size distribution and number size 
distribution are proportional to d³ and d, respectively, which gives a more realistic view of 
particle aggregation and polydispersity. 
2.2 Zeta Potential Measurements 
Particles in an aqueous suspension feature a zeta potential, which is the electrokinetic 
potential difference between a stationary layer of ions in a liquid attached to the dispersed 
particle and the liquid medium in the surroundings.
[3]
 Particles in colloidal suspensions can 
exhibit surface charges, which can originate from ionization of functional groups at the 
external particle surface, differential loss of ions from the particle, or adsorption of charged 
𝐼 ∝ 𝑑6  
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species, such as ions and ionic surfactants. The charged particle surfaces affect the 
distribution of ions in the dispersion medium generating different layers of counter ions, close 
to the surface, thus forming an electrical double layer which exists around single particles 
(Figure 2.1).
[4]
 
 
Figure 2.1: Schematic representation of the electric double layer around a negatively charged particle and 
location of the zeta potential.
[5]
 
Zeta potential measurements are used to investigate the charge of the particle surface 
depending on the pH value of the solution. The zeta potential of particles is highly affected by 
environmental changes in pH causing protonation or deprotonation of functional groups, such 
as amino or carboxy groups, on the particle surface. This results in an increased or decreased 
surface charge. Zeta potential is measured indirectly by determination of the electrophoretic 
mobility. By applying an external electric field, charged particles move towards the 
electrodes. The velocity of particle movement depends on the strength of the external electric 
field, the dielectric constant, the viscosity of the fluid, and the zeta potential of the particles. 
The Henry equation (2.3) describes the relation between the electrophoretic mobility and the 
zeta potential.  
2.3. IR- and Raman Spectroscopy 
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     (2.3) 
Henry equation: UE is the electrophoretic mobility, ε is the dielectric constant of the sample, ζ is the zeta 
potential, f(ka) is the Henry function, and η is the viscosity. 
To obtain the electrophoretic mobility, the velocity of the particles is measured using Laser 
Doppler Velocimetry (LDV). An electric field of known strength is applied to a capillary cell 
containing the particle suspension. The frequency shift of the laser light passing through the 
suspension is used to determine the velocity of the particles. For small particles (< 200 nm) in 
low dielectric constant media the Henry function f(a) becomes 1.0, known as the Hückel 
approximation. The Smoluchowski approximation is suitable for particles lager than 200 nm 
in diameter and for suspensions containing more than 1 mM salt concentrations. Using these 
simple approximations for the Henry function, the zeta potential of the particles within the 
colloidal suspension can finally be calculated. 
2.3 IR- and Raman Spectroscopy 
IR- and Raman spectroscopy offers the potential to study the properties of the chemical bonds 
in a molecule by excitation of vibrational modes. In the former, radiation in the infrared 
region of the electromagnetic spectrum (200 – 4000 cm
-1
) is used for the excitation in order to 
receive information about the vibrational and rotational energy states of a molecule.
[6-7]
 The 
infrared light interacts with the sample and the intensity of the transmitted or scattered light is 
measured. For detection of vibrational modes it is necessary that the molecule is IR-active, 
which implies that the dipole moment of the molecule has to change during the vibration. The 
absorption of the IR radiation results in transitions to higher energy levels and thus a 
characteristic absorption spectrum providing information about the chemical composition and 
bonding of the sample can be detected. Fourier transformation of a time-dependent signal 
which is detected by an interferometer while performing IR spectroscopy measurements, 
results in a frequency-dependent spectrum with information about characteristic vibrational 
bands of specific functional groups.
[8]
 
For Raman spectroscopy monochromatic light, usually generated by a laser, is used to 
characterize the sample. The Raman effect relies on the interaction of light with the electron 
𝑈𝐸 =
2𝜀𝜁𝑓(𝑎)
3
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shell of the molecules. It is based on the inelastic scattering of the monochromatic light by 
interaction with the electron cloud of a molecule. The Raman selection rule requires 
vibrations to induce a change in the polarizability in order to be Raman-active. Figure 2.2 
illustrates the possible excitation and relaxation processes occurring during a Raman 
experiment. 
 
Figure 2.2: Energy states and scattering processes (Stokes-, Rayleigh-, and anti-Stokes scattering, 
respectively) occurring in a Raman experiment.
[9]
 
An incident photon excites a bound electron from a given vibrational state into a virtual 
energy state. There are two different possibilities to scatter the incident light. Either the 
monochromatic light is scattered elastically, which is known as Rayleigh scattering, or 
inelastically, known as Raman scattering. In Raman scattering, the scattered light is either 
shifted to higher frequencies (Anti-Stokes scattering) or shifted to lower frequencies (Stokes 
scattering) with respect to the original frequency. The corresponding absorption frequencies 
are related to specific functional groups and the nature of a synthesized molecule can be 
identified. 
2.4 Fluorescence Spectroscopy 
Fluorescence, a certain kind of photoluminescence, is a physical process in which a substance 
absorbs photons and subsequently reradiates photons of lower energy. Fluorescence results of 
a three-stage process in the electron shell of certain molecules, including mainly polyaromatic 
2.4. Fluorescence Spectroscopy 
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hydrocarbons or heterocycles. These molecules consisting of a large conjugated -electron 
system are called fluorophores or fluorescent dyes. In Figure 2.3 a Jablonski diagram is 
depicted, which gives information about the process of fluorescence in a simplified manner. 
 
Figure 2.3: Jablonski diagram illustrating the process of fluorescence: Excitation of electrons by 
absorption of external photons, non-radiative relaxation to vibrational ground state (0) of excited 
electronical state (S1), and emission of photons (fluorescence).
[10]
  
First, a photon of energy hex is absorbed by the fluorophore, which results in an excitation of 
electrons from the ground state S0 to an excited state S1’. These photons are generated 
externally by incandescent lamp or a laser sources. The absorption occurs in a very short 
time-scale of about one femtosecond. Subsequently, a non-radiative relaxation process takes 
place caused by conformational changes of the fluorophore. These conformational changes 
lead to a loss of energy and are subject to environmental interactions. The electrons need 
typically about 1 – 10 nanoseconds to temporarily end up in a relaxed excited state S1. 
Finally, the electrons can reach the ground state S0 by emitting photons hem of lower energy 
compared to the external photons hex which led to electron excitation. Fluorescence features 
a red-shift of the emitted wavelength accompanied with energy loss compared to the initial 
photons generated by external sources. This phenomenon is called Stokes shift, which is a 
bathochromic shift of the emission maximum compared to the absorption.
[11-12]
 Fluorescence 
is not the only process causing a return of the excited molecules to the ground state. Other 
known processes are quenching, fluorescence energy transfer and intersystem crossing 
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(phosphorescence) which also can lead to depopulation of the excited state S1 without 
emitting a photon. 
2.5 Nitrogen Physisorption 
Adsorption and desorption measurements of a gas on a porous substrate give information 
about the shape and pore size distribution, the specific surface area and the pore volume of a 
material. Nitrogen sorption measurements are suitable to characterize porous materials 
concerning their pore characteristics, such as pore size, pore arrays, and surface areas.
[13]
 The 
nitrogen sorption process can be classified as physisorption, since only weak interactions 
including van-der-Waals forces occur for the adsorbed species and the absorbents. For 
nitrogen physisorption measurements, the amount of the adsorbed nitrogen gas at different 
pressures and constant temperature (77 K) is used to generate sorption isotherms (Figure 2.4). 
 
Figure 2.4: IUPAC classification of six different sorption isotherms.
[14]
 
Six different types of sorption isotherms were classified by IUPAC.
[14]
 The different types (I-
VI) distinguish porous materials regarding pore structure and size, and the interactions of the 
adsorbed gas molecules with the adsorbent. The most common models for the description of 
isotherms are those of Langmuir, Freundlich and Brunauer-Emmett-Teller (BET).
[15]
 The 
BET isotherm model assumes multilayer adsorption, neglecting interactions of the adsorbates 
among each other. The initial monolayer serves as a substrate for further adsorption processes, 
2.5. Nitrogen Physisorption 
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and consequently a change in adsorption enthalpy between the first and the subsequent layers 
occurs. With these approximations, the BET-equation can be derived (2.4). 
     (2.4) 
BET equation: n is the amount of the adsorbate at the pressure p, nm is the capacity of one monolayer, C is 
the BET constant, p is the equilibrium pressure, and p0 is the saturation vapor pressure of the adsorbate. 
Transformation of the BET equation leads to a linear relation between partial pressure and 
surface occupancy. The capacity of one monolayer nm can be easily calculated by this linear 
relation. The specific surface area can be calculated by the required space of one adsorbed 
molecule. For mesoporous materials, the pore shape influences the shape of the hysteresis 
loops of IUPAC type IV adsorption isotherms.
[16]
 The pore size distribution function is a very 
important characteristic of porous materials. The thermodynamic relation between the reduced 
pore radius rk (Kelvin radius, defined by the sum of the quotients of principal radii r1 and r2 of 
the curvature of the liquid meniscus in the mesopore)
[17]
  and the relative vapor pressure p/p0 
is described by  elvin’s equation (2.5). 
     (2.5) 
Kelvin’s equation: rk is the reduced radius, γ is the surface tension of the adsorbate, VL is the molar 
volume, R is the gas constant, T is the temperature, p is the equilibrium pressure, p0 is the saturation 
vapor pressure of the adsorbate. 
The reduced pore radius rk indicates the curvature of the adsorbate’s surface. However, pore 
si e calculations using  elvin’s equation are often not accurate, since the expressed pore 
radius does not include multilayer films. Consequently, pore sizes are underestimated. In the 
BJH method, corrections are made to account for the film formation. This method however is 
limited in so far as it disregards the impact of surface curvature on the formation of the film, it 
is only derived for cylindrical pores, it assumes formation of homogenous films and it does 
not explicitly account for surface forces between the film and the surface. Due to these 
limitations the BJH is known to underestimate the pore size, especially for small pores. The 
calculations involving density functional theory (DFT) can lead to more realistic results. Pore 
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size analyses with DFT and Monte Carlo methods describe the situation of an adsorbed fluid 
in equilibrium with a bulk fluid reservoir.
[18]
 The grand canonical Monte Carlo simulation 
represents the most common computer simulation for the study of adsorption processes. 
Equilibrium density profiles are obtained by applying the DFT approach. The free-energy 
function is minimized for a pore system in equilibrium with a bulk phase. This represents the 
exact situation during a sorption experiment. Two different DFT approaches, the local density 
functional theory (LDFT) and the non-local density functional theory (NLDFT), were 
developed for a more exact description of the porous system. NLDFT in combination with 
Monte Carlo simulations describes very well the local fluid structure near curved solid walls. 
2.6 Thermogravimetric Analysis 
Thermogravimetric analysis (TGA) can be performed for determining the composition of a 
sample containing volatile or combustible components.
[19-20]
 This method investigates the 
mass loss of a sample with increasing temperature. The sample is placed into an adjustable 
oven, usually heated up to 900 °C in this work, and the weight losses are detected by a 
coupled thermobalance. The mass loss results either from desorption of adsorbed molecules or 
from the decomposition of the material. The temperature is raised with a constant heating rate 
β = dT/dt in inert gas atmosphere or in synthetic air that passes the sample and removes 
desorbed components. The resulting thermogravimetric data contain information about the 
temperature stability of the observed sample. Furthermore, the thermogravimetric analysis of 
porous compounds can also quantify the amount of adsorbed cargo molecules in the 
mesopores. 
2.7 X-Ray Diffraction (XRD) 
X-ray diffraction measurements can be performed to gain direct information about the 
crystallinity of the investigated material. Furthermore, the particle shape and size of 
nanostructured materials can be analyzed in the nanometer range.
[21]
 The (ordered) pore 
structure of mesoporous silica materials can be analyzed by small angle X-ray scattering 
(SAXS). Here, the identification of the mesostructure of the synthesized silica materials was 
carried out at small angles ranging from 2θ = 0.1 – 10 °. X-ray radiation is emitted from a 
metal source, normally copper, with a characteristic wavelength (Cu-Kα is 1.54182 Å).
[22]
 
This wavelength has about the same order of magnitude as the distances of atoms in solids 
2.8. Transmission Electron Microscopy (TEM) 
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possibly causing scattering of an incident X-ray beam. Therefore, constructive and destructive 
interferences of X-rays scattered by the lattice planes of the porous materials gives 
information on the atomic structure of the material. The relationship between the incident X-
ray beam and the lattice plane distance of porous materials is described by  ragg’s law 2.6. 
     (2.6) 
Bragg’s relation: θ is the angle of incidence, d is the lattice plane distance, λ is the wavelength, and n is the 
order of interference. 
2.8 Transmission Electron Microscopy (TEM) 
Electron microscopy is a powerful imaging technique - achieving a spatial resolution down to 
0.1 nm - to observe structures at the atomic length scale, which makes it a very important 
characterization technique in nanotechnology.
[23]
 For imaging, highly accelerated electrons 
are generated by an electron gun and focused by using electromagnetic lenses. The strong 
interaction of electrons with matter requires ultrahigh vacuum to achieve the highest 
resolution. Limiting factors for high resolution are spherical aberrations, chromatic 
aberrations, and astigmatism.
[24]
 Various processes occur upon electron irradiation of a 
material, generating X-rays and a variety of resulting electrons, such as secondary, 
backscattered, and Auger electrons, which can be detected and are subsequently used to image 
the specimen. The described effects are utilized for different techniques in electron 
microscopy including selected area electron diffraction (SAED), energy dispersive X-ray 
(EDX) analysis, and electron energy loss spectroscopy (EELS). Another type of generated 
electrons are transmitted electrons that are not subjected to energy loss or directional change. 
Consequently, they are not influenced by the investigated material. For transmission electron 
microscopy (TEM), the transmitted electrons are detected by a fluorescent screen or a CCD 
camera. This technique offers the investigation of the internal structure of the specimen. A 
schematic construction of a transmission electron microscope is depicted in Figure 2.5, 
including the pathway of the electron beam. 
sin 𝜃 =
𝑛𝜆
2𝑑
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Figure 2.5: Schematic representation of a transmission electron microscope. The pathway of the electron 
beam is presented in yellow.
[25]
 
Information about the structure and morphology of the material, cell parameters, pore 
dimensions and wall thickness can be obtained from TEM investigations, since resolution 
down to the atomic level is provided by this technique. Structural results for porous materials 
derived from XRD and physisorption measurements can be verified by TEM analysis. 
Samples for TEM investigation have to be very thin to allow electron transmission. MSNs 
studied here have a diameter of about 80 nm and so they are in the appropriate range for TEM 
measurements. The sample has to be penetrated by radiation, this is possible due to the high 
acceleration voltage for electrons (80 – 300 keV). 
2.9 Nuclear Magnetic Resonance (NMR) 
Nuclear magnetic resonance (NMR) spectroscopy investigates the absorption of 
electromagnetic radiation by magnetic nuclei in a static magnetic field. The evaluation of 
NMR data provides information about the chemical environment and structural properties of 
nuclear isotopes, including chemical bonds, connectivity within molecules, and coordination 
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numbers. The elements need to have a non-zero nuclear spin which is, for instance, present in 
1
H, 
13
C, and 
29
Si. The applied external magnetic field influences the energy states of the 
nuclei possessing a permanent magnetic dipole moment. Consequently, this results in a 
differentiation of the magnetic energy levels into (2J+1) distinct energy states (J indicates the 
nuclear spin). This strictly depends on the alignment of the nuclear spins relative to the 
external magnetic field. A transition between these quantum states can be induced by 
electromagnetic radiation with radiofrequency, typically ranging from a few kHz to several 
hundred MHz (2.7). 
     (2.7) 
ω is the frequency of electromagnetic radiation at resonance conditions, γ is the gyromagnetic ratio, B0 is 
applied external magnetic field, and Bint is the internal field arising from electronic environments and 
surrounding magnetic moments. 
Nuclear magnetic resonance spectroscopy of liquids typically gives sharp spectra at high 
resolution. The mobility of the nuclei in liquid samples creates an averaging process, leading 
to an intrinsic elimination of the line broadening related to dipole-dipole interactions. In 
contrast, the investigation of solids by solid state NMR requires special methods to give 
comparable structural information. These dipole-dipole interactions between the magnetic 
moments of nearby nuclei lead to line broadening in the spectra. The “magic angle spinning” 
(MAS) technique provides a method to eliminate this anisotropic effect and sharpen the 
obtained broad peaks in solid state NMR, by rotating the sample at high velocity at an angle 
of 54.74° relative to the applied magnetic field. 
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3 “Liquid-Phase Calcination” of Colloidal Mesoporous Silica 
Nanoparticles in High-Boiling Solvents 
This chapter is based on the following publication: 
Valentina Cauda, Christian Argyo, Davin G. Piercey, and Thomas Bein, Journal of the 
American Chemical Society 2011, 133, 6484 – 6486. 
 
 
3.1 Introduction 
Colloidal mesoporous silica nanoparticles (MSNs) are of great interest for their unique 
properties regarding catalysis, separation, chemical sensing, and drug delivery.
[1-2]
 The 
defining factor of the synthesis of mesoporous silica is the use of a templating surfactant 
causing self-assembly of the material at mild temperatures. The subsequent removal of this 
template is the key step for obtaining accessible mesopores, large surface areas, and pore 
volumes.
[3-4]
 Established methods of template removal include calcination in air, extraction in 
ethanol with various solutes, microwave irradiation, and UV light.
[5-8]
 However, all these 
methods except the solution-phase ethanol-based template extraction are conducted in the 
solid phase, which is appropriate for bulk mesoporous silica or for particles with a size far 
greater than 100 nm.
[9-10]
 During calcination, condensation of silanol groups (Si-OH) into 
siloxane (Si-O-Si) bridges takes place, thus consolidating the mesoporous structure.
[11]
 
However, when colloidal MSNs (e.g., 20-100 nm in size) are calcined, strong aggregation 
prevents their subsequent redispersion as isolated nanoparticles in a colloidal solution. For 
3.2. Results and Discussion  
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this reason only solvent extraction, hydrogen peroxide oxidation, or dialysis can be applied,
[12-
14]
 but no further condensation of the silica network after the room temperature sol-gel 
synthesis is obtained. This implies the low stability of the extracted MSNs in aqueous media, 
which can pose a serious impediment for applications such as drug delivery. We have 
previously shown that the silanol groups are the point of initial attack and silica degradation, 
leading to rapid particle destruction in simulated biological fluids.
[15]
 Current attempts at 
increasing the stability of MSNs in biological media have mainly involved polymeric-shell 
functionalization of the outer particle surface.
[16]
 
Here we present for the first time the use of a liquid-phase high temperature “calcination” of 
MSNs in high boiling point organic solvents (HBS), leading to significant silica condensation 
and also to template removal. Trioctylphosphine oxide (TOPO), known for its stabilizing 
effect in nanoparticle and quantum dot synthesis,
[17-18]
 was used as solvent for high 
temperature treatment of the MSNs, in both thermal and microwave-assisted liquid 
calcination. In addition we have examined two other HBS, tri-n-octylamine (TOA, C24H51N) 
and squalene (C30H50).
[19]
 
3.2 Results and Discussion 
The synthesis of MSNs (sample UN-CMS) was carried out as previously reported.
[20]
 The 
ability of the HBS treatment to enhance the degree of silica condensation in the already 
template-extracted MSNs (sample ex-CMS) was examined with thermal liquid calcination at 
400 °C in squalene (sample LC-1), TOA (sample LC-2), and TOPO (sample LC- 3), in this 
last case also at 275 °C (sample LC-4), for 5 h under a N2 atmosphere. Moreover, we have 
combined the ability of the TOPO treatment to enhance silica condensation with the removal 
of the template phase in as-synthesized MSNs (template: cetyltrimethylammonium chloride 
(CTAC)). This was achieved in a thermal liquid calcination at both 275 °C (sample LC-5) and 
400 °C (sample LC-6) on UN-CMS nanoparticles. Microwave (MW) heating has been 
demonstrated to enhance reaction rates, selectivity, and product yields in chemical 
synthesis.
[21-22]
 Due to its polarity, TOPO can couple with microwaves and efficiently convert 
electromagnetic energy into heat, resulting in rapid heating of the bulk solution. TOPO 
microwave-assisted liquid calcination was carried out at 200 °C for 30 min (sample LC-7) or 
2 h (sample LC-8) with template-extracted MSNs (ex-CMS). All TOPO-calcined samples 
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were thoroughly washed. The degree of condensation of the silica network in the as-
synthesized (UN-CMS) and template-extracted MSNs (ex-CMS) is strongly enhanced by all 
the liquid-phase calcinations treatments, as observed by 
29
Si-MAS NMR spectroscopy (Figure 
3.1). 
 
Figure 3.1: 
29
Si-MAS NMR spectra of the as-synthesized (UN-CMS), template-extracted (ex-CMS), and 
air-calcined (calc-CMS) MSNs and the liquid-phase-calcined MSNs with squalene (LC-1), TOA (LC-2), 
and TOPO (from LC-3 to LC-8). 
Table 3.1: Quantification of the Integrated Area of Q
3
 and Q
4
 Peaks and Their Relative Change upon 
Thermal Treatment. 
Sample Treatment Q
3
/Q
4
 ratio Increase of Condensation
a
 (%) 
UN-CMS - 1.08 - 
ex-CMS EtOH@78 °C 1.02 + 5.56 
LC-1 Sqa@400 °C 0.755 + 30.1 
LC-2 TOA@400 °C 0.795 + 26.2 
LC-3 TOPO@400 °C 0.816 + 24.5 
LC-4 TOPO@275 °C 0.801 + 25.8 
LC-5 TOPO@275 °C 1.04 + 2.78 
LC-6 TOPO@400 °C 0.910 + 15.7 
LC-8 TOPO@200 °C MW 1.01 + 6.48 
calc-CMS 550 °C (air) 0.549 + 49.2 
a
Based on the decrease in % of the Q
3
/Q
4
 ratio of each sample with respect to the reference one (UN-
CMS). 
Quantification of the integrated area of the Q
n
 peaks is given in Table 3.1, clearly indicating a 
strengthening of the silica network due to the HBS calcination treatments. In order to 
quantitatively evaluate the degree of silica condensation after the TOPO-calcination process, 
3.2. Results and Discussion  
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the Q
3
 and Q
4
 peaks from the single-pulse 
29
Si-MAS NMR measurements were deconvoluted 
by using the deconvolution software Deconv2Dxy.
[23]
 The ratio of Gaussian to Lorentzian fit 
was set to 0.5 and the area under each Q
n
 peak was calculated. The results of this fitting 
procedure are shown in Table 3.1 and in Appendix 3.5. To better estimate the effect of the 
silica condensation, we also calculated the ratio of the Q
3
/Q
4
 areas for each sample and the 
percentage of variation of the Q
3
/Q
4
 ratio for one given sample after HBS-treatment with 
respect to the ratio values of the starting materials (Table 3.1). The general trend in all 
samples is an increase of the Q
4
 area after the HBS-thermal treatment. In particular, a clear 
indication of this trend is given by the decrease of the relative ratio Q
3
/Q
4
 for the samples LC-
1 to LC-4. It has to be noted that sample LC-4, thermally calcined in TOPO for 5 h at 275 °C, 
shows a similar Q
3
/Q
4
 area ratio as compared to sample LC-3, calcined at the same conditions 
at 400 °C. This indicates that a similar degree of silica condensation is already obtained at 
275 °C and no significant improvement is obtained by further increasing the temperature. In 
contrast, the microwave-calcined sample LC-8 shows no significant reduction of the Q
3
/Q
4
 
area ratio, thus indicating that the treatment with TOPO at only 200 °C for 2 h is not enough 
to improve the silica condensation. A reduction of the 
29
Si-MAS NMR peak area is also 
observed for the TOPO-calcined particles LC-5 and LC-6 starting from the unextracted ones 
(sample UN-CMS): the reduction of the Q
3
/Q
4
 area ratio is consistently higher as the 
temperature of TOPO treatment increases from 275 to 400 °C. It has to be noted that the ratio 
Q
4
/Q
3
 of the sample ex-CMS (template-containing MSNs) and sample UN-CMS (extracted 
MSNs) are quite similar, thus indicating that poor silica network condensation is retained 
using conventional solvent-extraction methods and that only a “liquid-calcination” procedure 
is able to consolidate the network of colloidal MSNs. Specifically, a consistent increase of the 
Q
4
 peak at -110 ppm [Q
n
 = Si(OSi)n(OH)4-n with n = 2-4, 4 representing the fully condensed 
silica] upon “liquid calcination” is observed with respect to the Q
3
 peak at -102 ppm (silica 
with one terminal hydroxyl group) in all HBS-calcined samples, except the MW-treated ones 
(only LC-8 is reported in Figure 3.1). We attribute the lower efficiency of the MW treatment 
to both its lower temperature (200 °C) and shorter time (2 h). For the two TOPO-calcined 
samples at 275 °C (sample LC-4) and 400 °C (LC-3), a similar Q
3
/Q
4
 ratio is obtained, thus 
indicating that no further increase of silica condensation is obtained above 275 °C. The 
highest Q
4
 fraction, implying the highest degree of silica condensation, was obtained upon 
calcination in squalene (LC-1). Air calcination at a still higher temperature (550 °C) can lead 
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to an even higher degree of condensation (sample calc- CMS); however, such a sample cannot 
be dispersed again as colloidal solution. Dynamic Light Scattering (DLS, Figure 3.2) shows 
that the colloidal stability in ethanol of all the MSNs is not affected after high-temperature 
treatment with HBS, and particle sizes do not change significantly as a result of different 
solvents and thermal treatments. 
 
Figure 3.2: Dynamic Light Scattering (DLS) measurements of as-synthesized (UN-CMS), template-
extracted (ex-CMS) and liquid-phase-calcined MSNs with TOPO (from LC-3 to LC-8), TOA (LC-2) and 
squalene (LC-1). For clarity reasons, the DLS measurements are shifted along the y-axis by 1.25 units. 
As previously mentioned, air-calcined MSNs are no longer able to form colloidal solutions. 
All the HBS-treated samples do not show any structural difference by X-ray diffraction; in 
particular no shift of the (100)-like reflection to higher angles is observed (Figure 3.4c). This 
indicates the absence of the unit cell shrinkage, in contrast to conventional air-calcined 
MSNs.
[24]
 Complete removal of TOPO by repetitive washing was confirmed by IR 
spectroscopy, whereas residual squalene and TOA are still present in both samples LC-1 and 
LC-2 (Figures 3.4 and 3.5). For this reason, the use of TOPO solvent is preferred with respect 
to squalene and TOA, even if the degree of silica condensation shown by 
29
Si-MAS NMR is 
slightly lower with TOPO treatments. The enhancement of silica condensation in combination 
with the template extraction ability of the TOPO treatment was investigated with the 
unextracted MSNs (UN-CMS), using the thermal calcination method. Indeed, the resulting 
sample LC-6 shows a strengthening of the silica network in 
29
Si-MAS NMR spectroscopy 
(Figure 3.1 and Table 3.1) and good colloidal stability in ethanolic solution with a 
homogeneous particle size distribution (Figure 3.2). TGA and IR spectroscopy show almost 
complete removal of the template (see Figure 3.8). The corresponding nitrogen sorption 
measurements (Figure 3.3) demonstrate that calcining unextracted MSNs in TOPO at 400 °C 
is as efficient as the solution-phase ethanol extraction method (see Table 3.2). 
3.2. Results and Discussion  
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Figure 3.3: Nitrogen sorption isotherms of the unextracted/TOPO-calcined MSNs (LC-5 and LC-6), 
compared to the template-extracted MSNs (ex-CMS) and extracted/TOPO-calcined MSNs (LC-3). The 
curves are shifted by 100 units each. 
However, calcination of the unextracted MSNs in TOPO at 275 °C (LC-5) is not sufficient to 
completely remove the template and to enhance the silica condensation as in the sample 
treated at 400 °C (LC-6). HBS-calcined CMS samples also exhibit a comparable porosity. 
The N2 sorption isotherms of the other HBS-treated samples are shown in Table 3.2. 
Table 3.2: Characterization of the Samples before and after HBS “Liquid-Calcination” Treatments. 
Sample 
BET surface area 
(m²/g) 
Pore volume
a
 
(cm³/g) 
DFT pore 
diameter
b
 (nm) 
DLS particle size
b
 
(nm) 
ex-CMS 978 0.78 3.9 59 
LC-1 918 0.71 3.5 51 
LC-2 968 0.76 3.8 59 
LC-3 1032 0.78 3.9 91 
LC-4 1052 0.80 3.9 106 
LC-5 928 0.60 3.5 68 
LC-6 998 0.77 3.9 106 
LC-7 850 0.75 3.9 59 
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LC-8 1087 0.83 3.8 106 
a
Pore volume was calculated only up to a pore size of 8 nm to remove the contribution of textural porosity. 
b
Referred to the peak value of the size distribution. 
Characterization of the MSNs after thermal liquid calcination (samples from LC-1 to 
LC-4) 
The high-boiling solvent (HBS) calcination was carried out thermally in reflux conditions for 
5 hours at 400 °C in squalene (LC-1), TOA (LC-2) and TOPO (LC-3) and at 275 °C in TOPO 
(LC-4). After repetitive washing to remove the residual HBS, as described in the 
Experimental section, the samples were characterized by nitrogen sorption measurements. 
Figure 3.4a compares the nitrogen sorption isotherms of the HBS calcination (from LC-1 to 
LC-4) with the starting template–extracted MSNs (ex-CMS). All the thermally calcined MSN 
samples retained their surface area and pore volume (see also Table 3.2). 
 
Figure 3.4: (a) Nitrogen sorption isotherms; (b) DFT pore size distributions; (c) small-angle XRD; and (d) 
infrared spectra for the thermal HBS-calcination at 400 °C with Squalene (LC-1), TOA (LC-2) and TOPO 
(LC-3) and at 275 °C in TOPO (LC-4), compared with ethanol-extracted MSNs (ex-CMS) and air-
3.2. Results and Discussion  
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calcined MSNs (calc-CMS in (c)). For clarity reasons, the nitrogen sorption isotherms in (a) are shifted 
along the y-axis by 100 units, the pore size distributions in (b) by 0.04 units, the XRD pattern in (c) by 
1500 units and the IR spectra in (d) by 0.03 units. 
Pore filling occurs at similar relative pressures in the type IV isotherms as for the initial 
particles (ex-CMS) and for both temperature of the TOPO calcination experiments, 400 and 
275 °C. Similarly, the DFT pore size distributions show only minor differences between the 
template-extracted MSNs (ex-CMS) and the TOPO calcinations at 400 (LC-3) and 275 °C 
(LC-4), showing mesopores of 3.9 nm (Figure 3.4b) In contrast, the squalene- and TOA-
calcined samples (LC-1 and LC-2 respectively) show a slight reduction of the DFT pore size 
distribution (3.5 for sample LC-1 and 3.8 for sample LC-2, see also Table 3.2). Small-angle 
X-ray diffraction shows that the first-order (100)-like reflection at 1.93°, diagnostic of the 
worm-like mesoporous structure, was maintained after thermal HBS-calcination (Figure 3.4c). 
It has to be noted that the (100)-like reflection at 1.93° of HBS-treated samples shows no shift 
to higher angles with respect to the ex-CMS nanoparticles. This indicates the absence of unit 
cell shrinkage, in contrast to the conventional air-calcined MSNs at 550 °C (calc-CMS), with 
a peak position at 2.28°. IR spectra were measured for the thermal HBS-calcined samples 
(from LC-1 to LC-4) and are shown in comparison to the template extracted one (ex-CMS, 
see Figure 3.4d). The spectra of all MSNs show strong vibrations typical of the silica 
framework at around 1240 – 1050 cm
-1
 (not shown here). In addition, for all samples small C-
H stretching modes at 2983, 2935 and 2904 cm
-1
 are observed, corresponding to the 
asymmetric CH3, asymmetric CH2, and symmetric CH3 stretch vibrations respectively of the 
ethoxy groups formed during the ethanolic template extraction.
[13]
 Similarly, C-H bending 
modes at 1396 and 1384 cm
-1
 are observed. After calcination with squalene (sample LC-1), 
additional C-H stretching bands at 2927 and 2854 cm
-1
 and –CH bending at 1459 and 
1381 cm
-1
 are observed. These bands correspond to the position of the alkyl vibrations of 
squalene,
[25]
 indicating that a small amount of squalene remains at the surface of sample LC-1 
after the repetitive washing. Thermogravimetry measurements (Figure 3.5a) on HBS-calcined 
samples in comparison with the template-extracted nanoparticles (ex-CMS) indeed show a 
higher weight loss for sample LC-1, treated with squalene, and sample LC-2, calcined with 
TOA. We assume that residual solvent, even after repetitive washing, is present in both 
samples. Figure 3.5b shows the scanning transmission electron microscopy (STEM) image 
detailing the small particle size and the worm-like mesoporous structure for the sample LC-4. 
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Figure 3.5: (a) Thermogravimetric measurements on thermal HBS-calcined samples (from LC-1 to LC-4) 
in comparison with the template extracted nanoparticles (ex-CMS); (b) STEM image of thermal TOPO-
calcined MSNs at 275 °C (LC-4). 
Characterization of the MSNs after microwave-assisted liquid calcination (samples LC-7 
and LC-8) 
Microwave-assisted calcinations of the template-extracted MSNs (ex-CMS) were only 
performed at 200 °C and conducted for thirty minutes and two hours. The nitrogen sorption 
isotherms (Figure 3.6a) show similar features for the 30 min microwave-calcined sample (LC-
7) and the 2 h microwave-calcined sample (LC-8) as compared to the starting MSNs (ex-
CMS). For both the thirty minutes (LC-7) and the two hour (LC-8) microwave-assisted 
calcinations the nitrogen sorption isotherm and DFT pore size distributions were similar to the 
initial MSNs (ex-CMS) (Figure 3.6a and b). 
3.2. Results and Discussion  
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Figure 3.6: (a) Nitrogen sorption isotherms; (b) DFT pore size distributions; (c) small-angle XRD; and (d) 
infrared spectra for the microwave-assisted TOPO calcinations at 200 °C for 30 min (LC-7) and 2 h (LC-
8) compared to the starting template-extracted MSNs (ex-CMS). For clarity reasons, the nitrogen sorption 
isotherms in (a) are shifted along the y-axis by 100 units, the pore size distributions in (b) by 0.02 units, 
the XRD pattern in (c) by 1000 units and the IR spectra in (d) by 0.03 units. 
The small-angle X-ray diffraction measurements (Figure 3.6c) show the retention of the 
worm-like nature of the pore structure, as evidenced by the (100)-like reflection after 
microwave calcination at 200 °C for either 30 minutes (LC-7) or 2 hours (LC-8). The calcined 
materials were studied by infrared spectroscopy (Figure 3.6d) and compared with the starting 
material, sample ex-CMS. The C-H stretching modes at 2983, 2935 and 2904 cm
-1
, 
corresponding to the asymmetric CH3, asymmetric CH2, and symmetric CH3 stretching 
vibrations respectively of the ethoxy groups formed during the ethanolic template 
extraction,
[13]
 are observed for the template-extracted sample ex-CMS, as well as for both the 
30 min (LC-7) and 2 h microwave-calcined (LC-8) samples. The lack of the C-H stretching 
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intensity at 3019, 2967, 2892 cm
-1
 assigned to TOPO,
[25]
 is indicative of efficient TOPO 
removal after the microwave calcination. Figure 3.7 shows the scanning transmission electron 
microscopy (STEM) image detailing the small particle size and the worm-like mesoporous 
structure for the sample LC-8. 
 
Figure 3.7: STEM image of 2 h microwave-assisted TOPO-calcined MSNs (LC-8). 
Characterization of the unextracted MSNs after thermal liquid calcination (samples LC-
5 and LC-6) 
It was of interest to determine whether the thermal calcinations that have been shown to 
increase the degree of silica condensation would simultaneously extract template from 
unextracted MSNs (UN-CMS); this would save a work-up step while preparing a more stable 
MSNs. Calcinations were done at 275 °C and 400 °C via the thermal method. From the 
nitrogen absorption isotherms (Figure 3.3) one can conclude that calcination in TOPO is as 
efficient as the solution-phase ethanolic template extraction, as similar surface areas and pore 
volumes are obtained. The DFT pore size distribution for sample LC-5 prepared from non-
extracted MSNs (UN-CMS) features slightly decreased values, due to a minimal residue of 
the template. Sample LC-6 shows a similar DFT pore size distribution as compared to the ex-
CMS sample. 
3.2. Results and Discussion  
 
66 
 
 
Figure 3.8: (a) DFT pore size distributions, (b) small angle XRD, (c) IR spectroscopy, and (d) 
thermogravimetric analysis (TGA) for the liquid-calcined MSNs with TOPO at 275 °C (LC-5) and 400 °C 
(LC-6) prepared from non-extracted particles (UN-CMS). For comparison the template-extracted non-
calcined MSNs (ex-CMS) are also shown. For clarity reasons, the pore size distributions in (a) are shifted 
along the y-axis by 0.03 units, the XRD patterns in (b) by 500 units and the IR spectra in (c) by 0.05 units. 
Small angle X-ray diffraction of both samples LC-5 and LC-6 shows an increase in intensity 
of the (100)-like reflection with respect to the UN-CMS pattern, as expected after the template 
removal from the mesopores. Only small shifts of the (100)-like reflection are observed for 
both samples LC-5 and LC-6, indicating only minor changes in the mesoporous structure 
(Figure 3.8b). Infrared spectroscopy was used to assess the removal of both the TOPO and of 
the template during the calcination step (Figure 3.8c). The spectrum of non-extracted MSNs 
(UN-CMS) shows the typical vibration modes of the CTAC template alkyl chains (C-H 
stretching at 2853 and 2925 cm
-1
 and a weaker band at 1480 cm
-1
). The absence of these 
stretching vibrations in the calcined particles (LC-5 and LC-6) indicates that the calcination in 
TOPO successfully removed most of the template. In addition, the absence of stretching 
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modes at 3019, 2967, 2892 cm
-1
 assigned to TOPO is indicative of efficient TOPO removal 
after thermal calcinations in both samples LC-5 and LC-6. At small intensities, C-H stretching 
modes at 2983, 2935 and 2904 cm
-1
 of ethoxy groups in both samples LC-5 and LC-6 are 
observed; they may be attributed to the repetitive washing steps in ethanol. Figure 3.8d 
illustrates the TGA profiles for both TOPO-calcined MSNs (LC-5 and LC-6) in comparison to 
the unextracted MSNs (UN-CMS) and the template extracted MSNs (ex-CMS). The first 
significant weight loss for the template-containing MSNs (UN-CMS) begins at around 
200 °C, corresponding to template loss, and results in a weight loss of about 55 wt%. For both 
samples LC-5 and LC-6 the initial 4-5% weight loss (up to about 100 °C) is attributed to 
physically adsorbed water at the MSN surface. The other weight loss occurs between 300 and 
600 °C, with a weight loss of 14 wt% for sample LC-5 calcined at 275 °C and of 10 wt% for 
sample LC-6, calcined at 400 °C. Similarly, the solvent extracted MSNs (ex-CMS) show a 
weight loss of 5 wt%, due to the loss of physisorbed water, occurring at 100 °C, and of 
10 wt% due to the decomposition of ethoxy groups and silanol condensation at temperatures 
above 300 °C. Therefore, no difference in weight loss is observed between the ex-CMS 
nanoparticles and sample LC-6, indicating in this last sample the complete removal of the 
template CTAC. The slight difference in weight loss (4 wt%) between the extracted sample 
(ex-CMS) and the TOPO-calcined MSNs at 275 °C(LC-5) could be mainly attributed to 
residual CTAC template due to the lower temperature used during the TOPO-treatment. 
3.3 Conclusion 
Summari ing, we describe a novel “liquid calcination” method for preparing highly 
condensed mesoporous silica nanoparticles that form stable colloidal suspensions. The MSNs 
calcined in high-boiling solvents (HBS) retain their original pore size, experience no unit cell 
shrinkage or particle agglomeration, and exhibit a significant decrease in silanol content. The 
thermal liquid calcination of unextracted MSNs in TOPO at 400 °C produces calcined MSNs 
with similar characteristics compared to the MSNs obtained from the liquid calcination of 
extracted MSNs; the surface area, pore volume, pore sizes, particle sizes, pore morphology 
and degree of silica condensation are all comparable. The high degree of condensation and the 
resulting stability will open up new fields of application for colloidal mesoporous 
nanoparticles. 
3.4. Experimental  
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3.4 Experimental 
3.4.1 Synthesis of MSNs 
A mixture of 14.2 g (95.6 mmol) of triethanolamine (TEA, Aldrich, 98%) and 1.92 g 
(9.22 mmol) of tetraethyl orthosilicate (TEOS, Fluka, >98%) was heated for 20 minutes at 
90 °C without stirring in a 100 mL polypropylene reactor (Solution 1). Meanwhile, a mixture 
(Solution 2) of 2.41 mL (7.29 mmol) of cetyltrimethylammonium chloride (CTAC, Fluka, 
25 wt% in H2O) and 21.7 g (1.21 mol) of bi-distilled water from a Millipore system (Milli-Q 
Academic A10) was heated at 60 °C and then added to the Solution 1. The resulting mixture, 
having a molar composition of 1 TEOS: 0.20 CTAC: 10.4 TEA: 130.2 H2O, was then stirred 
(500 rpm) at room temperature overnight. After addition of 100 mL ethanol, the UN-CMS 
nanoparticles were separated by centrifugation (19.000 rpm, 43.146 RCF, 20 min) and 
redispersed in ethanol. The MSN concentration was determined by drying and weighing a 
known volume of the colloidal suspension. 
3.4.2 Template Extraction 
Extraction of the organic template from the mesoporous silica nanoparticles (UN-CMS) was 
performed by heating the colloidal suspension for 45 minutes under reflux (90 °C oil bath) in 
100 mL of an ethanolic solution containing 2 g ammonium nitrate, followed by 45 minutes 
under reflux in a solution of 10 mL of concentrated hydrochloric acid and 90 mL absolute 
ethanol. The MSNs were then separated by centrifugation (19.000 rpm, 43.146 RCF, 30 min). 
The material was washed with ethanol after each extraction step. Ex-CMS materials were then 
redispersed in absolute ethanol, obtaining clear ethanolic colloidal suspensions. 
3.4.3 Thermal Liquid-Phase Calcination 
100 mg of the unextracted (UN-CMS) or the template-extracted MSNs (ex-CMS) in ethanolic 
suspension were respectively added to 7 g of molten trioctylphosphine oxide (TOPO), 10 mL 
of squalene or 10 mL of tri-n-octylamine (TOA) in a round bottom flask equipped with a 
reflux condenser. The ethanol was separated from the solution under vacuum (175 mbar at 
60 °C). The solution was heated to 275 °C or 400 °C using a silicon carbide (SiC) grain bath 
under a nitrogen atmosphere and the solution was maintained at this temperature for 5 h. At 
the end of this period, the solutions were cooled to 50 °C where TOPO is still liquid (whereas 
squalene and TOA are liquid also at RT), and 10 mL of absolute ethanol was added. The 
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ethanol solutions were centrifuged (19.000 rpm, 43.146 RFC, 20 min) to isolate the particles, 
which were then rinsed with ethanol, redispersed in 100 mL ethanol and centrifuged again 
under the same conditions. This process was repeated for a total of five times, in order to 
remove the residual high-boiling-point solvents. After the final centrifugation the particles 
were resuspended in absolute ethanol. 
For comparison, air-calcined MSNs were also prepared starting from the template-extracted 
ones (sample ex-CMS). This calc-CMS sample was heated in air to 550 °C for 7 h with a 
heating rate of 1,5 °C/min. 
3.4.4 Microwave-Assisted Liquid-Phase Calcination 
The amount of 100 mg of the template-extracted MSNs (ex-CMS) in ethanol was added to 7 g 
of molten TOPO in a 20 mL microwave-compatible vial. The ethanol was separated from the 
solution under vacuum (175 mbar at 60 °C). The solution was stirred and heated at 200 °C by 
means of microwave irradiation for two different times: 30 min (LC-7) and 120 min (LC-8). 
The solution was allowed to cool to 50 °C and was diluted with 10 mL absolute ethanol. The 
ethanolic solution was centrifuged (19.000 rpm, 43.146 RCF, 20 min) to isolate the particles, 
which were then rinsed with ethanol, redispersed in 100 mL ethanol and centrifuged again 
under the same conditions. This process was repeated for a total of five centrifugations. After 
the final centrifugation the particles were resuspended in absolute ethanol. 
3.4.5 Characterization 
All MSN samples were characterized by nitrogen sorption measurements, performed on a 
Quantachrome Instruments NOVA 4000e at -196 °C. Sample outgassing was performed at 
120 °C for 12 hours at a vacuum of 10 mTorr. Pore size and pore volume were calculated 
using a NLDFT equilibrium model of N2 on silica, based on the desorption branch of the 
isotherm. A BET model was used in the range of 0.05 – 0.20 p/p0 to estimate the specific 
surface area. Dynamic light scattering (DLS) measurements were carried out on ~1 mg/mL 
ethanolic colloidal solutions using a Malvern Zetasizer-Nano instrument with a 4 mW He-Ne 
laser (633 nm) with an avalanche photodiode detector. Thermogravimetric analyses (TGA) of 
the bulk samples (about 10 mg of powder dried at 60 °C) were performed on a Netzsch STA 
440 Jupiter thermobalance with a heating rate of 10 °C/min in a stream of synthetic air of 
about 25 mL/min. X-ray diffraction patterns were collected on solid samples at small angles 
on a Bruker D8 Discover with Ni-filtered Cu-Kα radiation and a position-sensitive detector 
(Vantec). Single pulse 
29
Si-MAS solid-state NMR measurements were performed on a Bruker 
3.5. Appendix  
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DSX Advance500 FT spectrometer in a 4 mm ZrO2 rotor at a frequency of 50 MHz. Infrared 
spectra were collected on a Bruker Equinox 55 operating under attenuated total reflectance 
(ATR) (spectra were background subtracted). For scanning transmission electron microscopy 
(STEM) at 300 kV using a Titan 80-300 kV microscope, samples were prepared by adding 3 
drops of the ethanolic MSN suspension (~3 wt%) to 4 mL absolute EtOH and drying of a drop 
of the resulting diluted colloidal suspension on a carbon-coated copper grid. 
3.5 Appendix 
Table 3.3: Quantification of the Q
3
/Q
4
 area ratio deconvolved by Gaussian/Lorentzian fitting using 
Deconv2Dxy software.
[23]
 The values for the shift, area and width of both peaks (Q
3
 and Q
4
) are obtained 
from 
29
Si-MAS NMR spectra. 
Sample Shift (ppm) Area (a.u.) Width (ppm) Chi² Q
3
/Q
4
 
UN-CMS 
-101 
-109 
2.62*10
6
 
2.42*10
6
 
8.42 
8.13 
0.0473 1.08 
ex-CMS 
-102 
-110 
1.65*10
6
 
1.61*10
6
 
7.47 
6.68 
0.0401 1.02 
LC-1 
-102 
-110 
2.89*10
6
 
3.83*10
6
 
10.3 
9.60 
0.0481 0.755 
LC-2 
-103 
-110 
2.99*10
6
 
3.76*10
6
 
8.82 
8.09 
0.0664 0.795 
LC-3 
-103 
-110 
3.99*10
6
 
4.89*10
6
 
9.23 
7.55 
0.0160 0.816 
LC-4 
-102 
-110 
3.10*10
6
 
3,87*10
6
 
8.85 
9.19 
0.0264 0.801 
LC-5 
-103 
-110 
4.21*10
6
 
4.03*10
6
 
8.89 
7.52 
0.0182 1.04 
LC-6 
-103 
-110 
3.83*10
6
 
4.21*10
6
 
11.7 
8.59 
0.0540 0.910 
LC-8 
-102 
-110 
4.00*10
6
 
3.97*10
6
 
9.01 
8.06 
0.0399 1.01 
calc-CMS 
-102 
-110 
3.22*10
6
 
5.87*10
6
 
9.51 
9.06 
0.0142 0.549 
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Figure 3.9: Deconvolution results of the Q
3
 and Q
4
 peaks from 
29
Si-MAS NMR measurements of the 
samples: (a) UN-CMS (unextracted MSNs); (b) ex-CMS (solvent extracted MSNs); (c) LC-1 (thermal 
squalene-calcined extracted MSNs at 400 °C for 5 h); (d) LC-2 (thermal TOA-calcined extracted MSNs at 
400 °C for 5 h); (e) LC-3 (thermal TOPO-calcined extracted MSNs at 400 °C for 5 h); (f) LC-4 (thermal 
TOPO-calcined extracted MSNs at 275 °C for 5 h); (g) LC-5 (thermal TOPO-calcined unextracted MSNs 
at 275 °C for 5 h); (h) LC-6 (thermal TOPO-calcined unextracted MSNs at 400 °C for 5 h); (i) LC-8 
(microwave-assisted TOPO-calcined extracted MSNs at 200 °C for 2 h); and (j) calc-CMS (air-calcined 
extracted MSNs at 550 °C for 7 h). 
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4 Superparamagnetic Nanocomposites with Multifunctional Mesoporous 
Silica Shells 
 
 
4.1 Introduction 
Magnetic nanocomposites consisting of magnetic cores and mesoporous silica shells have 
been extensively studied in the past decade, both in terms of precise control over the synthesis 
and appropriate applications.
[1-3]
 These magnetic nanoparticles have a wide range of 
applications including magnetic resonance imaging (MRI), hyperthermia treatment, and 
targeted drug delivery, since they combine different advantageous properties in one 
multifunctional nanocomposite.
[4-5]
 Their characteristics enable magnetic separation and 
targeting, surface modification, and high cargo loading capacity along with high chemical 
stability and biocompatibility.
[6-8]
 An on-demand magnetic behavior can be achieved by 
employing magnetic nanocrystals (NCs) as a core. For example, nano-sized iron oxide 
particles consisting of only one single crystal domain (diameter < 20 nm) exhibit 
superparamagnetic properties. Such NCs do not have permanent magnetic moments but allow 
for targeting of biological objects, such as tissues or organs, by exposure to an external 
magnetic field.
[9-10]
 Various synthesis strategies including thermal decomposition,
[11-12]
 co-
precipitation,
[13-14]
 and hydrothermal approaches
[15-16]
 have resulted in various precisely 
tunable magnetic properties, morphologies and structural phases such as cubic magnetite 
(Fe3O4) or maghemite (γ-Fe2O3) exhibiting an inverse spinel structure. Today, coated 
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superparamagnetic iron oxide NCs are widely used in biomedical applications, particularly as 
contrast agents for MRI.
[17-18]
 A coating with a mesoporous silica shell provides protection 
against fast degradation and improved dispersibility in biological fluids due to prevention of 
aggregation, accompanied by the ability to create functionalized surfaces and storage 
characteristics for cargo molecules.
[19]
 In 2008, Hyeon and coworkers first reported the 
synthesis of magnetic NCs coated with fluorescently labeled mesoporous silica shells that 
were utilized as drug nanocarriers.
[20]
 Surfactants such as cetyltrimethylammonium bromide 
(CTAB) simultaneously perform two different tasks in this synthesis approach. First, these 
molecules permit transfer of the hydrophobic NCs to the aqueous phase via a ligand-exchange 
process. Secondly, the surfactant molecules act as a template for the subsequent sol-gel 
reaction of the silica source creating mesoporous silica shells around the magnetic NCs. 
Nanovehicles with magnetic cores based on mesoporous silica can respond to an external 
magnetic field and feature high surface area and pore volume, along with the ability to 
implement functional groups which makes them promising candidates for controlled drug 
delivery.
[21-23]
 These multifunctional magnetic silica nanocomposites designed for 
magnetically targeted cell uptake and drug delivery in combination with imaging capabilities 
have already been synthesized and in vitro and in vivo investigations have been performed 
before.
[19-20]
 However, the imaging and targeting performance of many magnetic 
nanocomposites is seriously affected by only low magnetization due to high non-magnetic 
silica content.
[24-25]
 The magnetic properties can be improved by doping the iron oxide NCs, 
for instance with Zn
2+
 and Mn
2+
 ions, resulting in ferrite nanoparticles which offer precisely 
tunable and high magnetization values.
[26-28]
 
Here, we report on a new synthesis strategy to create multifunctional mesoporous silica 
nanoparticles (MSNs) consisting of a superparamagnetic Zn-doped manganese ferrite core. 
The mesoporous silica shell itself consists of several compartments enclosing functional 
groups for further modification. An inner functional pore modification allows for hosting 
cargo molecules and fluorescent labels, and an external functional layer offers selective 
grafting of required organic molecules such as stabilizing agents or targeting ligands. These 
magnetic nanocomposites hold promise as drug nanocarrier systems providing physical 
targeting capability in an external magnetic field. Moreover, they can additionally serve as 
imaging agents for magnetic resonance and fluorescence imaging. 
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4.2 Results and Discussion 
Magnetic nanocomposites based on mesoporous silica nanoparticles have been synthesized in 
two steps. First, a one-pot thermal decomposition procedure resulted in zinc-doped 
manganese ferrite NCs (Zn-MnFe NCs), as previously described.
[26]
 In brief, the precursors 
iron(III) acetylacetonate (Fe(acac)3), zinc chloride (ZnCl2) and manganese chloride (MnCl2) 
were dissolved in octylether. By addition of oleic acid and oleylamine which serve as capping 
agents, the particle growth can be limited. The reaction mixture was heated to 300 °C for 1 h 
under nitrogen atmosphere and dark-brown NCs were subsequently collected by 
centrifugation. Dynamic light scattering (DLS) measurements feature an average particle size 
of 10 nm with narrow particle size distribution and no agglomeration could be observed in 
toluene (Figure 4.1). 
 
Figure 4.1: Dynamic light scattering (DLS) measurement of Zn-doped manganese ferrite nanocrystals 
(Zn-MnFe NCs). 
Transmission electron micrographs (TEM) provide information about morphology, size and 
crystallinity of the ferrite NCs (Figure 4.2 a). The NCs consist of single crystal domains with 
an average size of about 8 nm. The lattice fringes of a single NC embedded in silica can be 
clearly seen in a high resolution TEM (HRTEM) image (Appendix 4.5). Crystallinity is 
further proven by selected area electron diffraction (SAED) (inset Figure 4.2 a). The doping 
of the manganese ferrite NCs with zinc ions can be confirmed by energy dispersive X-ray 
(EDX) analysis (Figure 4.2 b). The additional content of copper belongs to the sample holder 
for TEM specimen consisting of a carbon-coated copper grid. 
4.2. Results and Discussion  
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Figure 4.2: (a) Transmission electron micrograph of Zn-doped manganese ferrite NCs. The inset shows a 
SAED pattern proving crystallinity of the sample. (b) Energy dispersive X-ray (EDX) analysis of the 
sample Zn-MnFe. 
Further information about the crystallinity of the ferrite nanoparticles can be obtained by X-
ray diffraction (XRD) measurements. The XRD pattern in Figure 4.3a was collected with Cu-
Kα radiation and show several distinct reflections. Due to fluorescent interference of the 
ferrite NCs with the Cu-Kα radiation, a low signal-to-noise ratio is obtained. Therefore, 
another diffractogram (Figure 4.3b) was recorded with Co-Kα radiation. Both XRD patterns 
showed the formation of crystalline Zn-MnFe material. A Scherrer calculation suggests a 
crystalline domain size of about 9 nm. Since the sizes of the nanoparticles obtained from DLS 
measurements and TEM images are also on this scale, the synthesized NCs consist of only 
one single crystalline domain. This is an important requirement for superparamagnetism. Only 
nanoparticles sizes smaller than 20 nm exhibit superparamagnetic properties.
[29]
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Figure 4.3: X-ray Diffraction (XRD) patterns of Zn-doped manganese ferrite nanocrystals (Zn-MnFe) 
performed (a) with Cu-Kα radiation and (b) with Co-Kα radiation. 
Vibrational spectroscopy gives information about organic compounds within the sample. 
Oleic acid and oleylamine was used during the synthesis procedure to limit the particle 
growth by forming an organic capping shell around single NCs. Their existence in the Zn-
MnFe sample can be observed by infra-red (IR) spectroscopy (Figure 4.4a). Distinct bands at 
2923 and 2854 cm
-1
 can be assigned to the characteristic C-H stretching vibration of the alkyl 
chains of both capping agents. The characteristic band for the C=O stretching vibration of 
carboxyl groups is shifted to lower wavenumbers (1589 cm
-1
). This significant shift can be 
attributed to the coordination of the carboxy groups to iron or manganese metal centers at the 
interface of the NCs. Additional bands at 3205 cm
-1
 (broad, N-Hstr), 2422 and 2167 cm
-1
 
(C=Cstr), 1411 cm
-1
 (N-Hdef), and 910 cm
-1
 (C-Hdef) further prove the presence of oleylamine 
and oleic acid in the ferrite NC sample. 
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Figure 4.4: Infrared spectroscopy data of Zn-doped manganese ferrite nanocrystals (Zn-MnFe). 
The magnetization behavior of the ferrite NCs can be obtained with a superconducting 
quantum interference device (SQUID). The measurement of magnetic properties showed that 
the sample is superparamagnetic at room temperature (300 K). The field-dependent 
magnetization curve of the sample Zn-MnFe showed quick magnetization in an external 
magnetic field (10 kOe) with saturation magnetization values of about 200 emu/g (Figure 
4.5). In comparison, for superparamagnetic iron oxide nanoparticles magnetization values of 
only about 50 emu/g can be obtained.
[29]
 Doping with zinc ions efficiently modulates the 
manganese ferrite NCs resulting in 4-fold improved magnetization properties. The absence of 
a hysteresis proves the absence of remanence of magnetization and indicates a 
superparamagnetic character of the Zn-MnFe NCs. 
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Figure 4.5: Superconducting quantum interference device (SQUID) data of superparamagnetic Zn-doped 
manganese ferrite nanocrystals (Zn-MnFe). 
The second step to create magnetic nanocomposites with functionalized mesoporous silica 
shells was performed via a sol-gel synthesis approach. Before generating a mesoporous silica 
shell around the NCs, a phase transfer of the ferrite NCs capped with organic ligands from the 
organic phase to the aqueous phase was needed. This transfer was achieved by addition of a 
surfactant (cetyltrimethylammonium chloride, CTAC) following a previously described 
method.
[20]
 The ferrite NCs dispersed in chloroform were mixed with an aqueous solution of 
CTAC to gain water-dispersibility (Figure 4.6). 
 
Figure 4.6: Phase transfer of Zn-doped manganese ferrite nanocrystals (Zn-MnFe, brown) with surfactant 
molecules (CTAC) from A) chloroform (oleate-capped NCs) to B) aqueous solution (CTAC-stabilized 
NCs). 
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This emulsion was sonicated and the organic solvent was evaporated at elevated temperatures 
(70 °C). An excess of CTAC additionally served as a template in the following silica 
condensation reaction to form an outer mesoporous silica shell. For a heterogeneous 
nucleation to create magnetic cores and mesoporous silica shells, it was very important to 
avoid agglomeration of the ferrite NCs. We found intensive sonication to be essential to 
obtain monodispersed nanocrystals which can serve as nucleation seeds for the silica 
framework. Triethanolamine (TEA) was added as base catalyst for the hydrolysis of the silica 
precursor tetraethyl orthosilicate (TEOS) together with various organoalkoxysilanes. 
Simultaneously, TEA served as a stabilizing agent lowering the condensation rate to create 
particles at the nanoscale. A stepwise addition of silica precursors in small portions resulted in 
functionalized silica shells in a layer-by-layer manner. By using a delayed co-condensation 
approach, which has been established in our group for core-shell functionalized MSNs,
[30]
 we 
were able to create separate silica shells in the particles, bearing different functional groups in 
an onion-like structure. In the present work, we synthesized three different magnetic 
nanocomposite constructs, namely Zn-MnFe@MSN-NH2 OUT, Zn-MnFe@MSN-Ph/NH2 IN, 
and Zn-MnFe@MSN-SHIN-NH2 OUT. Ethanolic extraction with ammonium nitrate was carried 
out to remove the organic template, thus obtaining an accessible mesoporous system. 
DLS measurements showed an average particle size of about 106 nm and a narrow particle 
size distribution for all samples (cf. Table 4.1 and Appendix 4.5). No agglomeration occurred 
in ethanolic suspensions. All samples showed good colloidal stability. TEM images provide 
information about the morphology and structure of the nanocomposite systems (Figure 4.7). A 
typical mesoporous worm-like structure of spherically shaped nanoparticles with integrated 
magnetic cores could be observed for all samples. The mesoporous channels are clearly 
visible with near radial alignment. Small nanoparticles (about 8 nm) with higher contrast that 
were embedded in the center of the silica particles could be identified as crystalline magnetic 
ferrite NCs (Appendix 4.5). The total size of the nanocomposite particles ranges from 50 – 
80 nm depending on the number of integrated magnetic NCs. All samples feature 
homogeneous morphology and distribution of magnetic cores. For all samples only a small 
number of encapsulated cores (1 – 5) have been observed. Additionally, scanning TEM 
(STEM) images provide an even better contrast of the different composites of the samples 
(Appendix 4.5). 
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Figure 4.7: Transmission electron micrographs of magnetic nanocomposites. (a) Zn-MnFe@MSN-
NH2 OUT, (b) Zn-MnFe@MSN-Ph/NH2 IN and (c) Zn-MnFe@MSN-SHIN-NH2 OUT (blue). 
Nitrogen sorption measurements give information about the porosity of the silica shell. For all 
samples, a typical type IV isotherm with inflection points at around 0.3 p/p0 could be 
observed indicating a mesoporous structure. Interparticle textural porosity is shown for all 
samples by a second hysteresis loop at partial pressures of about 0.9 p/p0. All samples feature 
high BET surface area, high pore volume, and a defined pore size distribution (Table 4.1). 
The DFT pore size distribution exhibits an average pore size of 4.3 nm for all samples. 
 
Figure 4.8: (a) Nitrogen sorption isotherms and (b) pore size distribution of magnetic nanocomposites. Zn-
MnFe@MSN-NH2 OUT (red), Zn-MnFe@MSN-Ph/NH2 IN (green) and Zn-MnFe@MSN-SHIN-NH2 OUT 
(blue). 
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Table 4.1: Structural parameters of magnetic nanocomposites. 
Sample 
Particle size
a
         
(nm) 
BET surface 
area (m²/g) 
Pore volume
b
 
(cm³/g) 
Pore size
c
 
(nm) 
Zn-MnFe@MSN-NH2 OUT 106 860 0.72 4.3 
Zn-MnFe@MSN-Ph/NH2 IN 106 800 0.67 4.3 
Zn-MnFe@MSN-SHIN-NH2 OUT 106 930 0.80 4.3 
a
Average particle size refers to the peak value of the particle size distribution derived from DLS measurements; 
b
Pore volume is calculated up to a pore size of 8 nm to remove the contribution of interparticle porosity; 
c
DFT 
pore size refers to the peak value of the pore size distribution. 
The existence of functional groups in the samples can be confirmed with Raman spectroscopy 
(Figure 4.9a). The sample Zn-MnFe@MSN-SHIN-NH2 OUT shows a characteristic band at 
2585 cm
-1
 (#), which can be assigned to thiol groups (S-H stretching vibration). Bands at 
3060 cm
-1
 (*) (C-H stretching vibration of aromatic rings) and 999 cm
-1
 (*) (C-H deformation 
vibration of aromatic rings) are typical for the phenyl groups of the nanoparticles Zn-
MnFe@MSN-Ph/NH2 IN. All samples show additional bands at 2980, 2936 and 2899 cm
-1
, 
which indicate C-H stretching vibration modes deriving from alkyl chains including ethoxy 
groups of the silica framework and capping agents of the ferrite NCs (oleic acid, oleylamine, 
CTAC). Amino groups can barely be detected since they feature only characteristic bands 
similar to hydroxyl groups which are also abundant in our nanocomposite materials. Data 
derived from IR spectroscopy show typical bands of the silica framework appearing at 1245 – 
1050 cm
-1
 which can be assigned to asymmetric stretching vibration of Si-O-Si. Two 
additional bands at 965 cm
-1
 and 795 cm
-1
 for the asymmetric bending and stretching 
vibration of Si-OH are dominantly present in all samples. Complementary to Raman 
spectroscopy, the bands for the C-H stretching vibration (2981 – 2904 cm
-1
) and the C-H 
bending vibration (1446 cm
-1
) of alkyl groups were obtained. 
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Figure 4.9: (a) Raman and (b) IR spectroscopy data of magnetic nanocomposites: Zn-MnFe@MSN-
NH2 OUT (red), Zn-MnFe@MSN-Ph/NH2 IN (green) and Zn-MnFe@MSN-SHIN-NH2 OUT (blue). For clarity 
reasons, the curves for Raman spectroscopy are shifted along the y-axis by 1.0 units and for IR 
spectroscopy by 0.1 units. 
The zeta potential of the nanoparticles is dependent on the pH value of the aqueous solution. 
Zeta potential measures the surface charge of nanoparticles which provides information about 
functional groups at the external particle surface. Positive surface charge refers to protonated 
amino groups in an acidic milieu. The samples Zn-MnFe@MSN-NH2 OUT and Zn-
MnFe@MSN-SHIN-NH2 OUT show highly positive zeta potential values over the whole acidic 
pH range. The isoelectric point (IEP) is around pH 6.5 for both samples featuring amino 
groups at the outer particle surface. Sample Zn-MnFe@MSN-Ph/NH2 IN features a more 
neutral surface charge which is comparable to unfunctionalized MSNs (data not shown). 
Here, a significant shift of the IEP to lower pH values (4.6) can be observed. Only hydroxyl 
groups are present at the particle surface leading to a more negative surface charge when 
deprotonation occurs. The phenyl and amino groups need to be located at the inner part of the 
silica shell and are not able to influence the zeta potential of these nanoparticles. We assume 
that only for the samples Zn-MnFe@MSN-NH2 OUT and Zn-MnFe@MSN-SHIN-NH2 OUT the 
amino groups are located at the outer surface of the nanocomposite materials. 
4.2. Results and Discussion  
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Figure 4.10: Zeta potential titrations of magnetic nanocomposites. Zn-MnFe@MSN-NH2 OUT (red), Zn-
MnFe@MSN-Ph/NH2 IN (green) and Zn-MnFe@MSN-SHIN-NH2 OUT (blue). 
To prove the physical targeting ability of our magnetic samples, the nanoparticles were 
exposed to an external magnetic field. As depicted in Figure 4.11 the sample Zn-
MnFe@MSN-NH2 OUT can be collected by a magnet from a well-dispersed aqueous solution. 
 
Figure 4.11: Magnetic nanocomposite particles (sample Zn-MnFe@MSN-NH2 OUT) (a) colloidally 
dispersed in an aqueous solution (b) can be collected by applying an external magnetic field (magnet). 
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4.3 Conclusion 
From the above data, we conclude the successful synthesis of superparamagnetic Zn-doped 
manganese ferrite NCs, which have been incorporated into multifunctional mesoporous silica 
nanoparticles as a magnetic core. Different functional silica shells can be created following a 
delayed co-condensation approach. In the future, a more precise characterization of the 
location of the functional groups within the silica shell could be performed by quenching 
experiments with gold colloids (<5 nm) and dye molecules which are covalently attached to 
the amino groups. Furthermore, the formation of iridium clusters at the location of amino 
groups can be investigated by tomography analysis, as has already been shown for colloidal 
MSNs in our group.
[31]
 The combination of superparamagnetic NCs with a multifunctional 
mesoporous silica shell may enable the generation of an integrated system for imaging-
guided, physically targeted drug delivery that comprises functions for triggered drug release at 
the targeted site. 
4.4 Experimental 
Materials. Iron(III) acetylacetonate (Fe(acac)3, Aldrich, 97 %), zinc(II) chloride (ZnCl2, 
Merck) manganese(II) chloride (MnCl2, Merck), octylether (Aldrich, 99%), tetraethyl 
orthosilicate (TEOS, Fluka, > 99 %), triethanolamine (TEA, Aldrich, 98 %), 
cetyltrimethylammonium chloride (CTAC, Fluka, 25 % in H2O), (3-aminopropyl)-
triethoxysilane (APTES, ABCR, 96 %), (3-mercaptopropyl)-triethoxysilane (MPTES, ABCR, 
> 92 %), (3-phenyl)-triethoxysilane (PTES, Sigma, > 98 %), ammonium nitrate, were used as 
received. Absolute ethanol (EtOH, Aldrich), chloroform (CHCl3, Aldrich) and toluene 
(Aldrich) were used as solvents without further purification. Bidistilled water was obtained 
from a Millipore system (Milli-Q Academic A10). Oleic acid (Alfa Aesar, 90 %) and 
oleylamine (Aldrich, 70 %) were freshly distilled prior to use. 
Synthesis of superparamagnetic ferrite nanocrystals. Zn-doped MnFe NCs were 
synthesized following a thermal decomposition process as previously described.
[26]
 In brief, 
0.353 g (1.00 mmol) Fe(acac)3, 30.0 mg (0.220 mmol) ZnCl2 and 63.3 mg (0.320 mmol) 
MnCl2 were placed in a 50 mL three-neck flask equipped with a refluxer under nitrogen 
atmosphere. 2.00 mL oleic acid, 4.00 mL oleylamine and 2.06 mL octylether were added and 
the reaction mixture was heated to 300 °C (SiC bath) for 1 h. The reaction mixture was cooled 
to room temperature and absolute ethanol was added. The resulting nanoparticles were 
4.4. Experimental  
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washed three times with a mixture of toluene and ethanol (1:9) by centrifugation (10 min, 
15,000 rpm, 26,892 rcf) and finally redispersed in 15 ml toluene. 
Synthesis of multifunctional nanocomposites. 
Fe3O4@MSN-NH2 OUT. Prior to the sol-gel reaction, the ferrite NCs were transferred form the 
organic phase to the aqueous phase. 30 mg of ferrite NCs were dispersed in 10 mL chloroform 
and placed in a polypropylene reactor. 21.7 g H2O and 2.41 mL of aqueous CTAC solution 
(25 wt%) was added generating a second phase. The mixture was sonicated for 15 min (60 % 
of continuous power (250 W), frequency 20 KHz) using a sonication horn and subsequently 
the chloroform was evaporated at elevated temperatures (70 °C) for 2 h. After a second 
sonication step lasting 15 min, the mixture was added to 14.3 g TEA and stirred (700 rpm) at 
60 °C. The silica source TEOS (10-times 155 µL, 692 µmol) was added stepwise every 
10 min over a total time period of 90 min at constant temperature of 60 °C. After 30 min of 
stirring, a mixture of TEOS (20.5 µL, 92.2 µmol) and APTES (21.5 µL, 92.2 µmol) was 
added and the synthesis mixture was stirred at 1000 rpm at room temperature for 12 hours. 
After addition of ethanol (100 mL), the Zn-MnFe@MSNs were separated by centrifugation 
(19.000 rpm, 43.146 RCF.for 20 min) and redispersed in ethanol. The template extraction was 
performed twice by heating the Zn-MnFe@MSN suspension under reflux at 90 °C (oil bath) 
for 45 min in an ethanolic solution (100 mL) containing ammonium nitrate (2 g). The Zn-
MnFe@MSNs were purified by centrifugation and washed with ethanol after each extraction 
step. The resulting nanoparticles were stored in an ethanolic solution. 
Fe3O4@MSN-Ph/NH2 IN. 30 mg of ferrite NCs were dispersed in 10 mL chloroform and 
placed in a polypropylene reactor. 21.7 g H2O and 2.41 mL of aqueous CTAC solution 
(25 wt%) was added generating a second phase. The mixture was sonicated for 15 min using a 
sonication horn and subsequently the chloroform was evaporated at elevated temperatures 
(70 °C) for 2 h. After a second sonication step for 15 min, the mixture was added to 14.3 g 
TEA and stirred (700 rpm) at 60 °C. The silica source TEOS (147 µL, 658 µmol) was added 
and the reaction mixture was stirred for 10 min. Subsequently, a mixture of TEOS (5-times 
147 µL, 658 µL), APTES (5-times 8.1 µL, 34.6 µmol) and PhTES (5-times 8.4 µL, 
34.6 µmol) was added stepwise every 10 min over a total time period of 40 min at constant 
temperature of 60 °C. Afterwards, TEOS (4-times 147 µL, 658 µmol) was added stepwise 
every 10 min and finally the synthesis mixture was stirred at 1000 rpm at room temperature 
for 12 hours. After addition of ethanol (100 mL), the Zn-MnFe@MSNs were separated by 
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centrifugation (19.000 rpm, 43.146 RCF.for 20 min) and redispersed in ethanol. The template 
extraction was performed twice by heating the Zn-MnFe@MSN suspension under reflux at 
90 °C (oil bath) for 45 min in an ethanolic solution (100 mL) containing ammonium nitrate 
(2 g). The Zn-MnFe@MSNs were purified by centrifugation and washed with ethanol after 
each extraction step. The resulting nanoparticles were stored in an ethanolic solution. 
Fe3O4@MSN-SHIN-NH2 OUT. 30 mg of ferrite NCs were dispersed in 10 mL chloroform and 
placed in a polypropylene reactor. 21.7 g H2O and 2.41 mL of aqueous CTAC solution was 
added generating a second phase. The mixture was sonicated for 15 min using a sonication 
horn and subsequently the chloroform was evaporated at elevated temperatures (70 °C) for 
2 h. After a second sonication step for 15 min, the mixture was added to 14.3 g TEA and 
stirred (700 rpm) at 60 °C. The silica source TEOS (147 µL, 658 µmol) was added and the 
reaction mixture was stirred for 10 min. Subsequently, a mixture of TEOS (5-times 147 µL, 
658 µL) and MPTES (5-times 16.7 µL, 69.2 µmol) was added stepwise every 10 min over a 
total time period of 40 min at constant temperature of 60 °C. Then, TEOS (4-times 147 µL, 
658 µmol) was added stepwise every 10 min. After 30 min of stirring, a mixture of TEOS 
(20.5 µL, 92.2 µmol) and APTES (21.5 µL, 92.2 µmol) was added and finally the synthesis 
mixture was stirred at 1000 rpm at room temperature for 12 hours. After addition of ethanol 
(100 mL), the Zn-MnFe@MSNs were separated by centrifugation (19.000 rpm, 43.146 RCF 
for 20 min) and redispersed in ethanol. The template extraction was performed twice by 
heating the Zn-MnFe@MSN suspension under reflux at 90 °C (oil bath) for 45 min in an 
ethanolic solution (100 mL) containing ammonium nitrate (2 g). The Zn-MnFe@MSNs were 
purified by centrifugation and washed with ethanol after each extraction step. The resulting 
nanoparticles were stored in an ethanolic solution. 
Characterization. DLS and zeta potential measurements were performed on a Malvern 
Zetasizer Nano instrument equipped with a 4 mW He-Ne-Laser (633 nm) and an avalanche 
photodiode detector. DLS measurements were directly recorded in diluted colloidal 
suspensions of the particles at a concentration of 1 mg/mL. Zeta potential measurements were 
performed using the add-on Zetasizer titration system (MPT-2) based on diluted NaOH and 
HCl as titrants. For this purpose, 1 mg of the particles was diluted in 10 mL bi-distilled water. 
Thermogravimetric analyses (TGA) of the bulk extracted samples (approximately 10 mg) 
were recorded on a Netzsch STA 440 C TG/DSC. The measurements proceed at a heating rate 
of 10 °C/min up to 900 °C in a stream of synthetic air of about 25 mL/min. Nitrogen sorption 
measurements were performed on a Quantachrome Instrument NOVA 4000e at -196 °C. 
4.4. Experimental  
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Sample outgassing was performed for 12 hours at a vacuum of 10 mTorr at 120 °C. Pore size 
and pore volume were calculated by an NLDFT equilibrium model of N2 on silica, based on 
the desorption branch of the isotherms. In order to remove the contribution of the interparticle 
textural porosity, pore volumes were calculated only up to a pore size of 8 nm. A BET model 
was applied in the range of 0.05 – 0.20 p/p0 to evaluate the specific surface area. Infrared 
spectra of dried sample powder were recorded on a ThermoScientific Nicolet iN10 IR-
microscope in reflexion-absorption mode with a liquid-N2 cooled MCT-A detector. Raman 
spectroscopy measurements were performed on a Bruker Equinox 55 with a Nd:YAG laser 
(λ= 1064 nm) at a laser power of 50 mW and 20,000 scans. X-ray diffraction patterns were 
collected in the range of 20-80 ° on a STOE Stadi P powder diffractometer equipped with an 
image plate detector system, in transmission geometry, with Cu-Kα radiation and on a STOE 
Stadi MP with Co-Kα radiation. For transmission electron microscopy (TEM) at 300 kV using 
a Titan 80-300 kV microscope, samples were prepared by adding 3 drops of the ethanolic 
particle suspension (~3 wt%) to 4 mL absolute EtOH and drying of a drop of the resulting 
diluted colloidal suspension on a carbon-coated copper grid. Field-dependent magnetization 
measurements were performed on a superconducting quantum interference device (SQUID) 
magnetometer at 300 K. 
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4.5 Appendix 
 
Figure 4.12: Dynamic light scattering (DLS) measurements of magnetic nanocomposites. Zn-
MnFe@MSN-NH2 OUT (red), Zn-MnFe@MSN-Ph/NH2 IN (green) and Zn-MnFe@MSN-SHIN-
NH2 OUT (blue). 
 
Figure 4.13: High resolution Transmission electron micrograph of sample Zn-MnFe@MSN-SHIN-NH2 OUT. 
The lattice fringes of the cryystalline ferrite core are clearly visible. 
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Figure 4.14: Scanning transmission electron micrographs of magnetic nanocomposites. 
 
Figure 4.14: Small-angle XRD pattern of magnetic nanocomposites. Zn-MnFe@MSN-NH2 OUT (red), Zn-
MnFe@MSN-Ph/NH2 IN (green) and Zn-MnFe@MSN-SHIN-NH2 OUT (blue). 
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Figure 4.15: Thermogravimetirc analysis (TGA) of magnetic nanocomposites. Zn-MnFe@MSN-NH2 OUT 
(red), Zn-MnFe@MSN-Ph/NH2 IN (green) and Zn-MnFe@MSN-SHIN-NH2 OUT (blue). 
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5 Heparin-Coated Colloidal Mesoporous Silica Nanoparticles Efficiently 
Bind to Antithrombin as an Anticoagulant Drug-Delivery System 
This chapter is based on the following publication: 
Christian Argyo, Valentina Cauda, Hanna Engelke, Joachim Rädler, Gregor Bein, and 
Thomas Bein, Chemistry – A European Journal 2012, 18, 428 – 432. 
 
 
5.1 Introduction 
Colloidal mesoporous silica nanoparticles (MSNs) have attracted great attention as potential 
injectable drug delivery and cancer cell targeting systems.
[1]
 In addition to their high 
biocompatibility and biodegradability,
[2-3]
 they can be selectively modified at their inner and 
outer surfaces to efficiently encapsulate molecules in their tunable pore system,
[4]
 and they 
can be specifically functionalized on their outer surface for the application of interest.
[5-9]
 
Recent efforts have addressed the prevention of their fast degradation and hemolytic behavior 
by poly(ethylene glycol) coating.
[10-11]
 To deliver such multiple core-shell functionalized 
MSNs to the blood stream additional efforts are critical to guarantee adequate circulation 
times and to prevent thrombogenic effects. Heparin (Hep), a highly sulfated, anionic 
polysaccharide, is best known for its anticoagulant properties and is conventionally injected 
subcutaneously or intravenously.
[12]
 Free Hep always involves an increased bleeding risk and 
other side effects, for example, Hep-induced thrombocytopenia, while diffusing throughout 
5.2. Results and Discussion  
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the whole blood circulation system. However, specifically tissue-targeted nanocarriers with 
Hep coating should be harmlessly injectable into the blood stream, and prevent activation of 
the clotting system only in the immediate vicinity of the nanocarriers without systemic side 
effects.
[13-14]
 In addition, the Hep coating prolongs the circulation time of the nanoparticles in 
blood vessels and improves biocompatibility, and thus enhances their chances of serving their 
purpose in vivo, as shown in previous studies.
[15-16]
 Recently, the biological properties of Hep 
combined with polymeric and metallic nanomaterials and their application as anticoagulants 
have been reviewed.
[17]
 Here we present heparin-coated core-shell MSNs, in which Hep is 
covalently bound to the outer surface of amino-functionalized MSNs. The combination of 
Hep with the highly porous features of MSNs should lead to an efficient multifunctional drug-
delivery system that can act as an anticoagulant drug and allow for incorporation of 
biologically functional molecules as deliverable cargos. 
5.2 Results and Discussion 
In this work we focus on the efficiency of the anticoagulant coating on MSNs, and thus move 
towards the first step for the preparation of smart drug-delivery systems by improving 
biocompatibility and hemocompatibility. The MSNs were synthesized by sol-gel synthesis, as 
previously reported.
[4]
 In the present case we selectively functionalized the outer nanoparticle 
surface with aminopropyl groups. After template extraction, the amino groups of the core-
shell nanoparticles were treated via EDC amidation with the carboxyl groups of Hep (Scheme 
5.1), and thus a heparin coating covalently bound to the outer surface of the colloidal MSNs 
(CMS–Hep) was obtained. 
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Scheme 5.1: Treatment of the CMS-NH2 nanoparticles (the external functionalized shell is represented in 
dark grey) with the carboxylic groups of the polysaccharide chain of Hep, catalyzed by EDC and 
sulfoNHS to create amide bonds for covalent attachment of Hep (yellow) to the outer particle surface. The 
molecular structure of Hep and the MSNs are not to scale. 
The amino-functionalized sample CMS-NH2 consists of nano-sized particles of about 50 nm 
in diameter. The wormlike structure of the mesopores is clearly visible (Figure 5.1a). For 
CMS–Hep nanoparticles the mesoporous structure was hardly detectable due to the additional 
organic layer (Figure 5.1b). 
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Figure 5.1: Characterization of mesoporous silica nanocarriers. Transmission electron micrographs 
(TEM) of: a) CMS-NH2, and b) CMS–Hep. c) Thermogravimetric analysis, and d) ζ-potential 
measurements of CMS-NH2 (black squares) and CMS–Hep (empty triangles). 
Additional TEM images show that the MSNs, coated with heparin, are surrounded by a thick 
organic layer (Figure 5.2a). However the mesopores are barely visible. For a better imaging of 
the mesoporous structure of the heparin-coated MSNs scanning transmission electron 
micrograph (STEM) is shown in Figure 5.2b. STEM images feature a better contrast 
correlated with the atomic mass number of the different elements in the specimen. With this 
technique the mesoporous structure of the MSNs is better visualized, thus confirming the 
maintenance of the porous features after heparin modification. 
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Figure 5.2. (a) Transmission electron micrograph (TEM) and (b) scanning transmission electron 
micrograph (STEM) of the heparin-coated MSNs (CMS-Hep). 
The effective attachment of Hep was confirmed by the higher weight loss (about 5%, w/w) 
between 170–650 °C in the thermogravimetric analysis with respect to the unmodified CMS-
NH2 (Figure 5.1c). The ζ-potential measurements show the surface charge of the particle at 
different pH values, and reveal the presence of charged functional groups. The sulfate groups 
of Hep carry a strong negative charge even at low pH values, thus the negative profile of the 
CMS–Hep nanoparticles confirms the presence of Hep at the outer surface (Figure 5.1d). In 
contrast, the ζ-potential profile of the CMS-NH2 sample shows a high positive charge at 
acidic pH values, since the unreacted amino groups are positively charged upon protonation. 
Evidence for the successful attachment of Hep is also provided by 
13
C solid state NMR 
spectroscopy (Figure 5.4a, resonances of the propyl chain at 8, 20, and 43 ppm, a broad signal 
at 69 ppm due to the carbon atoms of the carbohydrate backbone (disaccharide units), and the 
carboxyl resonance at 174 ppm). The coating with organic moieties of the nanoparticle 
surface was also investigated by infrared spectroscopy (Figure 5.3a). The spectra A and B 
related to MSNs with amino groups and heparin coating respectively, indicate strong 
vibrations of the silica framework at around 1240 – 1050 cm
-1
 (asymmetric stretching 
vibration of Si-O-Si), and at 964 and 796 cm
-1
 (asymmetric bending and stretching vibration 
of Si-OH). Furthermore a broad band at 3600 – 3100 cm
-1
 corresponding to water and silanol 
groups on the particle surface can be observed for both samples. The peak at 1629 cm
-1
 
indicates the bending modes of the water molecules adsorbed on the surface of the particles 
appearing in all spectra. For comparison the spectrum of pure heparin (curve C) is also 
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reported. Several characteristic peaks for heparin are covered by the massive silica peak. 
However, by zooming-in in the region between 3500 – 1200 cm
-1
 (Figure 5.3b), it is possible 
to detect additional bands for the sample CMS-Hep in the range of 2980 – 2850 cm
-1
, 
associated with the C-H (2854 cm
-1
) and CH2 (2925 cm
-1
) stretching vibrational modes of the 
polysaccharide backbone chain. The peak at 1710 cm
-1
 can be related to the carbonyl 
stretching vibrational mode of the carboxylic acids of Hep. The carbonyl stretching vibration 
of amide groups is shifted to smaller wavenumbers. Therefore the peak at 1650 cm
-1
 is 
attributed to the amide group which was built by EDC amidation creating a covalent bond 
between the amino-functionalized MSNs and carboxy groups of Hep. Further proof for the 
amide bond formation is shown by the peak at 1577 cm
-1
 for the N-H deformation mode of 
the amide group. The peak at 1629 cm
-1
 arises due to the N-H deformation vibrational mode 
of the sulfonamide groups of Hep. The stretching mode of SO2 at 1456 cm
-1
 shows the 
presence of the sulfonic groups. We note that the samples were extensively washed with water 
and ethanol before measurements, thus the detection of only physically adsorbed heparin can 
be excluded, as also confirmed by ssNMR. 
 
Figure 5.3: (a) Infrared spectra (for clarity reasons, the IR spectra are shifted along the y-axis by 0.2 units 
each) of the aminopropyl-functionalized (CMS-NH2, curve A), heparin-coated (CMS-Hep, curve B) MSNs 
and pure heparin (curve C). (b) Zoom-in in the area of interest for better detection of organic moieties. 
Relatively high values of specific surface area and pore volume were obtained for the CMS–
Hep nanoparticles (Figure 5.4b and Table 5.1). We attribute the reduced pore volume in 
comparison with the CMS-NH2 sample to the increased sample weight by the addition of the 
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nonporous Hep, and to the blocking of some pores by frozen Hep in the surface layer of the 
nanoparticles. 
Table 5.1: Structural parameters of the heparin-coated MSNs and the unmodified CMS-NH2. 
Sample DFT pore size
a
 [nm] BET surface area [m²/g] Pore volume
b
 [cm³/g] 
CMS-NH2 3.93 949 0.75 
CMS-Hep 3.66 465 0.32 
a
DFT pore size refers to the peak value of the pore size distribution 
b
Pore volume is calculated up to a pore size of 8 nm to remove the contribution of interparticle porosity. 
As previously found for PEGylated MSNs,
[10]
 the colloidal stability in water was improved by 
the Hep coating (average particle size: 95 nm) compared to the unmodified CMS-NH2 
particles, for which a fraction of aggregates of up to 700 nm in size was formed (Figure 5.4d). 
 
Figure 5.4: a) 
13
C solid state NMR spectra, b) nitrogen sorption isotherms relative to the total sample 
weight, c) DFT pore size distributions, and d) dynamic light scattering (DLS) measurements of CMS-NH2 
(black squares) and CMS–Hep (empty triangles). 
From this we concluded that the covalent binding of Hep to the outer surface of the MSNs 
was successful. We preclude the presence of free Hep due to extensive washing steps after the 
synthesis and the good solubility of Hep in water. Hep specifically binds to antithrombin 
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(AT), and thus accelerates the inhibiting effect of AT on the coagulation proteins by up to 
1000-fold; in this way it prevents the formation of thrombin.
[18-19]
 The specific interaction of 
Hep at the outer surface of MSNs with AT and hence thrombin (TR) was evaluated with 
binding experiments by using fluorescence correlation spectroscopy (FCS). FCS measures the 
amount of bound protein as a function of the MSN concentration based on the size 
dependence of diffusion.
[20]
 The isotherms in Figure 5.5 confirm binding of AT to the CMS–
Hep (binding constant: 160 mL/mg). 
 
Figure 5.5: a) Fluorescence correlation spectroscopy (FCS) curves: the characteristic decay of the 
autocorrelation curve resulting from freely diffusing fluorescently labeled proteins (AT, black circles) is 
shifted towards longer timescales with increasing amount of protein bound to CMS–Hep nanoparticles 
(30%, empty triangles; 70%, empty squares; 100% black triangles) as indicated by the arrow. b) Binding 
isotherm of AT to the CMS–Hep. 
Additional FCS experiments were carried out in order to gain an understanding of the 
influence of CMS-Hep on TR (see Appendix 5.5). To evaluate the anticoagulant activity of 
CMS–Hep nanoparticles, activated partial thromboplastin time (aPTT) and antifactor Xa 
(FXa) activity assays were performed. The physiological target proteases of AT are those of 
the contact activation pathway, mainly the activated forms of factor X (FXa) and factor II 
(TR); these activate the formation of fibrin, which polymerizes and creates the blood clot with 
thrombocytes. For these measurements we prepared three samples of CMS–Hep with 
different Hep contents (0.4–1.0 IU/mL). As reference, we provided three samples of CMS-
NH2 nanoparticles with the same particle concentration as the CMS–Hep samples and pure 
Hep solutions without nanoparticles with the same Hep concentration. Since the effect of 
identical doses of Hep varies between individuals, all experiments were carried out with 
plasma samples from three different consenting adult donors. The anti-FXa test is a 
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chromogenic assay for determining Hep activity in plasma.
[21]
 The CMS–Hep samples 
showed significant Hep activity, which was only slightly lower than that of free Hep in 
solution in the reference sample (Figure 5.6a and Table 5.2) with almost exactly the 
calculated Hep concentration. More than half of the covalently bound Hep was still able to 
form the inhibitory complex of the anti-FXa assay. Slight deviations can be attributed to 
variations in the individual response of each donor to Hep. As expected, the CMS-NH2 
nanoparticles showed no Hep activity. The reference measurements with PBS did not exhibit 
inhibitory activity. The aPTT is a coagulometric measurement in which the activity of 
coagulation factors relevant for clinical investigations is evaluated.
[22]
 All reference samples, 
containing CMS-NH2 and pure PBS, showed normal blood clotting times (30–35 s). The 
CMS–Hep nanoparticles showed (for all Hep contents) prolonged blood clotting times of 
about 160 s and longer; this is comparable with the expected aPTT of the pure Hep solutions 
(Figure 5.6b and Table 5.3). 
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Figure 5.6: a) Hep activity in IU/mL (anti-FXa assay), and b) the aPTT assay (in seconds) evaluated for 
the CMS–Hep samples (1, 2 and 3) with various Hep concentrations (1.0, 0.7 and 0.4 IU/mL, respectively). 
Reference samples: CMS-NH2 nanoparticles with the same particle concentration as CMS–Hep: 
1.0 IU/mL (4), 0.7 IU/mL (5) and 0.4 IU/mL (6); free Hep in solution with calculated concentrations of 
1.0 IU/mL (7), 0.7 IU/mL (8) and 0.4 IU/mL (9); sample 10 contains PBS only (no particles or Hep). All 
samples were added to the citrated blood plasma of three different consenting adult subjects (A, B, C). 
The BCS coagulation system measures coagulation time only up to 160 s.  
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Table 5.2: The heparin activity in IU/mL was evaluated by the anti-FXa activity test. The MSN samples 
with various heparin concentrations and diverse reference samples were added to the citrated blood 
plasma of three different subjects (A, B, C). 
Sample A [IU/mL] B [IU/mL] C [IU/mL] 
CMS-Hep (1.0 IU/mL) 0.49 0.72 0.46 
CMS-Hep (0.7 IU/mL) 0.34 0.45 0.32 
CMS-Hep (0.4 IU/mL) 0.12 0.31 0.20 
CMS-NH2 (1.0)
a
 0.00 0.00 0.00 
CMS-NH2 (0.7)
a
 0.00 0.00 0.00 
CMS-NH2 (0.4)
a
 0.00 0.02 0.00 
Hep (1.0 IU/mL) 1.09 1.09 1.09 
Hep (0.7 IU/mL) 0.72 0.86 0.83 
Hep (0.4 IU/mL) 0.45 0.56 0.52 
PBS 0.00 0.02 0.06 
a
These samples of unmodified CMS-NH2 nanoparticles feature the same particle concentration as the CMS-Hep 
ones. Obviously they cannot contain any heparin activity in IU/mL. 
Table 5.3: The aPTT in seconds was evaluated for all samples and references added to the citrated blood 
plasma of three different subjects (A, B, C). The BCS Coagulation System measures coagulation time only 
up to 160 s. Blood clotting times about and above 160 s are presented in this way: > 160 s. 
Sample A B C 
CMS-Hep (1.0 IU/mL) > 160 s > 160 s > 160 s 
CMS-Hep (0.7 IU/mL) > 160 s > 160 s > 160 s 
CMS-Hep (0.4 IU/mL) 97 s > 160 s 108 s 
CMS-NH2 (1.0)
a
 34 s 32 s 35 s 
CMS-NH2 (0.7)
a
 34 s 32 s 35 s 
CMS-NH2 (0.4)
a
 33 s 31 s 35 s 
Hep (1.0 IU/mL) > 160 s > 160 s > 160 s 
Hep (0.7 IU/mL) > 160 s > 160 s > 160 s 
Hep (0.4 IU/mL) 160 s > 160 s 156 s 
PBS 33 s 30 s 34 s 
a
These samples of unmodified CMS-NH2 nanoparticles feature the same particle concentration as the 
CMS-Hep ones. Obviously they cannot contain any heparin activity in IU/mL. 
The graph of one measurement of the chromogenic assay for determination of the heparin 
activity in human blood plasma is shown in Figure 5.8a (Appendix 5.5). Heparin considerably 
accelerates inactivation of coagulation factor FXa and thrombin (FIIa) by antithrombin (AT). 
5.3. Conclusion  
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During the incubation phase of the test FXa is inactivated by AT catalyzed by the presence of 
heparin. The quantity of FXa which remains after incubation is determined via the increase in 
absorbance at the wavelength 405 nm, since the coagulation factor is able to crack a 
chromogenic substrate into a tripeptide and a dye. The curve in Figure 5.8a shows a linear 
increase in absorbance during time. The slope of this curve is determined for 60 s. This value 
is evaluated on a reference curve resulting in the heparin activity of the analyzed sample (here 
sample CMS-Hep (1.0 IU/mL) features heparin activity of 1.09 IU/mL). The activated partial 
thromboplastin time (aPTT) test was accomplished to determine the coagulation time of 
citrated human blood plasma in presence of modified heparin-coated and unmodified MSNs. 
The incubation of citrated plasma with phospholipids and a surface activator leads to the 
activation of several factors of the intrinsic coagulation system. The addition of Ca
2+
 cations 
triggers the coagulation process. The time until the formation of fibrin clot starts is measured 
and detected photo optically. Figure 5.8b shows the aPTT for two different samples. Amino-
functionalized MSNs (filled squares) feature normal blood clotting time within 32 s. These 
particles are not able to influence the coagulation system. On the contrary the heparin-coated 
MSNs (empty triangles) show prolonged blood clotting time up to 97 s. The covalently 
attached heparin on the external surface of the MSNs is able to catalyze the inhibition of the 
coagulation system. Both the anti-FXa and aPTT assays indicate that a high amount of Hep is 
covalently bound to the outer nanoparticle surface, which offers enough free active sites for 
efficient inhibition of coagulation. Previous studies on the immobilization of Hep on 
substrates have shown low nonspecific protein adsorption behavior when in contact with 
blood or plasma.
[23-24]
 
5.3 Conclusion 
To the best of our knowledge, this is the first report on covalently bound Hep at the outer 
surface of nano-sized mesoporous silica particles showing efficient anticoagulant properties; 
these could possibly reduce unintended immunogenic response. The CMS–Hep nanoparticles 
are expected to have potential as a blood-stream-injectable drug-delivery system, and offer 
new options for cancer therapy. As a future outlook, their selectivity could be further 
enhanced by functionalizing the heparin layer with site-specific targeting ligands. 
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5.4 Experimental 
Chemicals. Tetraethyl orthosilicate (TEOS, Fluka, >98%), triethanolamine (TEA, Aldrich, 
98%), cetyltrimethylammonium chloride (CTAC, Fluka, 25% in water), aminopropyl-
triethoxy silane (APTES, Sigma Aldrich, 99%), heparin sodium salt (HEP, Alfa Aesar, 
100%), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC, Aldrich), N-
hydroxysulfosuccinimide sodium salt (sulfoNHS, Aldrich), antithrombin (AT, 50 IU/mL, 
American Diagnostics INC.), thrombin (Human Thrombin, 500 IE/mL, Baxter), Atto 488 
NHS-ester (ATTOTEC), Atto 633 NHS-ester (ATTO-TEC), ammonium nitrate (Fluka) and 
hydrochloric acid (37%) were used as received. Ethanol (absolute, Aldrich) was used as 
solvent without further purification. Bidistilled water was obtained from a Millipore system 
(Milli-Q Academic A10). 
Synthesis procedures. Particle synthesis. For the outer aminopropyl-functionalized MSNs, 
tetraethyl orthosilicate (TEOS) (1.92 g, 9.22 mmol) and triethanolamine (TEA) (14.3 g, 
95.6 mmol) were heated to 90 °C without stirring in a 100 mL polypropylene reactor. After 
20 min a solution of cetyltrimethylammonium chloride (CTAC, 25% in water) (2.41 mL, 
1.83 mmol) in bi-distilled water (21.7 g, 1.21 mol) from a Millipore system (Milli-Q 
Academic A10), preheated to 60 °C, was added to the polypropylene reactor. The resulting 
mixture, having a molar composition of 1 TEOS: 0.20 CTAC: 10.4 TEA: 130.2 H2O, was 
stirred at 500 rpm at RT for 30 min. Afterwards aminopropyl-triethoxy silane (APTES) 
(20.4 mg, 0.0922 mmol, 1.0 mol% of the total amount of TEOS) together with TEOS 
(19.2 mg, 0.0922 mmol) were added and the synthesis mixture was stirred at 500 rpm at RT 
for 12 hours. After addition of ethanol (100 mL), the MSNs were separated by centrifugation 
(19.000 rpm, 43.146 RCF.for 20 min) and redispersed in ethanol. The template extraction was 
performed by heating the MSN suspension under reflux at 90 °C (oil bath) for 45 minutes in 
an ethanolic solution (100 mL) containing ammonium nitrate (2 g), followed by 45 minutes 
under reflux in a solution of concentrated hydrochloric acid (10 mL) and ethanol (90 mL). 
The MSNs were purified by centrifugation and washed with ethanol after each extraction step. 
Heparin functionalization. For the surface functionalization of the MSNs with Hep, 216 mg 
(16.2 μmol, 5 equiv. to the amino groups of the particles) of heparin sodium salt were 
dissolved in 8 mL bidistilled H2O. Then 62.1 mg (324 μmol, 20 equiv. to Hep) EDC and 
70.4 mg (324 μmol, 20 equiv. to Hep) sulfoNHS were added successively and stirred for 
5 min at RT. The amount of 1.12 mL ethanolic solution with 20 mg of the amino-
functionalized MSNs (contains 3.25 μmol amino groups) was added to the reaction mixture 
5.4. Experimental  
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and stirred for 12 h at RT. Afterwards the nanoparticles were separated by centrifugation and 
washed several times with copious amounts of water and ethanol to remove additional free 
polysaccharide. Finally they were redispersed in 5 mL ethanol, leading to a colloidal solution. 
AT labeling. For labeling the AT with the dye Atto 488, the lypholized AT (50 IU/mL) was 
dissolved in 0.5 mL bidistilled H2O. 50 μL of this solution were added to 1 mL of a 0.1 M 
NaHCO3 buffer solution in an eppendorf tube. A pH value of 8.3 is desired for the labeling 
reaction. A threefold molar excess (65 μL, 2 mg/mL) of an ethanolic solution of Atto 488 
NHS-ester was added to the AT solution and the reaction mixture was incubated for 1 h at RT 
in the dark. Afterwards the solution was dialyzed against 500 mL bidistilled H2O for 12 h. 
Thrombin labeling. For TR labeling with the dye Atto 633, the lyophilized TR (500 IU/mL) 
was dissolved in 5 mL bidistilled H2O. 50 μL of this solution were added to 1 mL of a 0.1 M 
NaHCO3 buffer solution in an Eppendorf tube, showing a pH value of 8.3. A threefold molar 
excess (38.8 μL, 2 mg/mL) of an ethanolic solution of Atto 633 NHS-ester was added to the 
thrombin solution and the reaction mixture was incubated for 1 h at RT in the dark. 
Afterwards the solution was dialyzed against 500 mL bidistilled H2O for 12 h. 
Characterization. Nitrogen sorption measurements were performed on a Quantachrome 
Instrument NOVA 4000e at -196 °C. Sample outgassing was performed for 12 hours at a 
vacuum of 10 mTorr at 120 °C, thus the functional groups should remain unaffected at this 
temperature. Pore size and pore volume were calculated by a NLDFT equilibrium model of 
N2 on silica, based on the desorption branch of the isotherms. In order to remove the 
contribution of inter-particle textural porosity, pore volumes were calculated only up to a pore 
size of 8 nm. A BET model was applied in the range of 0.05 – 0.20 p/p0 to evaluate the 
surface area. Infrared spectra were recorded on a Bruker Equinox 55; the dried powder of the 
nanoparticles was measured in the Attenuated Total Reflectance (ATR) mode. For all spectra 
the background was subtracted. Thermogravimetric analyses of the bulk extracted samples 
were performed on a Netzsch STA 440 C TG/DSC with a heating rate of 10 °C/min in a 
stream of synthetic air at about 25 mL/min. To evaluate the amount of covalently bound 
heparin the weight loss was normalized to the weight loss of the CMS-NH2 sample. Dynamic 
Light Scattering (DLS) and zeta potential measurements were performed on a Malvern 
Zetasizer-Nano instrument equipped with a 4 mW He-Ne laser (633 nm) and an avalanche 
photodiode detector. DLS measurements were directly recorded in diluted colloidal 
suspensions of the MSNs at a constant concentration of 1 mg/mL for all sample solutions. The 
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zeta potential measurements were recorded with a mixture of ethanolic suspension of the 
sample (~3 %wt) and about 1 mL commercial Hydrion Buffer solutions having pH values of 
2, 3, 4, 5, 6 and 7. Transmission electron microscopy (TEM) was performed at 300 kV on an 
FEI Titan 80-300 equipped with a field emission gun. For sample preparation, colloidal 
mesoporous nanoparticles were diluted in ethanol and a drop of the suspension was then 
deposited on the sample holder, a copper grid with holey carbon film, and the solvent was 
allowed to evaporate. Solid state NMR measurements were performed on a BRUKER DSX 
Avance 500 FT (
13
C NMR data were acquired at 125.8 MHz under cross-polarization 
conditions with 13688 transients). 
AT-Heparin binding constant measurement with FCS. Binding experiments were 
performed on an Axiovert 200 microscope equipped with a ConfoCor 2 unit (Carl Zeiss, Jena, 
Germany). A 40x (NA = 1.4) water immersion objective (Carl Zeiss Jena, Germany) was used 
for observation and an argon ion laser for Atto 488 excitation at a wavelength of 488 nm and 
a HeNe laser for Atto 633 excitation at a wavelength of 633 nm. Fluorescence emission was 
separated from the laser light using a bandpass filter (505-530 nm) and a longpass filter 
(650 nm), respectively. Samples were measured in 8-well chambers (nunc, Rochester, NY). 
Data were analyzed and binding isotherms were fitted using Langmuir isotherms according to 
Ref.
[20]
 
Blood clotting tests, aPTT and anti-FXa activity test. Blood clotting tests were performed 
on an automatic BCS XP Coagulation System (Siemens Healthcare Diagnostics, Marburg, 
Germany). For both tests 100 μL of the samples with a heparin content in the therapeutic 
range of 0.4 – 1.0 IU/mL dispersed in PBS were mixed with 900 μL of citrated blood plasma. 
For reference measurements unmodified CMS-NH2 samples and pure heparin solutions were 
also prepared. Blood from three different blood donors was used for the coagulation tests. 
 onor’s consent was supplied by each individual blood donation. The study was approved by 
the institutional review board of the Medical Faculty of Justus-Liebig-University Giessen (file 
number: 05/00). For aPTT measurements, 100 μL of the heparin-coated MSNs are pipette 
with citrated human blood plasma into a test tube and pre-warmed to 37 °C. After addition of 
100 μL Pathromtin SL  eagent (Siemens Healthcare  iagnostics) the solution was incubated 
for 2 min at 37 °C. This solution contains phospholipids and surface activators, thus leading 
to the activation of factors of the intrinsic coagulation system. After addition of 100 μL CaCl2 
solution the coagulation analyzer was started. The Ca
2+
 triggers the coagulation process 
leading to clouding of the solution. The formation time of fibrin clots is measured optically. 
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The resulting coagulation time is given in seconds. As reference, the time of fibrin clot 
formation is also measured for the unmodified CMS-NH2 nanoparticles and the free heparin 
molecules, in the same concentration (in IU/mL) as of the CMS-Hep. The anti-FXa activity 
test is a chromogenic assay determining the heparin activity in plasma. During the incubation 
phase of the test, FXa is inactivated upon formation of an inhibitory complex with AT in the 
presence of heparin. The amount of FXa remaining after the incubation phase is determined in 
a kinetic test via an increase in absorbance at 405 nm, since the coagulation factor FXa is able 
to cleave a chromogenic substrate into a tripeptide and a dye. The results are evaluated upon 
comparison with a calibration curve, showing the heparin activity of the examined sample. 
For the anti-FXa activity measurements, 50 μL of the particle containing plasma sample, 
50 μL  T reagent and 500 μL factor Xa reagent were mixed and incubated for exactly 1 
minute at 37 °C. Then 100 μL of the chromogenic substrate reagent were added and the 
absorbance at 405 nm was detected. 
5.5 Appendix 
 
Figure 5.7. (a) Binding of TR to CMS-Hep in the presence of AT (filled squares) is enhanced as compared 
to the binding without AT (empty triangles). (b) Binding of TR to MSNs without Hep in the absence of AT 
(empty triangles) is reduced upon addition of AT (filled squares). 
Figure 5.7a reveals the experiments on TR binding to CMS-Hep in the presence and absence 
of AT. Comparison of the resulting binding isotherms shows a clear shift towards enhanced 
binding upon addition of AT, indicating a specific interaction of CMS-Hep bound AT and 
TR. A control experiment on MSNs without Hep (Figure 5.7b) shows that in this case, 
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addition of AT leads to a decrease of binding possibly due to competitive binding effects, 
which indicates the absence of the specific interaction observed for CMS-Hep. This suggests, 
that AT bound to CMS-Hep exhibits specific interaction with TR and thus leads to the 
observed influence of CMS-Hep on blood coagulation. In the presence of AT, the binding of 
TR to the nanoparticles was enhanced; this indicates a specific interaction between CMS–Hep 
bound AT and TR. In the absence of CMS–Hep, no binding of AT and TR could be detected. 
We concluded that the MSN-bound Hep induces a specific interaction between AT and TR, 
and thus should show a pronounced anticoagulation effect. 
 
Figure 5.8. (a) FXa activity test of the sample CMS-Hep(1.0 IU/mL) and (b) the aPTT test of the 
aminopropyl functionalized MSNs (CMS-NH2(0.4), filled squares) and heparin-coated ones (CMS-
Hep(0.4 IU/mL), empty triangles). The absorbance on the y-axis is given in arbitrary units. 
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6 Matrix Metalloproteinase-9 Responsive Mesoporous Silica 
Nanoparticles for Local Drug Delivery to Tumor Cells 
This chapter is based on the following manuscript: 
Christian Argyo
†
, Deniz A. Bölükbas
†
, Silke Meiners, Oliver Eickelberg, Thomas Bein*, and 
Sabine van Rijt*, submitted. 
 
6.1 Introduction 
In the past decade, the use of nanoparticles as inert carriers for therapeutic drugs with the 
possibility to target specific cells or tissues has revolutionized the field of drug delivery. Up to 
date, many kinds of nanoparticles such as liposomes, micelles, and polymer-based particles 
are being investigated for their therapeutic use as drug delivery devices.
[1]
 Such nanocarrier 
systems have shown advantageous features resulting in improved accumulation of active 
drugs at the disease site and have contributed to reduced drug toxicity.
[2]
 However, the release 
system of many of these drug carriers relies on spontaneous degradation in vivo (e.g., 
hydrolysis) of the nanoparticle and does not allow for controlled release of the cargo. Recent 
breakthroughs in the development of multifunctional mesoporous silica nanoparticles (MSNs) 
have made them attractive alternative carriers for drug delivery.
[3-6]
 MSNs offer unique porous 
properties, providing high loading capacity that allows for efficient encapsulation of guest 
molecules. They feature tunable pore sizes and volumes for the specific transport of a wide 
variety of cargo molecules with different sizes, including chemotherapeutic molecules, 
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peptides, and oligonucleotides.
[7]
 More importantly, these particles can be selectively 
functionalized at specific sites within the nanoparticle.
[8]
 For example, decoration of the 
particle core with organic moieties can offer covalent attachment of cargos via cleavable 
linkers or binding of fluorescent dye molecules for particle tracking in in vitro and in vivo 
studies.
[9-11]
 In addition, orthogonal shell functionalizations enable the attachment of external 
functions, exclusively on the outer particle surface, that do not interfere with the pore 
environment. This can be exploited to create stimuli-responsive pore sealing and opening for 
controlled drug release by surface coating and/or external functions.
[9, 12-14]
 More specifically, 
MSN pore closing can be achieved by utilizing the biotin-avidin complexation, which can 
serve as a bulky biomolecule-based valve to efficiently block the pore entrances of MSNs.
[15-
16]
 
Lung cancer accounts for more than 30 % of all cancer deaths, and is by far the leading cause 
of cancer deaths in the Western world (http://globocan.iarc.fr/). Disease survival continues to 
be poor with a 5-year mortality of about 90 %. The two major lung cancer forms are non–
small cell lung cancer and small cell lung cancer, the latter of which exhibits only very limited 
treatment options. Furthermore, lung cancer treatment is complicated by limitations in early 
detection and the correspondingly advanced stages at diagnosis. Most patients face an 
intensive and invasive treatment regimen comprising surgery, radiotherapy, chemotherapy, or 
combinations thereof.
[17]
 Cisplatin is a commonly used chemotherapeutic agent used to treat 
many solid cancers, including lung cancer.
[18]
 Drawbacks of the use of cisplatin include 
nephrotoxicity, nausea, hair loss, and acquired resistance of tumors towards cisplatin. A more 
targeted and local delivery of cisplatin may result in lower administrated therapeutic doses, 
and consequently reduced systemic toxicity. To overcome the problem of acquired resistance, 
cisplatin is often given in a combination treatment with other chemotherapeutics.
[17]
 Multiple 
clinical trials suggest the use of proteasome inhibitors as combinatorial drugs as they 
effectively inhibit proliferation of lung tumor cells, sensitize these cells to apoptosis, and 
overcome drug resistance.
[19]
 The proteasome inhibitor Bortezomib (Bz) is FDA approved for 
treatment of multiple myeloma, and currently tested in phase II clinical trials for lung cancer. 
Accordingly, local and targeted drug delivery of proteasome inhibitors in combination with 
cisplatin into the lung may reduce systemic side effects as well as overcome acquired 
resistance towards cisplatin, and represents a novel approach for combating lung cancer. 
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Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that can cleave many 
extracellular matrix proteins and are overexpressed during advanced stages of cancer while 
they are minimally expressed in normal tissue.
[20]
 For tumor cells, increased expression of 
MMP-9 is favorable as MMP-mediated matrix degradation increases the metastatic potential 
of tumor cells. Accordingly, tumor-cell mediated MMP-9 expression correlates with tumor 
progression, angiogenesis, and metastasis.
[21]
 In particular, increased expression of MMP-9 
has been associated with poor prognosis of lung cancer patients. Thus, the use of MMP-9 
cleavable peptides for controlled drug release from drug carriers represents a promising 
targeting strategy for local drug delivery and controlled treatment of lung cancer. 
In this work, we present avidin-coated MSNs that have been functionalized with linkers that 
can be specifically cleaved by matrix metalloproteinases (MMPs) 2 and 9,
[22]
 allowing 
controlled release of chemotherapeutic drugs from the MSNs in the presence of high levels of 
MMP-2/9. These biomolecule-coated MSNs showed efficient protease sequence-specific 
controlled release of the incorporated chemotherapeutic cisplatin. Furthermore, this newly 
designed nanocarrier system is capable of highly efficient drug combination treatment. This 
novel drug delivery system represents a promising platform for controllable site-specific drug 
delivery and shows potential for new clinical applications to combat malignant growth of 
(lung) tumor cells. 
6.2 Results and Discussion 
Synthesis and Characterization of the MMP-9 Responsive MSNs. According to previous 
reports,
[8, 23]
 the MSNs were synthesized by a sol-gel procedure using tetraethyl orthosilicate 
(TEOS) as a silica source and cetyltrimethylammonium chloride (CTAC) as template. In the 
present work, we created core-shell functionalized MSNs (MSN-SHIN-NH2 OUT) via a delayed 
co-condensation approach, providing a thiol-functionalized core of the nanoparticles and an 
external particle surface decorated with amino groups. The amino groups on the external 
surface of the MSNs were treated via EDC amidation with the carboxyl groups of the 
heptapeptide (HP) linker consisting of a biotin functionality on the periphery (HP-biotin), 
resulting in the coating of the MSNs with HP-biotin (MSN-HP). This HP sequence is known 
to be selectively cleaved by MMP-9. For reference, MSNs containing a non-cleavable 
heptapeptide attached at the outer particle surface were also synthesized (MSN-NHP). In this 
NHP-biotin linker, the specific cleavage site for MMP-9 is lost due to exchange of one single 
amino acid. After dye/drug uptake into the mesopores of both particle types, the glycoprotein 
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avidin (66 kDa, av. diameter ~8 nm) was attached to the outer particle surface via linkage to 
the biotin groups (samples MSN-HP-AVI or MSN-NHP-AVI). Avidin shows a high affinity 
to biotin and therefore acts as bulky gatekeeper to block the mesopores of the silica 
nanoparticles. The complete synthesis strategy is depicted in Figure 6.1. 
 
Figure 6.1. Synthesis scheme of core(green)-shell(red) functionalized mesoporous silica nanoparticles 
(MSN-SHIN-NH2 OUT). (a) EDC amidation of amino groups with carboxy groups of the cleavable HP biotin 
linker (HP, black) or the non-cleavable HP-biotin linker (NHP, red) for a covalent attachment to the 
external particle surface (MSN-HP, MSN-NHP). (b) After cargo incorporation (drug or dye, yellow star), 
(c) the strong binding affinity of biotin to avidin leads to a blocking of the mesopores (MSN-HP-AVI, 
MSN-NHP-AVI). 
The core-shell functionalized sample MSN-SHIN-NH2 OUT consisted of nano-sized 
mesostructured particles of about 70 nm as derived from transmission electron microscopy 
(TEM, Appendix 6.5). Dynamic Light Scattering (DLS) measurements revealed a mean 
particle size of 106 nm (Table 6.1) and good colloidal stability. This increase in particle size 
compared to TEM was attributed to the involvement of the hydrodynamic diameter and weak 
transient agglomeration of a few nanoparticles during the DLS measurements.
[24]
 After the 
modification of the MSNs with the short HP linkers and further attachment of avidin, the 
mean particle sizes slightly increased due to these additional organic layers. Importantly, a 
narrow particle size distribution and no significant agglomeration were observed after each 
synthesis step (particle size distribution, see Appendix 6.5). Thermogravimetric analysis 
showed a stepwise additional weight loss for the samples MSN-HP and MSN-HP-AVI 
EDC, sulfo NHS
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MSN-SHIN-NH2 OUT 
RSWMGLP
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RSWMLLP
RSWMGLP
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MSN-NHP
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Drug/dye(b) 
(c) 
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MSN-NHP-AVI
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compared to MSN-SHIN-NH2 OUT during heating from 150 – 900 °C (Figure 6.1a). This 
confirmed an effective attachment of the short organic heptapeptide linker (+ 3 % additional 
weight loss) and the bulky protein avidin (+ 43 % additional weight loss). The zeta potential 
measurements showed no significant change in the surface charge at different pH values of 
the MSN-HP and MSN-NHP samples compared to MSN-SHIN-NH2 OUT, since the quantity of 
charged groups at the external surface was not increased by the attachment of the 
heptapeptide linkers (mainly consisting of unprotonable residues). The isoelectric points were 
around pH = 6. Only after attachment of the avidin (MSN-HP-AVI), a drastic change in the 
surface charge of the coated nanoparticles occurred at pH values of about 7 (Figure 6.1b). Due 
to various functional groups in the protein sequence including arginine, lysine and histidine 
residues, avidin-coated MSNs still showed positive surface charge at neutral pH values. 
Nitrogen sorption measurements were performed to gain information about the porosity and 
the surface area of the functionalized MSNs. Figure 6.2c shows typical type IV isotherms for 
samples MSN-SHIN-NH2 OUT, MSN-HP, and MSN-NHP with inflection points at around 
0.3 p/p0, indicating mesoporous structure for all these samples. Relatively high BET surface 
area and pore volume were obtained for the MSN-SHIN-NH2 OUT nanoparticles. A summary of 
the porosity parameters is given in Table 6.1. A slight reduction in specific surface area and 
pore volume occurred for the MSNs containing the HP linkers (MSN-HP and MSN-NHP, for 
more details see Appendix 6.5). The narrow pore size distribution with a maximum at around 
3.6 nm confirmed an accessible porous system even after modification with the HP linkers. 
After the attachment of avidin to the silica nanoparticles, we obtained a type II isotherm 
indicating a massive loss of specific surface area and pore volume (Figure 2c). These data 
showed that the mesopores of the avidin-coated MSNs almost completely blocked the access 
of nitrogen molecules, proving that avidin is a suitable gatekeeper to efficiently seal the 
mesopores of our nanoparticles. Infrared spectroscopy showed a band at 1629 cm
-1
for non-
coated particles (i.e. MSN-SHIN-NH2 OUT), indicating the bending modes of physisorbed water 
(Figure 6.1d). This band was present in all spectra but was partially covered by other more 
intensive bands of the coated particles. The nanoparticles MSN-HP and MSN-NHP showed 
an additional band at 1654 cm
-1
 (C=O stretching vibration), which can be attributed to the 
amide bonds of the short HP linkers. Subsequently, this band was fully obscured after 
modification with avidin, and typical amide vibration bands (amide I: C=O stretching 
vibration at 1643 cm
-1
; amide II: N-H deformation and C-N stretching vibration at 1535 cm
-1
) 
of high intensities were detected giving evidence for the presence of the protein. From these 
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data, we conclude that the attachment of the avidin gatekeepers via short HP-biotin linkers 
(cleavable and non-cleavable for MMP-9) to the external surface of MSNs was successful. 
 
Figure 6.2. Characterization of functionalized mesoporous silica nanoparticles. a) Thermogravimetric 
analysis, b) zeta potential measurements, c) nitrogen sorption isotherms, and d) infrared spectroscopy (all 
curves are shifted by a value of 0.02 along the y-axis for clarity) of MSN-SHIN-NH2 OUT (black), MSN-HP 
(red), MSN-NHP (blue), and MSN-HP-AVI (green).  
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Table 6.1. Structural parameters of functionalized MSNs. 
Sample 
Particle 
size
a
 (nm) 
BET surface 
area (m²/g) 
Pore volume
b
 
(cm³/g) 
DFT pore size
c
 
(nm) 
MSN-SHIN-NH2 OUT 106 1150 0.67 3.6 
MSN-HP 142 882 0.55 3.6 
MSN-HP-AVI 164 90 0.05 - 
MSN-NHP 142 825 0.52 3.6 
a
Particle size refers to the peak value of the size distribution derived from DLS measurements. 
b
Pore volume was 
calculated up to a pore size of 8 nm to remove the contribution of inter-particle textural porosity. 
c
DFT pore size 
refers to the peak value of the pore size distribution. 
Stimuli-Responsive Release of Fluorescein. To prove MMP-9 stimuli-responsive release 
behavior of our nanoparticle system, time-based release experiments of the fluorescent guest 
fluorescein were performed at 37 °C as previously reported.
[16]
 The avidin-coated sample 
(MSN-HP-AVI) preloaded with fluorescein showed no premature release of the cargo 
molecules. Moreover, long-term stability of the capping system for at least up to 16 h was 
observed (Figure 6.3 and Appendix 6.5) indicating that the avidin gatekeepers result in a 
perfect sealing of the mesopores and prevent unintended release of the cargo. Only upon 
addition of recombinant MMP-9 (1 µg/mL) to the particle solution, an increase in 
fluorescence intensity over time was observed (Figure 6.3). This release behavior gave 
evidence for protease-responsive release behavior of our nanoparticle system. After around 
16 h, a plateau was reached, which suggests a complete release of the loaded cargo molecules 
within this time range. Additionally, we investigated the release behavior of MSNs containing 
a non-cleavable heptapeptide linker (MSN-NHP-AVI) after addition of MMP-9. No release of 
the loaded fluorescein was observed, showing that neither the NHP-biotin linkers nor the 
avidin gatekeepers are cleavage targets for the MMP-9 enzyme. Consequently, this 
experiment proved a highly specific release behavior of the MSN-HP-AVI by MMP-9. 
Because the HP linker can also be cleaved by MMP-2, we investigated the ability of 
recombinant MMP-2 to release the cargo from the same system. MMP-2 was also able to 
release fluorescein from the particles, but with slower kinetics compared to MMP-9 
(Appendix 6.5). We therefore chose to continue with MMP-9 throughout the following 
studies. However, it is important to note that both enzymes are overexpressed in lung cancer 
and so we expect a cumulative effect on cargo release in vivo. 
6.2. Results and Discussion  
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Figure 6.3. Release kinetics of fluorescein from the MSNs before and after addition of MMP-9. Before 
addition of MMP-9 almost no premature release of the cargo can be observed, which indicates a near 
perfect closure of the mesopores. Only MSN-HP-AVI (red) shows a significant increase in fluorescence 
intensity in the presence of MMP-9, demonstrating a protease-responsive release behavior. Specific 
cleavage of the HP-biotin linker by MMP-9 is proven by the absence of cargo release of the reference 
MSN-NHP-AVI (blue). 
Toxicity Studies. The toxicity of the novel drug delivery particles was assessed in non-small-
cell lung cancer (NSCLC) cell lines A549 and H1299 using the WST-1 assay. WST-1 is a 
stable tetrazolium salt that is cleaved to form a soluble formazan by a complex cellular 
mechanism that is largely dependent on the glycolytic production of NAD(P)H in viable cells. 
Therefore, the colorimetric analysis of the formed formazan dye directly correlates to the 
number of metabolically active cells in the cell culture. To determine whether the avidin 
functionalization had an effect on the toxicity of these particles, the non-coated particles (i.e. 
MSN-SHIN-NH2 OUT) were included in the study as well. Thus, A549 and H1299 cells were 
directly exposed to either MSN-HP-AVI or MSN-SHIN-NH2 OUT particles at different 
concentrations at normal cell growing conditions. After 4 h of particle exposure, no toxic 
effects could be detected in either cell line even at high particle concentrations of 500 µg/mL 
(Appendix 6.5). After 24 h of exposure, a minor reduction in cell viability for both cell lines 
at high particle concentrations (> 200 µg/mL) was observed, with H1299 cells being more 
affected (Figure 6.4a, right panel). Interestingly, in both cell lines the non-coated particles 
(MSN-SHIN-NH2 OUT) showed increased toxicity at these high particle concentrations 
compared to the avidin-capped particles (MSN-HP-AVI). 
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Figure 6.4. Toxicity of different concentrations of MSNs containing the MMP-9 responsive release system 
(MSN-HP-AVI) and of non-coated particles (MSN-SHIN-NH2 OUT) after 24 h exposure, determined by a) 
WST-1 assay in A549 (left) and H1299 lung cancer cell lines (right) and b) Annexin-V/PI staining and 
FACS analysis. 
To assess whether these particles induce a specific form of cell death, namely necrosis or 
apoptosis, at high concentrations, we performed a live/dead assay using Annexin-V-FITC and 
propidium iodide (PI) staining. Externalization of phosphatidylserine (PS) from the inner face 
of the plasma membrane to the cell surface is a hallmark of early apoptosis. The FITC labeled 
Annexin-V binds to PS, resulting in fluorescent staining of early apoptotic cells (lower right 
quadrant, Figure 6.4b). In late stage apoptotic and in necrotic cells, propidium iodide 
(fluorescent DNA intercalating agent) is able to enter the cell and binds strongly to DNA 
(upper left quadrant for necrotic cells PI and upper right quadrant for late stage apoptotic 
cells). Similar to the results obtained with the WST-1 assay, no apoptotic or necrotic cell 
death was detected at low particle concentrations of below 100 µg/mL at both 4 and 24 h 
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time-points (Table 6.2 and 6.3 for 24 h exposure). Importantly, at the dose we used in the 
following experiments (50 µg/mL) no induction of apoptosis/necrosis could be observed after 
24 h in either cell line (Figure 6.4b). At high particle concentrations of 250 µg/mL, some cells 
were undergoing early apoptosis already after 4 h of exposure (Appendix 6.5), whereas after 
24 h, the apoptotic cells were mainly in the late apoptotic phase (Appendix 6.5). Furthermore, 
as was observed with the WST-1 assay, the avidin capping system had a positive effect on the 
toxicity, where particles with the avidin capping system induced less apoptosis compared to 
the amino-functionalized particles (Table 6.2 and 6.3, Appendix 6.5). This was especially 
evident in the H1299 cell line (Table 6.3, Appendix 6.5). 
Table 6.2. Percentage of A549 cells in different stages of cell death after 24 h exposure to 
MSNs containing MMP-9 responsive release system (MSN-HP-AVI) and non-coated 
particles (MSN-SHIN-NH2 OUT), as quantified by FACS analysis of Annexin-V/PI stained 
cells. The values given are average of two independent experiments ± SD. 
A549 healthy necrotic early apoptotic late apoptotic 
non treated control 92.2 ± 1.1 2.4 ± 2.3 4.5 ± 1.8 0.8 ± 0.3 
50 µg/mL MSN-HP-AVI 91.9 ± 2.0 0.8 ± 0.3 6.4 ± 1.8 0.6 ±0.1 
50 µg/mL MSN-SHIN-NH2 OUT 93.6 ± 0.6 0.8 ± 0.2 4.9 ±0.9 0.8 ± 0.1 
100 µg/mL MSN-HP-AVI 92.8 ± 0.8 1.1 ± 0.6 5.2 ± 1.3 0.9 ± 0.1 
100 µg/mL MSN-SHIN-NH2 OUT 91.7 ± 1.8 0.7 ± 0.1 6.3 ± 1.8 1.3 ± 0.1 
250 µg/mL MSN-HP-AVI 89.2 ± 2.7 2.5 ± 0.9 6.5 ± 3.6 1.8 ± 0.1 
250 µg/mL MSN-SHIN-NH2 OUT 83.2 ± 0.1 1.2 ± 0.9 12.1 ± 1.3 3.6 ±0.4 
  
 
123 
 
Table 6.3. Percentage of H1299 cells in different stages of cell death after 24 h exposure to 
MSNs containing MMP-9 responsive release system (MSN-HP-AVI) and non-coated 
particles (MSN-SHIN-NH2 OUT), as quantified by FACS analysis of Annexin-V/PI stained 
cells. The values given are average of two independent experiments ± SD. 
H1299 healthy necrotic early apoptotic late apoptotic 
non treated control 92.8 ± 2.3 0.2 ± 0.1 5.2 ± 0.1 0.4 ± 0.1 
50 µg/mL MSN-HP-AVI 81.4 ± 2.3 8.0 ± 0.4 5.0 ± 0.5 6.5 ± 1.0 
50 µg/mL MSN-SHIN-NH2 OUT 73.2 ± 1.3 6.2 ± 0.5 9.6 ± 0.6 8.9 ± 0.3 
100 µg/mL MSN-HP-AVI 74.3 ± 2.3 7.2 ± 1.0 7.5 ± 0.3 6.7 ± 0.4 
100 µg/mL MSN-SHIN-NH2 OUT 67.1 ± 0.4 6.3 ± 0.3 8.6 ± 0.4 16.8 ± 0.7 
250 µg/mL MSN-HP-AVI 68.2 ± 4.0 6.2 ± 0.4 9.2 ± 0.6 12.4 ± 0.9 
250 µg/mL MSN-SHIN-NH2 OUT 51.8 ± 3.9 3.5 ± 0.3 19.1 ± 1.5 20.6 ± 1.6 
 
Although MSNs are widely considered as potential drug delivery carriers, only few studies 
report on their biomedical applications and in vivo toxicity.
[25]
 Moreover, assessing the 
biocompatibility of specific MSN systems is complicated due to the great variation of 
characteristics possible for MSNs such as the chemical composition, surface chemistry, and 
diameter that cannot be easily compared between studies. For instance, Huang et al. found 
that only altering the shape of MSNs without changing other characteristics effected their 
cellular uptake and modulation of cellular function.
[26]
 Similarly, particle functionalization 
such as PEGylation has shown to greatly impact their biodistribution.
[27]
 It is therefore 
necessary to evaluate the biocompatibility for each specific MSN system. Here we showed 
that functionalizing MSNs with avidin protein has a positive effect on the toxicity of these 
particles and may be a promising strategy to increase their overall biocompatibility. 
MMP-9 Responsive Release of Calcein-AM. Triggered drug release from the particles was 
first assessed with confocal microscopy using the model drug, calcein-AM in both H1299 and 
A549 cell lines. Calcein-AM is a non-fluorescent cell-membrane permeable compound that is 
hydrolyzed by intracellular esterases into non-cell permeable, green fluorescent calcein. More 
specifically, calcein-AM is taken up in the cells via endocytosis and can be detected even at 
low doses (Figure S6). In this system, calcein-AM functions as a model drug that is released 
in the extracellular region, and is subsequently actively taken up by the cancerous cells where 
it is metabolized and becomes active (starts fluorescing). MSNs containing MMP-9 cleavable 
and non-cleavable linkers (MSN-HP-AVI and MSN-HP-AVI) encapsulating either 20 or 
6.2. Results and Discussion  
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50 µM solutions of calcein-AM were incubated with 0, 1 or 2 µg/mL recombinant MMP-9 in 
HBSS buffer for 2 h at 37 °C. After the incubation time, particles were removed from the 
suspension by centrifugation and the cells were exposed to the supernatant for 30 min 
allowing endosomal uptake of the released calcein-AM dye. Cells were counterstained with 
Hoechst nuclei stain (blue channel) to allow for the identification of all live adherent cells. 
After only 2 h of incubation with the different concentrations of recombinant MMP-9, calcein 
delivery to the cytosol could be observed in both cell lines (Figure 6.5, left panel). Notably, 
the amount of calcein delivery was dependent on both MMP-9 concentration and the amount 
calcein-AM encapsulated in the MSNs in both cell lines. The MSNs containing non-cleavable 
linkers (i.e. MSN-NHP-AVI, differing only one amino acid from HP) displayed only limited 
release of the calcein dye (Figure 6.5, right panel). The minor calcein-AM release observed 
for the non-cleavable particles could be due to some dye leakage out of the particles and/ or 
due to a small amount of dye sticking to the outside of the particles during the preparation 
step, which is then released over time. Because the dye concentration does not need to be very 
high to get a visible signal (Appendix 6.5), this could already result in some staining. 
Nevertheless, MSN-HP-AVI particles that were pre-activated with MMP-9 showed a 
significant increase in fluorescence intensity and consequently resulted in efficient and 
stimuli-responsive release of the cargo. The H1299 cells were more sensitive to calcein 
staining compared to the A549 cells, with already significant release observed when 20 µM 
solution of calcein-AM encapsulated MSNs were exposed to 1 µg/mL MMP-9. This coincides 
with the observation that H1299 cells were more sensitive towards calcein staining, as seen in 
the calcein-AM titration curves (Appendix 6.5) and may relate to an increased endosomal 
uptake capacity of these cells. 
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Figure 6.5. Confocal images showing MMP-9 responsive release of calcein-AM (Cl-AM, green) from 
MSNs containing MMP-9 cleavable linkers (MSN-HP-AVI) and MSNs containing non-cleavable linkers 
(MSN-NHP-AVI) after 2 h incubation with 0, 1, or 2 µg/mL MMP-9 in a) A549 cells and b) H1299 cells. 
Hoechst dye was used as counterstain (nuclei, blue). Pictures show representative micrographs from three 
independent experiments. 
MMP-9 Responsive Release of Cisplatin. Next, we assessed whether the functionalized 
MSNs were also able to efficiently release the chemotherapeutic drug cisplatin to the cells. 
For this purpose, MSN-HP-AVI particles encapsulating increasing amounts of cisplatin were 
directly incubated with the cells in media containing 0, 0.5 or 1 µg/mL of recombinant MMP-
9. Due to the longer exposure time of 24 h to allow cisplatin-mediated cell death, compared to 
2 h for the calcein-AM release experiments, we chose to use lower concentrations of MMP-9 
for this experiment. After 24 h of particle exposure, cell viability was tested. A low particle 
dose of 50 µg/mL was used, as this dose is a non-toxic dose after 24 h of incubation 
(Figure 6.4). Cells exposed to particles loaded with cisplatin, but with no MMP-9 present in 
the media, showed only minor loss of cell viability compared to non-treated control cells in 
both cell lines (white bars in Figure 6.6a and b). This clearly demonstrates the tight sealing of 
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the cisplatin-loaded MSNs by the peptide-biotin-avidin system. Interestingly, release of 
cisplatin from the particles was dependent on both the MMP-9 and the cisplatin dose in both 
cell lines (Figure 6.6a and b). Significant cell death could already be observed for cells 
exposed to particles loaded with a 10 µM solution of cisplatin when 1 µg/mL MMP-9 was 
present in the medium, and exposed to particles loaded with a 20 µM solution of cisplatin 
when 0.5 µg/ml MMP-9 was present. H1299 cells were slightly more sensitive towards the 
cisplatin-loaded MSNs, in analogy to the calcein release experiments. Importantly, MSNs 
with non-cleavable linkers (MSN-NHP-AVI) did not induce any cell death in either cell line, 
indicating that the linker is cleaved specifically by MMP-9 enzymes and that the sealing of 
the MSN pores is tight (Appendix 6.5). It is important to note that the particles were loaded by 
diffusing a cisplatin solution into the particles, after which the particles were sealed and 
washed. This is referred to in the figures as cisplatin concentration used to load the particles. 
The amount of cisplatin released from the particles and therefore the cisplatin concentration 
the cells were exposed to is much lower since the volume inside the MSNs is very small. To 
estimate what the actual concentration of released cisplatin was, we performed a dose-
responds curve of cisplatin alone in A549 and H1299 cells. Comparing cell death caused by 
the cisplatin released from the MSNs to that of cisplatin alone we can estimate that the 
cisplatin concentration released is about 10-20x diluted (e.g. 1 µM cisplatin caused 43 % cell 
survival compared to 33 % survival after exposure to 20 µM cisplatin loaded particles in 
H1299 cells). This can also be observed when comparing the calcein titration curve to the 
release of calcein loaded particles (Figure 6.5 and Appendix 6.5). 
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Figure 6.6. Controlled release of cisplatin from MSN-HP-AVI (particles loaded with 2, 10, 20 or 100 µM 
solutions of cisplatin) incubated with 0 (white bars), 0.5 (light-grey bars), or 1 µg/mL (dark-grey bars) 
MMP-9 as measured by cell survival using the MTT assay after 24 h exposure for a) H1299 cells and b) 
A549 cells (non-exposed cells were set to 100 % survival). 
To assess whether biologically relevant conditions and physiological concentrations of MMP-
9 are able to efficiently trigger cisplatin release from the MSNs, A549 and H1299 cells were 
transiently transfected with MMP-9 cDNA to induce MMP-9 expression in these cells. 
Secretion of the soluble MMP-9 into the cell supernatant was validated by zymography. This 
method uses denaturing SDS-gels which contain 1 % of the MMP-9 substrate gelatin. Proteins 
from the cell supernatant are separated according to their molecular weight and the presence 
of active MMP-9 complexes can be detected by digestion of the gelatin inside the gel which 
results in a clear band after gel protein staining. Endogenous secretion of MMP-9 is very low 
in both cell lines, as only a low signal was detected in the zymography for cells transfected 
with a non-coding control vector (Figure 6.7A, first two lanes). However, when cells were 
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transfected with the cDNA encoding MMP-9, both cell lines could secrete significant amounts 
of MMP-9 as detected by distinct zymography signals. Expression levels of active MMP-9 
were higher for H1299 compared to A549, but lower compared to the signal obtained with 
0.25 µg/mL of recombinant MMP-9 run on the same gel (Figure 6.7). These results indicate 
that the biologically relevant expression level of MMP-9 is lower compared to in vitro 
addition of recombinant MMP-9. To assess cisplatin release under these physiological 
conditions, MMP-9 cDNA and a non-coding control vector transfected cells were exposed to 
MSN-HP-AVI cisplatin containing particles. Transfected cells with non-coding control vector 
(white bars in Figure 6.7b and c) were slightly more sensitive to particle exposure compared 
to the non-transfected cells (white bars in Figure 6.6) which might be due to the additional 
stress of the cells undergoing the transfection procedure. Importantly, cisplatin loaded MSNs 
showed a significant increase in cell death compared to control transfected cells, clearly 
indicating that biologically relevant concentrations of cellular MMP-9 are able to trigger 
release of chemotherapeutic drugs from the stimuli responsive MSNs. Similar to the previous 
experiments, H1299 cells were more sensitive, and significant cell death was observed with 
particles loaded with 20 µM cisplatin solution. In A549 cells, only a minor albeit significant 
cytotoxic effect was seen at the highest cisplatin dose of 100 µM. This reduced 
responsiveness of A549 cells corresponds well with the reduced expression of MMP-9 in 
these cells, suggesting that with lower levels of MMP-9 longer exposure times are needed to 
open the MSNs. 
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Figure 6.7. Controlled release of cisplatin from MSN-HP-AVI (loaded with 2, 10, 20 or 100 µM solutions 
of cisplatin) incubated with either MMP-9 cDNA (grey bars) or empty vector transfected cells (white bars) 
as measured by cell survival after 24 h exposure for a) H1299 cells and b) A549 cells (non-exposed cells 
were set to 100 % survival). 
In conclusion, we were able to show that MSN-HP-AVI particles loaded with cisplatin induce 
cell death in a both MMP-9 and cisplatin dose-dependent manner. In addition, the 
effectiveness of this system was validated in a relevant biological setting using MMP-9 cDNA 
transfected human lung tumor cells. A few recent studies report on the use of MMP-2/9 
sensitive peptides for targeted delivery of chemotherapeutics.
[28-30]
 MMP-responsive MSNs 
were reported only recently by Zhang et al.,
[31]
 who could show tumor-triggered cell targeting 
by utilizing cellular-uptake-shielding multifunctional envelope-type MSNs. Turn-on targeting 
properties of the multifunctional MSNs were observed via cleavage of a protection shell by 
MMPs to achieve a specific cellular uptake by cancer cells. After cell uptake, the cargo 
release (doxorubicin) was obtained by redox-driven release mechanism. In another study by 
Xu et al.,
[32]
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MMPs in gelatin-coated MSNs. Nevertheless, the efficiency of pore sealing to prevent 
premature drug release was poor in this system. Here we show efficient protease sequence-
specific controlled release of incorporated chemotherapeutic cisplatin from our novel 
biomolecule-coated MSN system in two non-small cell lung cancer cell lines. 
Cisplatin and Bortezomib Combination Treatment. Cisplatin is often used in combination 
treatment with other chemotherapeutics to overcome the problem of acquired tumor resistance 
towards cisplatin for treatment of lung cancer.
[17]
 As MSNs can encapsulate multiple drugs in 
their mesoporous system with high efficiency, they offer an opportunity for controlled local 
delivery of two drugs at the same time. This is anticipated to result in lower administered 
doses of chemotherapeutics necessary to achieve a similar therapeutic effect. Proteasome 
inhibitor Bz is a selective inhibitor of the proteasome, an enzyme that is responsible for the 
degradation of over 90 % of all cellular proteins. As such, Bz induced proteasome inhibition 
interferes with many cellular processes, including cell cycle control.
[33]
 The application of 
proteasome inhibitors in cancer therapy is hampered by difficulties in administration and high 
systemic toxicity.
[34]
 In addition, high doses and long exposure times are needed to induce 
toxicity. Several clinical trials suggest that these inhibitors would be better suited for 
combination therapy since they effectively inhibit proliferation of tumor cells, sensitize these 
cells to apoptosis, and overcome drug resistance.
[19]
 
To investigate whether we could reduce the amount of cisplatin to achieve a similar 
therapeutic effect when Bz was present, we exposed A549 cells to MSNs loaded with a 
solution containing 2, 10 or 20 µM cisplatin and 1 µM of Bz. MSN-HP-AVI particles loaded 
with only 1 µM Bz (and no cisplatin) were included as controls and did not show an effect on 
cell viability after 24 h of exposure (Appendix 6.5). Cells exposed to MSNs loaded with 2, 10 
or 20 µM cisplatin and 1 µM Bz, but with no MMP-9 present also showed no significant loss 
in cell viability (Figure 6.8, white bars). Interestingly, when using toxic doses of cisplatin, the 
concomitant release of Bz had no significant effect on cell death. However, when non-toxic 
doses of cisplatin were used (i.e., particles loaded with 2 and 10 µM solutions), a significant 
increase in cell death was observed for particles that contained both drugs in A549 cells 
(Figure 6.8). Remarkably, this increase was largest for the lowest cisplatin dose (2 µM), with 
an increased cell death of over 35 % when Bz was present. The effect of 2 µM cisplatin + Bz 
is in-between that of 10 and 20 µM when cisplatin alone is used. This is a remarkable 5 to 
10 x increase in potency when Bz is added. For 10 µM cisplatin loaded particles this 
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difference was 17 %. These results are in accordance with the combinatorial treatment of 
cisplatin and proteasome inhibitor on ovarian cancer cells where both drugs were directly 
applied to the tumor cells.
[35]
 Using proteasome inhibitors in combination with a known 
cytotoxic drug is a new approach in the treatment of cancer in general and lung cancer in 
particular. Several clinical and preclinical trials have shown that Bz can be successfully 
combined with multiple cytotoxic agents as well as radiotherapy, showing good tolerability 
and without significant overlapping toxicity.
[36-37]
 In particular, the phase II clinical trial study 
with Bz in combination with carboplatin (another platinum based chemotherapeutic) showed 
promising progression-free and improved overall survival rates in the treatment of non-small 
cell lung cancer.
[38]
 To our knowledge, this is the first report in which nanoparticle-based 
controlled release of a proteasome inhibitor combined with cisplatin shows vastly enhanced 
antitumor activity. 
 
Figure 8. Effect of particle mediated cisplatin and Bortezomib (Bz) combination treatment on cell 
survival. MSN-HP-AVI particles co-encapsultaed with 2, 10, or 20 µM solutions of cisplatin and 1 µM 
solution of Bz incubated with 1 µg/mL MMP-9 for 24 h in A549 cells (non-exposed cells were set to 100 % 
survival). 
6.3 Conclusions 
In this study, we report the synthesis of novel mesoporous silica nanoparticles containing an 
MMP-9 responsive avidin capping system. Since MMP-9 enzymes are overexpressed during 
advanced stages of cancer, whereas they are minimally expressed in normal tissue, this system 
allows for stimuli-responsive local delivery of cytotoxic drugs in cancer therapy. We 
demonstrate stimuli-responsive controlled drug release from MSNs only in the presence of 
MMP-9 enzymes in two non-small-cell lung cancer cell lines. Specifically, dose-dependent 
release was shown for model cargo calcein-AM as well as chemotherapeutic cisplatin. These 
results were also validated in a more biological setting, using MMP-9 cDNA transfected cells. 
Importantly, the MSNs were non-toxic up to high concentrations, where the avidin 
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functionalization reduced the toxicity of these particles. Additionally, in this work we show 
for the first time that this novel drug delivery system can be used to efficiently deliver a 
combination of two drugs, Bz and cisplatin, in a stimuli-controlled manner. Remarkably, 
MSNs that contained non-toxic doses of cisplatin along with the proteasome inhibitor Bz 
resulted in a 5 to 10 x increase in potency compared to cisplatin alone. 
6.4 Experimental 
Materials. Tetraethyl orthosilicate (TEOS, Fluka, > 98 %), triethanolamine (TEA, Aldrich, 
98 %), cetyltrimethylammonium chloride (CTAC, Fluka, 25 % in H2O), mercaptopropyl 
triethoxysilane (MPTES, Fluka, > 80 %), aminopropyl triethoxysilane (APTES, Sigma 
Aldrich, 99 %), ammonium fluoride (NH4F, Fluka), ammonium nitrate (NH4NO3, Fluka), 
hydrochloric acid (HCl, 37 %), Bio-PLGMWSR (HP-biotin, GenScript, 96.3 %), Bio-
PLLMWSR (NHP-biotin, GenScript, 90.1 %), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC, Aldrich), N-hydroxysulfosuccinimide sodium salt 
(sulfoNHS, Aldrich), Avidin, egg white (Merck, Calbiochem), fluorescein disodium salt 
dihydrate (Acros), calcein acetoxymethyl ester (calcein-AM, Sigma Aldrich), cisplatin (Sigma 
Aldrich), Bortezomib (Bz, Velcade, Millennium Pharmaceuticals), were used as received. 
Ethanol (EtOH, Aldrich, absolute), dimethylsulfoxide (DMSO, Aldrich), and HBSS buffer 
(Gibco) were used as solvents without further purification. Bi-distilled water was obtained 
from a Millipore system (Milli-Q Academic A10). 
Synthesis procedures. Particle synthesis (MSN-SHIN-NH2 OUT). Core-shell functionalized 
MSNs were synthesized according to a slightly modified method, as previously reported.
[8]
 In 
brief, a mixture of tetraethyl orthosilicate (TEOS, 1.63 g, 7.82 mmol), mercaptopropyl 
triethoxysilane (MPTES, 112 mg, 0.48 mmol) and triethanolamine (TEA, 14.3 g, 95.6 mmol) 
was heated under static conditions at 90 °C for 20 min in a polypropylene reactor. Then, a 
solution of cetyltrimethylammonium chloride (CTAC, 2.41 mL, 1.83 mmol, 25 wt% in H2O) 
and ammonium fluoride (NH4F, 100 mg, 2.70 mmol) in H2O (21.7 g, 1.21 mmol) was 
preheated to 60 °C and added quickly to the TEOS solution. The reaction mixture was stirred 
vigorously (700 rpm) for 20 min while cooling down to room temperature. Subsequently, 
TEOS (138.2 mg, 0.922 mmol) was added in four equal increments every three minutes. After 
another 30 min of stirring at room temperature, TEOS (19.3 mg, 92.5 µmol) and aminopropyl 
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triethoxysilane (APTES, 20.5 mg, 92.5 µmol) were added to the reaction. The resulting 
mixture was then allowed to stir at room temperature overnight. After addition of ethanol 
(100 mL), the MSNs were collected by centrifugation (19,000 rpm, 43,146 rcf for 20 min) and 
re-dispersed in absolute ethanol. The template extraction was performed by heating the MSN 
suspension under reflux (90 °C oil bath temperature) for 45 min in an ethanolic solution 
(100 mL) containing ammonium nitrate (NH4NO3, 2 g), followed by 45 min under reflux in a 
solution of concentrated hydrochloric acid (HCl, 10 mL) and absolute ethanol (90 mL). The 
mesoporous silica nanoparticles were collected by centrifugation and washed with absolute 
ethanol after each extraction step. 
Heptapeptide functionalization (MSN-HP and MSN-NHP). Bio-PLGMWSR (HP-biotin 
96.3 %, 5.1 mg, 4.6 µmol) or Bio-PLLMWSR (NHP-biotin, 90.1 %, 5.0 mg, 4.0 µmol) were 
dissolved in 100 µL DMSO. The solution was diluted by addition of 400 µL H2O. Then, EDC 
(0.8 mg, 5.2 µmol) was added and the reaction mixture was stirred for 5 min at room 
temperature. Subsequently, sulfoNHS (1 mg, 5.0 µmol) was added and the reaction mixture 
was stirred for another 5 min at room temperature. This mixture was added to a suspension 
containing 50 mg of MSN-SHIN-NH2 OUT in a total volume of 8 mL (EtOH:H2O 1:1). The 
resulting mixture was then allowed to stir at room temperature overnight. The MSNs were 
thoroughly washed by EtOH and H2O (3 times) and finally collected by centrifugation 
(19,000 rpm, 43,146 rcf, 20 min). The HP-biotin or NHP-biotin functionalized MSNs were 
stored as colloidal suspension in absolute ethanol. 
Cargo-loading. 1 mg of MSNs (MSN-HP or MSN-NHP) were immersed in 500 µl HBSS 
buffer solution containing fluorescein disodium salt dihydrate (1 mM), calcein-AM (20 µM or 
50 µM), cisplatin (2 µM, 10 µM, 20 µM, or 100 µM), or a combination of cisplatin and Bz 
(2 µM + 1 µM, 10 µM + 1 µM, or 20 µM + 1 µM) for 2 h at room temperature. Afterwards 
the particles were coated with avidin. Fluorescein-loaded particles have been washed once by 
centrifugation and redispersion prior to the addition of avidin. All other samples have been 
coated with avidin without a previous washing procedure. 
Avidin-coating (MSN-HP-AVI and MSN-NHP-AVI). 1 mg of loaded or non-loaded MSNs 
(in 500 µL HBSS buffer) were added to 500 µL HBSS buffer containing 1 mg of avidin. The 
solution was mixed by using 5 s of vortexing and allowed to react for 30 min under static 
conditions at room temperature. The resulting suspension was then centrifuged (5000 rpm, 
2200 rcf, 4 min, 15 °C) and washed three times with HBSS buffer solution. The particles were 
6.4. Experimental  
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finally re-dispersed in HBSS buffer and used for cuvette release experiments or in vitro 
studies. 
Characterization methods. Transmission electron microscopy (TEM) was performed at 
300 kV on an FEI Titan 80-300 equipped with a field emission gun. For sample preparation, 
the colloidal solution of MSNs was diluted in absolute ethanol and one drop of the suspension 
was then deposited on a copper grid sample holder. The solvent was allowed to evaporate. 
Dynamic light scattering (DLS) and zeta potential measurements were performed on a 
Malvern Zetasizer-Nano instrument equipped with a 4 mW He-Ne laser (633 nm) and an 
avalanche photodiode detector. DLS measurements were directly recorded in diluted colloidal 
aqueous suspensions of the MSNs at a constant concentration of 1 mg/mL for all sample 
solutions. Zeta potential measurements were performed using the add-on Zetasizer titration 
system (MPT-2) based on diluted NaOH and HCl as titrants. For this purpose, 1 mg of the 
MSN sample was diluted in 10 mL bi-distilled water. Thermogravimetric analyses (TGA) of 
the bulk extracted samples (approximately 10 mg) were recorded on a Netzsch STA 440 C 
TG/DSC. The measurements proceed at a heating rate of 10 °C/min up to 900 °C in a stream 
of synthetic air of about 25 mL/min. Nitrogen sorption measurements were performed on a 
Quantachrome Instrument NOVA 4000e at -196 °C. Sample outgassing was performed for 12 
hours at a vacuum of 10 mTorr at 120 °C. Pore size and pore volume were calculated with an 
NLDFT equilibrium model of N2 on silica, based on the desorption branch of the isotherms. 
In order to remove the contribution of the interparticle textural porosity, pore volumes were 
calculated only up to a pore size of 8 nm. A BET model was applied in the range of 0.05 – 
0.20 p/p0 to evaluate the specific surface area. Infrared spectra were recorded on a 
ThermoScientific Nicolet iN10 IR-microscope in reflexion-absorption mode with a liquid-N2 
cooled MCT-A detector. Time-based fluorescence spectra were recorded on a PTI 
spectrofluorometer equipped with a xenon short arc lamp (UXL-75XE USHIO) and a 
photomultiplier detection system (model 810/814). The measurements were performed in 
HBSS buffer solution at 37 °C to simulate human body temperature. For time-base release 
experiments of fluorescein a custom-made container consisting of a Teflon tube, a dialysis 
membrane (ROTH Visking type 8/32, MWCO 14,000 g/mol) and a fluorescence cuvette were 
used (Appendix 6.5).
[16]
 The excitation wavelength was set to λ = 495 nm for fluorescein-
loaded MSNs. Emission scans (505 – 650 nm) were performed every 5 min. All slits were 
adjusted to 1.0 mm, bandwidth 8 nm). 
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Cell culture. The NSCLC A549 human alveolar epithelial and the H1299 human lung cancer 
cell lines were obtained from ATCC (American Type Culture Collection, Manassas, USA). 
Both cell lines were maintained in DMEM media (LifeSciences). Media were supplemented 
with 10 % FBS (fetal bovine serum) and 1 % penicillin/streptomycin. All cells were grown at 
37 °C in a humidified atmosphere containing 5 % CO2. 
WST-1 assay. Cytotoxicity of the MSNs was assessed using the WST-1 assay (Roche). 
Briefly, 1.5 x 10
4
 cells/well were seeded in 96-well plates. 24 h after seeding, the cells were 
exposed to MSN-HP-AVI or MSN-SHIN-NH2 OUT particles for 4 or 24 h. After treatment, 
10 µL of WST-1 reagent solution (Roche) was added to each well and incubated at 37 °C for 
30 min. Absorbance was measured at 450 nm using a Tristar LB 941 plate-reader (Berthold 
Technologies). 
Live/dead assay using Annexin-V. Induction of apoptosis or necrosis was investigated in 
both cell lines using Annexin-V-FITC and propidium iodide (PI) double staining. Initially, 4 x 
10
5
 cells were seeded per well in 6-well plates. After 24 h, the cells were treated with MSN-
HP-AVI or MSN-SHIN-NH2 OUT for 4 or 24 h. The particle containing media were then 
removed, cells were washed, trypsinized, and stained with Annexin-V-FITC and propidium 
iodide in binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4) at 37 °C for 
15 min. Samples were then analyzed by FACS analysis (BD LSRII). 
MTT assay. The MTT assay was performed to assess cell viability after cisplatin release from 
the particles. Briefly, 1 x 10
4
 cells/well for H1299 and 0.5 x 10
4
 cells/well for A549 were 
seeded in 96-well plates. 48 h after seeding, cells were exposed to 50 µg/mL MSN-HP-AVI 
particles that had been loaded with 2, 10, 20 or 100 µM solutions of cisplatin with or without 
1 µM solution of Bz,  to 0, 0.5 or 1 µg/mL recombinant MMP-9 (Enzo life sciences) in 50 µL 
of fresh media. In the case of transfected cells, 24 h after seeding, the cells were transfected 
with 0.15 µg of MMP-9 cDNA (DNASU) or empty vector cDNA per well using 
SatisFection
TM
 transfection reagent (Agilent Technologies) according to manufacturer’s 
instructions. 24 h after transfection, the cells were exposed to 50 µg/mL MSN-HP-AVI 
particles that had been loaded with 2, 10, 20 or 100 µM solutions of cisplatin, in 50 µL of 
fresh media. After treatment, 10 µL of freshly prepared solution of 5 mg Thiazolyl Blue 
Tetrazolium Bromide/mL PBS (Sigma) was added to each well and incubated at 37 °C for 
1 h. The supernatant was then aspirated, and the blue crystals were dissolved in 500 µL 
isopropanol + 0.1 % Triton X-100. Absorbance was measured at 570 nm, using a Tristar LB 
6.4. Experimental  
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941 plate-reader (Berthold Technologies). Experiments were done in triplicate. Data analyses 
were performed in Prism graphpad (version 6) software. 
Calcein-AM release experiments. The release of calcein-AM, hence the staining of the cells 
from the particles was assessed using confocal microscopy. Thus, freshly prepared calcein-
AM containing MSN-HP-AVI or MSN-NHP-AVI particles were incubated with 0, 1 or 
2 µg/mL recombinant MMP-9 (Enzo life sciences) for 2 h at 37 °C in a thermoblock that was 
shaking mildly at 700 rpm. After the incubation time, the particles were removed by 
centrifugation and the cells were incubated with the supernatant for 30 min, such that the 
released calcein could be uptaken by the cells. Afterwards, the nuclei of the cells were 
counterstained using Hoechst dye (Enzo life sciences). The cells were imaged using a 
confocal microscope (Zeiss LSM 710). 
Zymography. To assess catalytically active MMP-9 expression and transfection efficiency in 
A549 and H1299 cells, gelatin zymography was performed. In short, collected cell culture 
media were centrifuged to get rid of cellular debris and then electrophoresed on 10 % SDS-
gels containing 1 % gelatin substrate in non-reducing conditions (i.e. no β-mercaptoethanol) 
so that the proteins could renature after electrophoresis. After electrophoresis, the enzymes 
were renatured to ensure that the proteins were catalytically active by incubation with 2.5 % 
Triton-X-100 in developing buffer (50 mM Tris, 200 mM NaCl, 5 mM CaCl2, pH 7.5) for 1 h 
at room temperature. Afterwards, the gels were incubated in developing buffer at 37 °C for 
24 h to allow the enzyme reaction. Thereafter, the gels were stained using PAGE-Blue
TM
 
(Fermentas) protein staining, according to the manufacturer’s instructions. Gels were 
analyzed using the ChemiDoc
TM
 XRS+ software (BioRad). Band intensity was quantified 
with the Image Lab
TM
 software package (version 3.0.1 beta 2) from BioRad. 
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6.5 Appendix 
 
Figure 6.9. Further characterization of functionalized mesoporous silica nanoparticles. a) Transmission 
electron micrograph of sample MSN-SHIN-NH2 OUT. b) Particle size distributions derived from DLS 
measurements, c) DFT pore size distributions, and d) infrared spectroscopy data (full range) of MSN-
SHIN-NH2 OUT (black), MSN-HP (red), MSN-NHP (blue), and MSN-HP-AVI (green). 
Further Characterization. The TEM image shows a spherical particle shape, and the worm-
like structure of the mesopores is clearly visible (Figure 6.9a). Infrared spectra of all MSNs 
show typical bands of the silica framework (Si-O-Si) between 1000 and 1300 cm
-1
. Two 
additional bands at 780 and 900 cm
-1
 are also present (asymmetric stretching and bending 
vibrations of Si-OH groups). Furthermore, additional vibrational bands at around 2900 cm
-1
 
(C-H stretching modes of ethoxy groups and propyl chains) can be observed for all samples. 
Nitrogen sorption isotherms show a second hysteresis loop at around 0.9 p/p0 for all samples, 
which is attributed to interparticle textural porosity. The slight reduction in BET surface area 
and pore volume, compared to MSN-SHIN-NH2 OUT, can be attributed to the increased sample 
weight by addition of non-porous organic material (HP-biotin and NHP-biotin), and to the 
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blocking of some pores towards the access of nitrogen molecules by frozen organic moieties 
in the surface layer of the nanoparticles. 
 
Figure 6.10. A) Long-term stability of avidin capping for MSNs (MSN-HP-AVI) in the absence of MMP-9 
(100% of released fluorescein are defined as the total amount being released from MSN-HP-AVI after 
addition of MMP-9, cf. Figure 3). B) Custom-made release setup consists of a reservoir for the particles 
(Teflon tube (a), a dialysis membrane (b), and a fluorescence cuvette (c).  
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Figure 6.11. Release kinetics of fluorescein from the MSNs (MSN-HP-AVI) before (black dots) and after 
(red dots) addition of MMP-2 (100% of released fluorescein are defined as the total amount being released 
from MSN-HP-AVI after addition of MMP-9, cf. Figure 3). 
 
Figure 6.12. Toxicity of different concentrations of MSNs containing the MMP-9 responsive release system 
(MSN-HP-AVI, denoted as AVI) and of non-coated particles (MSN-SHIN-NH2 OUT) after 4 h of exposure, 
as determined by a) WST-1 assay in A549 (left) and H1299 (right) lung cancer cell lines and by b) 
Annexin-V/PI staining and FACS analysis, numbers represent percentage of cells that are counted in 
marked boxes. 
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Figure 6.13. Toxicity of 250 µg/mL of MSNs containing the MMP-9 responsive release system (MSN-HP-
AVI) and of non-coated particles (MSN-NH2) after 24 h of exposure in A) A549 and B) H1299 lung cancer 
cell lines by Annexin-V/PI staining and FACS analysis, numbers represent percentage of cells that are 
counted in marked boxes. 
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Figure 6.14. Confocal images showing increasing concentrations of calcein-AM (calcein, green) directly 
given to A) A549 and B) H1299 cells. Hoechst was used as counterstain (nuclei, blue).  
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Figure 6.15. MSN-NHP-AVI particles encapsulated with 2, 10, 20 or 100 µM solution of cisplatin and 
incubated with 1 µg/mL MMP-9 for 24 h did not result in signifcant toxicity in a) H1299 cells and b)A549 
cells (non-exposed cells were set to 100 % survival). 
 
Figure 6.16. MSN-HP-AVI particles encapsulated with 1 µM solution of Bz and incubated with 1 µg/mL 
MMP-9 for 24 h did not result in any toxicity in A549 cells (non-exposed cells were set to 100 % survival).  
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7 Carbonic Anhydrase-Based pH-Responsive Cap System for Mesoporous 
Silica Nanoparticles 
This chapter is based on work in cooperation with: 
Michael Gattner, Stefan Datz, Veronika Weiss, Christoph Bräuchle, Thomas Carell, and 
Thomas Bein 
 
 
7.1 Introduction 
The development of effective systems for targeted drug delivery with release on-demand 
properties is a challenging field in nanoscience. In particular, porous nanocarriers with high 
drug loading capacity and tunable surface properties are viewed as promising candidates for 
biomedical applications such as cancer therapy and bioimaging.
[1-3]
 Multifunctional 
mesoporous silica nanoparticles (MSNs) have recently achieved advantageous performance in 
drug delivery applications due to their excellent porous features and the possibility to attach 
targeting ligands and adjustable release mechanisms for a variety of cargos.
[4-6]
 In the last 
decade, remarkable efforts were made to establish various capping systems to efficiently seal 
the porous system of MSNs, including CdS or gold nanoparticles,
[7-8]
 iron oxide 
nanocrystals,
[9]
 bio-macromolecules,
[10-11]
 enzymes,
[12]
 and polymers.
[13]
 Control over a 
stimuli-responsive cargo release can be achieved via different triggers such as redox 
reactions,
[14]
 pH changes,
[15]
 light-activation,
[5]
 or change in temperature.
[6]
 Among these 
techniques, drug delivery vehicles equipped with acid-sensitive capping mechanisms are 
highly desirable in acidified targets, such as tumors and inflammatory tissues. In particular, 
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nanoparticles taken up by cells through endocytosis are exposed to a natural pH change from 
the early endosome (pH 7.4) to late endosome or endolysosome (pH 5.5).
[16]
 
Here, we present pH-responsive MSNs consisting of a cleavable capping structure based on 
carbonic anhydrase (CA) gatekeepers which are attached to the silica nanoparticle surface via 
benzene sulfonamide groups. The sulfonamide derivatives have been commonly used as 
enzyme inhibitors, efficiently blocking the active site of the carbonic anhydrase.
[17]
 This 
inhibition is reversible depending on pH. The CA gatekeepers were used to exploit the 
endosomal pH change as an internal trigger and gain control over the release of cargo 
molecules from the mesoporous system. Specifically, our pH-responsive capping system 
consists of two essential components. First, the bulky gatekeeper CA is crucial to efficiently 
block the pore entrances of the porous host system. Due to its capable size (hydrodynamic 
diameter of 5.4 nm), the CA can block the entrances of the mesopores with diameters of about 
4 nm, thus showing high potential to serve as a bulky gatekeeper for MSNs.
[4, 18]
 The second 
component is the surface-bound benzene sulfonamide linker, which efficiently binds to the 
active site of the enzyme. Upon changing the pH, the connection is cleaved, which leads to a 
removal of the gatekeepers, providing access to the porous system. CA has been widely 
studied as a model enzyme in different research fields such as biophysics, bioanalysis and 
medical chemistry.
[17]
 This broad range of applications is mainly based on its well-known 
catalytic mechanism and its excellent stability under standard laboratory conditions. The 
enzyme is abundant in various human tissues such as kidney, stomach, eye, bones, and in the 
blood stream. Since CA has been found to be involved in different disease processes such as 
glaucoma and diabetes, several inhibitors have been examined, often consisting of 
sulfonamide derivatives.
[19]
 In particular, aryl sulfonamides coordinate to the Zn
2+
-ion of the 
catalytic center. This inhibition is reversible upon acidification, causing a cleavage of the 
coordination bond.
[20]
 Benzene sulfonamide derivatives can be attached to the surface of 
MSNs to bind CA in the active site at physiological pH values of 7.4. A detachment is caused 
by mildly acidic pH conditions of 5.5 prevailing in endolysosomes. In the following, we 
present a novel pH-sensitive CA-based capping system on MSNs. The MSN nanocarriers 
containing biomolecular valves based on carbonic anhydrase are anticipated to offer 
promising potential for controlled drug delivery applications, for instance in cancer therapy. 
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7.2 Results and Discussion 
pH-responsive MSNs consisting of biomolecular valves based on the enzyme carbonic 
anhydrase (CA) were synthesized in a two-step approach. First, MSNs containing thiol-
functionality exclusively at the external particle surface were established following our 
previously described delayed co-condensation approach.
[4]
 In brief, the silica source tetraethyl 
orthosilicate (TEOS) and the template cetyltrimethylammonium chloride (CTAC) were mixed 
at elevated temperatures in an aqueous solution including the base triethanolamine (TEA), 
which additionally serves as a structure-directing agent to form colloidal nanoparticles. A 
mixture of TEOS and mercaptopropyl triethoxysilane (MPTES) was added at the very last 
step of the silica framework formation to create a very thin external functional shell consisting 
of thiol groups (sample MSN-SH). This organic moiety offers the possibility to attach further 
functionality exclusively on the outer surface of the MSNs, while not affecting the porous 
system. In a second step, benzene sulfonamide (phSA) groups were covalently attached to the 
silica nanoparticles via a short bifunctional crosslinker (maleimide-C6-NHS) at mild reaction 
conditions (sample MSN-phSA). The particle sizes of functionalized MSNs were determined 
with dynamic light scattering (DLS) measurements (Figure 7.1a). All samples featured narrow 
particle size distribution implying a good colloidal stability. No agglomeration occurred due 
to the additional attachment of organic moieties to the particle surface. Samples MSN-SH and 
MSN-phSA show a maximum for particles sizes at 122 and 142 nm, respectively. For 
enzyme-coated particles MSN-phSA-CA a slight shift to higher values can be observed 
(190 nm). 
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Figure 7.1: a) Dynamic light scattering (DLS) and b) zeta potential measurements of functionalized MSNs. 
MSN-SH (black), MSN-phSA (red), and MSN-phSA-CA (green). 
DLS data provide increased values for particle sizes compared to transmission electron 
microscopy (TEM) images, since the hydrodynamic radius of the particles is taken into 
account. Random weak particle agglomeration during the DLS measurements may also 
further increase the measured values.
[21]
 TEM analysis provides additional insights regarding 
the morphology and porosity of MSNs. Thiol-functionalized MSNs are depicted in Figure 7.2, 
showing mostly spherically shaped particles with a worm-like structure of the mesopores. The 
average diameter of the MSNs was about 70 nm. 
 
Figure 7.2: Transmission electron micrograph of thiol-functionalized MSNs (MSN-SH). 
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Furthermore, the first-order reflection of the mesoporous material observed with small-angle 
X-ray diffraction (XRD) suggests the formation of a mesoporous structure with regular but 
not periodic channel structure (cf. Appendix 7.5). The surface charge of silica nanoparticles, 
measured as the zeta potential, changed due to stepwise attachment of organic moieties 
(Figure 7.1b). The isoelectric point (IEP) of MSN-SH (pH 3.6) was shifted to a more acidic 
pH value (< 2) for MSNs containing the benzene sulfonamide groups on the outer surface. 
The tendency for sulfonamide groups to be protonated is relatively low due to the stabilizing 
resonance effect, consequently causing an increase of negative surface charge. After 
attachment of the carbonic anhydrase a drastic change can be observed. This enzyme consists 
of various amino acid residues which can be easily protonated, including arginine, histidine 
and lysine. Therefore, a highly positive surface charge occurs over the whole acidic pH range. 
MSN-phSA-CA features an IEP at neutral pH values (pH ~7). Vibrational spectroscopy 
including infrared (IR) and Raman spectroscopy, were performed to investigate specific 
vibrational bands originating from organic groups. IR data for all samples show typical 
vibration bands of the silica framework (Figure 7.3a). A broad peak in the range between 
1300 and 1000 cm
-1
 can be assigned to Si-O-Si stretching vibration modes. Two additional 
bands at 900 and 780 cm
-1
 are related to asymmetric stretching and bending vibrations of Si-
OH groups, respectively. Furthermore, a group of bands in the range between 3000 and 
2800 cm
-1
 can be observed, which indicates C-H stretching vibrations of methylene and 
methyl groups from the propyl chain of organosilane moieties and residual ethoxy silane 
groups. Sample MSN-SH features a band at 1633 cm
-1
 which can be assigned to the bending 
modes of physisorbed water. This band is present in all spectra but partially overlapped by 
other more intensive bands for the coated particles. MSNs containing the benzene 
sulfonamide groups show additional C=O stretching vibration bands at 1700 and 1627  cm
-1
 
which can be referred to the carbonyl groups of the short maleimide-C6-NHS linker 
(maleimide and amide, respectively). Furthermore, a peak of weak intensity at 1340 cm
-1
 is 
present in the spectrum of sample MSN-phSA, which belongs to the typical asymmetric SO2 
stretching vibration modes of the sulfonamide groups. For the sample MSN-phSA-CA, amide 
vibrations (Amide I: 1639 cm
-1
, C=O stretching vibration; Amide II: 1535 cm
-1
, N-H 
deformation and C-N stretching vibration) of high intensity are observed in the range between 
1700 and 1500 cm
-1
; these are typical for enzymes. 
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Figure 7.3: a) Infrared (IR) and b) Raman spectroscopy data of functionalized MSNs. MSN-SH (black), 
MSN-phSA (red), and MSN-phSA-CA (green). For better clarity, the spectra are shifted along the y-axis 
by 0.2 units and for Raman spectroscopy by 0.1 units. 
Raman spectroscopy provides data complementary to IR spectroscopy. In Figure 7.3b a more 
detailed view of the spectra for MSN-SH and MSN-phSA in the range between 1900 and 
600 cm
-1
 is depicted (data for MSN-phSA-CA not shown, full range of Raman spectra refer to 
Appendix 7.5). Various additional bands (*) can be observed for the benzene sulfonamide-
functionalized particles. A sharp band at 1780 cm
-1
 can be assigned to the carbonyl stretching 
vibration of the diacylamine group of the maleimide residue that is covalently attached to the 
thiol groups of the MSN surface. The presence of phenyl groups is confirmed by 
characteristic bands of aromatic C=C stretching vibrations (1600 cm
-1
 and 1055 cm
-1
) and 
aromatic =C-H out-of-plane deformation vibrations (693 cm
-1
). The broadening of the signal 
at 1600 cm
-1
 can be assigned to the partial overlap by amide II vibration modes. The bands at 
1326 and 1156 cm
-1
 are related to the characteristic asymmetric and symmetric stretching 
vibrations of the sulfonamide group, respectively. The amount of attached organic moieties on 
the MSNs was investigated by thermogravimetric analysis (TGA). MSN-phSA particles show 
an additional weight loss of 3 % in the range between 130 and 900 °C due to the attachment 
of the benzene sulfonamide linker (Figure 7.4). This is in good accordance with expected 
values since only 1 mol% MPTES (of total Si content) was used for the functionalization of 
the external silica particle surface. Enzyme-coated MSNs (MSN-phSA-CA) feature a 
relatively high additional weight loss compared to sample MSN-SH (+14 % at 900 °C). 
Apparently, degradation of the carbonized enzymes occurs only at very high temperatures, 
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and is not even finished at 900 °C. This was already observed before for thermogravimetric 
analysis of enzyme-coated MSNs.
[22]
 
 
Figure 7.4: Thermogravimetric analysis of MSN-SH (black), MSN-phSA (red), and MSN-phSA-CA 
(green). 
Nitrogen sorption measurements show type IV isotherms for MSN-SH and MSN-phSA, 
confirming mesoporosity of the silica nanoparticles. The corresponding nitrogen sorption 
isotherms are depicted in Figure 7.5a showing inflection points at p/p0 = 0.3. Another 
hysteresis loop at about 0.9 p/p0 is present for all samples, and can be attributed to 
interparticle textural porosity. Relatively high surface areas (up to 1200 m²/g) and pore 
volumes (0.8 cm³/g) can be observed for MSN-SH and MSN-phSA (Table 7.1). 
Table 7.1. Porosity parameters of functionalized MSNs. 
Sample BET surface area (m²/g) Pore volume
a
 (m³/g) Pore size
b
 (nm) 
MSN-SH 1170 0.83 3.8 
MSN-pSA 1004 0.72 3.7 
MSN-pSA-CA 99 0.07 – 
a
Pore volume is calculated up to a pore size of 8 nm to remove the contribution of interparticle porosity. 
b
DFT pore size refers to the peak value of the pore size distribution. 
The slight reduction in these porosity parameters for benzene sulfonamide-functionalized 
MSNs can be assigned to the increase of sample weight by additional non-porous organic 
moieties. Furthermore, the DFT pore size distribution (Figure 7.5b) still shows accessible 
7.2. Results and Discussion  
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pores. Importantly, the porous system is not affected by the attachment of the benzene 
sulfonamide linkers and no incorporation of organic groups inside the mesopores can be 
observed, which is confirmed by a constant pore size distribution. The attachment of the 
bulky enzyme carbonic anhydrase results in a drastic reduction of the surface area and pore 
volume for sample MSN-phSA-CA. Enzyme-coated MSNs feature a type II isotherm which 
corresponds to non-porous materials. The carbonic anhydrase enzymes act like bulky 
biomolecular valves that are able to efficiently block the mesopores even towards the access 
of small nitrogen molecules. We observed no pore size distribution for MSN-phSA-CA in the 
range between 2 and 9 nm. 
 
Figure 7.5: a) Nitrogen sorption isotherms and b) DFT pore size distributions of functionalized MSNs. 
MSN-SH (black), MSN-phSA (red), and MSN-phSA-CA (green). 
All the above data confirm the successful synthesis of carbonic anhydrase coated MSNs via 
benzene sulfonamide linkers. In order to investigate the pH-responsive removal of the bulky 
gatekeepers from the particles, in vial cargo release experiments were performed. We used a 
custom-made two-compartment system to analyze the time-based release of the fluorescent 
model drug fluorescein.
[11]
 After incorporation of fluorescein molecules into the mesoporous 
system, carbonic anhydrase was added to block the pore entrances. An efficient sealing of the 
pores and no premature release of the cargo can be observed for the sample MSN-phSA-CA 
dispersed in HBSS buffer (pH 7.4) at 37 °C (Figure 7.6a, closed state, black curve). After 3 h 
the solution was exchanged and the particles were dispersed in citric-acid phosphate buffer 
(CAP buffer, pH 5.5). The change to acidic milieu, which simulates the acidification of 
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endosomes, causes a significant increase in fluorescence intensity over time reaching its 
maximum after 18 hours (open state, red curve). Furthermore, we could show a long-term 
stability of the capping system for more than 16 hours in HBSS buffer and cell medium at 
pH 7.4 (Figure 7.6b). These in vial release experiments demonstrate an efficient sealing of the 
pores with the carbonic anhydrase as bulky gatekeepers, preventing premature cargo release 
and a stimuli-responsive release behavior upon acid-sensitive detachment of the capping 
system. 
Figure 7.6: In vial release kinetics of fluorescein molecules from the enzyme-coated MSNs at different pH 
values. (a) Sample MSN-pSA-CA features no premature release of the fluorescent cargo molecules in 
HBSS buffer solution at pH 7.4 (closed state, black curve). After 3 h the medium was changed to slightly 
acidic milieu (CAP buffer, pH 5.5, red curve) resulting in a significant increase in fluorescence intensity. 
The gatekeepers are detached from the particle surface upon acidic pH values causing an efficient and 
precisely controllable release of the fluorescein from the mesoporous system. (b) Long-term stability of the 
capping system was investigated in HBSS buffer (pH 7.4, black curve) and cell medium (blue curve). No 
unintended cargo release was observed within about 16 h. 
Enzyme activity assays provide information about the binding affinity of carbonic anhydrase 
on the surface of sulfonamide-functionalized MSNs (Figure 7.7). The enzyme activity assay 
investigates the hydrolysis in TRIS-buffered solution of a chromogenic substrate (p-
nitrophenyl acetate, NPA) in the presence of the enzyme, generating nitrophenol. UV-Vis 
spectroscopy is used to measure the resulting absorption maximum at 400 nm. Figure 7.7 
shows the resulting curve for the non-catalyzed (no carbonic anhydrase) reaction, which can 
be taken as baseline. The slight slope for this curve is due to the hydrolysis rate of the pure 
substrate in aqueous solution in the absence of catalytic enzymes. In the presence of 100 nM 
enzyme (non-inhibited) the maximum conversion of the substrate can be obtained. A slight 
decrease in conversion efficiency can be observed upon addition of 50 µg of MSN-SH 
particles due to marginal reduction of enzyme activity in the presence of silica nanoparticles. 
7.2. Results and Discussion  
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We assume that this effect corresponds to minor unspecific attachment of the carbonic 
anhydrase to the silica nanoparticles causing blocking of the active sites to some extent. In 
comparison, the addition of inhibitor-containing particles (MSN-phSA) causes a significant 
decrease of the slope of the resulting curve. Thus we have shown conclusively that the 
sulfonamide-functionalized MSNs are able to inhibit/bind the enzyme carbonic anhydrase. At 
neutral pH values, the enzyme is specifically attached to the sulfonamide-functionalized 
particle surface resulting in an inhibition of the en yme’s active site. This leads to a drastic 
decrease in enzyme activity.  
 
Figure 7.7: Enzyme activity assay of CA catalyzing the hydrolysis of the chromogenic substrate p-
nitrophenyl acetate measured by UV-Vis spectroscopy (absorbance at 400 nm). Non-catalyzed (green) and 
non-inhibited (blue) reaction and after addition of MSN-SH (black) or MSN-phSA (red). 
Employing fluorescent live-cell imaging, we investigated the in vitro release behavior of the 
host MSN-phSA-C , loaded in the channel system with 4’,6-diamidino-2-phenylindole 
(DAPI), on HeLa cancer cells. The size of DAPI is similar to fluorescein molecules and 
therefore may be efficiently encapsulated in the mesoporous system of our CA-capped silica 
nanoparticles. DAPI is commonly used as a nuclei counterstain in cell imaging due to its 
effective turn-on fluorescence upon intercalation with DNA double strands (about 20 fold 
enhancement in fluorescence intensity).
[23]
 Since DAPI is cell membrane permeable, free 
fluorescent dye molecules are able to stain the nucleus within very short time periods (1-
5 min), as suggested by several staining protocols.
[24]
 After incorporation of DAPI into the 
mesoporous system of the silica nanocarriers, the pores were sealed by addition of carbonic 
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anhydrase enzymes. The HeLa cells were incubated for a total time period of 24 h with the 
loaded particles, which were additionally labeled with Atto 633 dye (red), as depicted in 
Figure 7.8. After 7 h of incubation, MSNs were efficiently uptaken by the cells and were 
found to be located in endosomes. Importantly, almost no staining of the nuclei with DAPI 
(blue) could be observed at this time point. Only after 15 h, blue fluorescent color (even more 
intensive after 24 h) provides evidence about an efficient release of DAPI from the MSNs. 
Reference experiments with the sample supernatant after particle separation (centrifugation) 
showed no significant nuclei staining even after 24 h (Figure 7.8d). This proves a substantial 
release from the mesopores of our nanocarrier system, and also shows that no free dye 
molecules were present in the solution. These cell experiments illustrate the time-dependent 
release behavior of DAPI to HeLa cells. We suggest that this delayed nuclei staining results 
from a cascaded release mechanism. First, acidification throughout the endosomal pathway to 
late endosomes or endolysosomes is of key importance. The pH change to mildly acidic 
values (about 5.5) is essential for the detachment of the bulky gatekeepers from the MSN 
hosts, and subsequently the opening of the pores leads to an efficient cargo release. 
 
Figure 7.8: Fluorescence microscopy of HeLa cells incubated with MSN-phSA-CA nanoparticles loaded 
with DAPI and labeled with Atto 633 (red) after a) 7 h, b) 12 h and c) 24 h of incubation with the cells. The 
delayed nuclei staining with DAPI (blue) is caused by a time-dependent release of DAPI based on the need 
for an acidic environment. d) In a reference experiment, the incubation with the supernatant solution 
(without MSNs) showed no staining of the nuclei with DAPI after 24 h, suggesting that no free DAPI 
molecules are present in the particle solution. The nuclei are indicated with dashed circles. The scale bar 
represents 10 µm. 
In order to verify the fate of our drug delivery vehicles ending up in acidic cell compartments, 
co-localization experiments with labeled MSNs and endosomes or lysosomes were performed. 
Simultaneous with particle incubation, the HeLa cells were treated with different fusion-
constructs of green fluorescent protein (GFP) and early/late endosome or lysosome markers, 
respectively. After 24 h of incubation with fluorescently labeled nanoparticles, almost no co-
localization (yellow) between early endosomes and MSNs could be observed, as can be seen 
in Figure 7.9a. In contrast, multiple yellow spots indicating co-localization between GFP 
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(green) and MSNs (red) were clearly visible in the case of late endosomal and lysosomal 
staining after 21 h (Figure 7.9b/c, denoted by arrows). This shows that the localization of our 
nanocarriers in an acidic compartment is crucial to initiate cargo release. 
 
Figure 7.9: Fluorescence microscopy of HeLa cells incubated with Atto 633-labeled MSN-phSA-CA (red) 
after a) 24 h on GFP-early endosome (green) tagged cells, b) 21 h incubation on GFP-late endosome 
(green) tagged cells, and c) 21 h on GFP-lysosome (green) tagged cells. Co-localization (yellow) could be 
primarily observed for late endosomes and lysosomes (indicated with arrows) suggesting that the 
multifunctional MSNs are located in acidic compartments after endocytosis. The scale bar represents 
10 µm. 
As depicted in Figure 7.10, a detailed view on GFP-lysosome tagged cells revealed that the 
MSNs loaded with DAPI were co-localized (white) with lysosomes (cf. Figure 7.9c, for 
clarity reasons the blue DAPI channel was not shown before). Additionally, a successful 
DAPI release could be observed by efficient nuclei staining (blue) after 21 h of incubation on 
HeLa cells. For the present pH-responsive drug nanocarrier system, it is crucial to gain access 
to an acidic cell compartment such as late endosome or lysosome. Subsequently, the on-
demand release can be triggered by the low pH. The above co-localization studies provide 
good evidence for the delayed release kinetics observed after several hours of particle 
incubation. 
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Figure 7.10: Fluorescence microscopy of HeLa cells incubated with MSN-phSA-CA nanoparticles loaded 
with DAPI (blue) and labeled with Atto 633 (red) after 21 h on GFP-lysosome (green) tagged cells. The 
white spots indicate co-localization between MSNs and lysosomes. A successful DAPI delivery is clearly 
visible by efficient nuclei staining (blue). The scale bars represent 10 µm. 
7.3 Conclusions 
In summary, we conclude that the novel capping system concept based on pH-responsive 
detachment of carbonic anhydrase is a suitable candidate for a highly controllable drug release 
from porous nanocarriers. Our drug delivery system provides an on-demand release 
mechanism shown by in vial and in vitro cargo release experiments. The multifunctional 
MSNs were capable of efficient endocytosis by cancer cells and were subsequently located in 
acidic cell compartments including late endosomes and lysosomes. The acidic milieu caused 
cleavage of the coordination bond between the sulfonamide linkers and the bulky gatekeepers 
and successful cargo release occurred. This was proven by the appearance of strong 
fluorescent nuclei staining with DAPI. We note that our pH-responsive gatekeeper system 
might show potential for reversible pore blocking behavior. Once the nanocarriers are 
exocytosed, they will be exposed to neutral pH values agian. Since carbonic anhydrase is 
abundant in the blood stream it is anticipated that a re-capping of the MSNs is feasible and 
that it could prevent subsequent leakage of not yet released cargo molecules, provided that the 
sulfonamide linker survives the lysosome. Consequently, spreading of chemotherapeutics in 
the organism would be limited and systemic side-effects could be further reduced. A detailed 
investigation of this intriguing aspect is subject of future work. Our newly developed concept 
for pH-responsive gatekeepers provides a promising basis for future work on mesoporous 
silica particles serving as powerful and versatile drug delivery platform. 
7.4. Experimental  
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7.4 Experimental 
Materials. Tetraethyl orthosilicate (TEOS, Fluka, > 99 %), triethanolamine (TEA, Aldrich, 
98 %), cetyltrimethylammonium chloride (CTAC, Fluka, 25 % in H2O), (3-mercaptopropyl)-
triethoxysilane (MPTES, Sigma Aldrich, > 80 %), 6-maleimidohexanoic acid N-
hydroxysuccinimide ester (Fluka, > 98 %), bovine carbonic anhydrase (bCA, Sigma, > 95 %), 
4-(2-aminoethyl)benzenesulfonic acid (Aldrich, 98 %), ammonium nitrate (NH4NO3, 
Aldrich), ammonium fluoride (NH4F, Aldrich), hydrochloric acid (37 %), fluorescein 
disodium salt dihydrate (Aldrich, 90 %), and Hank´s balanced salt solution (HBSS-buffer, 
Sigma Aldrich) were used as received. Ethanol (EtOH, absolute, Aldrich) and 
dimethylformamide (DMF, dry, Aldrich) were used as solvent without further purification. 
Bidistilled water was obtained from a millipore system (Milli-Q Academic A10). Citric-acid 
phosphate buffer (CAP-buffer, pH 5.5) was freshly prepared by carefully mixing a certain 
amount of disodium hydrogen phosphate (Na2HPO4, 0.2 M in H2O) and citric acid (0.2 M in 
H2O) to adjust a pH value of 5.5. Subsequently, the solution was diluted with bidistilled H2O 
to a total volume of 500 mL. 
Synthesis of thiol-functionalized MSNs (MSN-SH). A mixture of TEOS (1.92 g, 9.22 mol) 
and TEA (14.3 g, 95.6 mmol) was heated to 90 °C for 20 min under static conditions in a 
polypropylene reactor. Then, a preheated (60 °C) mixture of CTAC (2.41 mL, 1.83 mmol, 
25 % in H2O) and NH4F (100 mg, 0.37 mmol) in bidistilled H2O (21.7 g, 1.21 mol) was added 
and the resulting reaction mixture was stirred vigorously (700 rpm) for 30 min while cooling 
down to room temperature. Afterwards, TEOS (18.2 mg, 92 µmol) and MPTES (18.1 mg, 
92 µmol) were premixed briefly before addition to the reaction mixture. The final reaction 
mixture was stirred over night at room temperature. After dilution with absolute ethanol 
(100 mL), the nanoparticles were collected by centrifugation (19,000 rpm, 43,146 rcf, 20 min) 
and redispersed in absolute ethanol. Template extraction was performed in an ethanolic 
solution of MSNs (100 mL) containing NH4NO3 (2 g) which was heated at reflux conditions 
(90 °C oil bath) for 45 min. This was followed by a second extraction step (90 mL absolute 
ethanol and 10 mL hydrochloric acid (37 %)) under reflux conditions for 45 min (the material 
was washed with absolute ethanol after each extraction step and collected by centrifugation); 
finally the particles were redispersed in absolute ethanol and stored as colloidal suspension. 
 
159 
 
Synthesis of sulfonamide-functionalized MSNs (MSN-phSA). For the covalent attachment 
of a sulfonamide derivative to the external particle surface, a thiol-reactive linker was 
synthesized. 6-maleimidohexanoic acid N-hydroxysuccinimide ester (mal-C6-NHS, 10 mg, 
33 µmol) was dissolved in DMF (500 µL, dry) and was added to an ethanolic solution 
(15 mL) containing 4-(2-aminoethyl)benzene sulfonamide (6.7 mg, 33 µmol). The resulting 
reaction mixture was stirred for 1 h at room temperature. Afterwards, thiol-functionalized 
silica nanoparticles (MSN-SH, 100 mg) in absolute ethanol (10 mL) were added and the 
mixture was stirred over night at room temperature. Subsequently, the particles were collected 
by centrifugation (19,000 rpm, 41,146 rcf, 20 min), washed twice with absolute ethanol and 
were finally redispersed in ethanol (15 mL) to obtain a colloidal suspension. 
Cargo loading and particle capping. MSNs (MSN-phSA, 1 mg) were immersed in an 
aqueous solution of fluorescein (1 mL, 1 mM) or DAPI (500 µL, 14.3 mM) and stirred over 
night or for 1 h, respectively. After collection by centrifugation (14,000 rpm, 16,837 rcf, 
4 min), the loaded particles were redispersed in a HBSS buffer solution (1 mL) containing 
carbonic anhydrase (1 mg) and the resulting mixture was allowed to react for 1 h at room 
temperature under static conditions. The particles were thoroughly washed with HBSS buffer 
(4 times), collected by centrifugation (5,000 rpm, 2,200 rcf, 4 min, 15 °C), and finally 
redispersed in HBSS buffered solution. 
Characterization. DLS and zeta potential measurements were performed on a Malvern 
Zetasizer Nano instrument equipped with a 4 mW He-Ne-Laser (633 nm) and an avalanche 
photodiode detector. DLS measurements were directly recorded in diluted colloidal 
suspensions of the particles at a concentration of 1 mg/mL. Zeta potential measurements were 
performed using the add-on Zetasizer titration system (MPT-2) based on diluted NaOH and 
HCl as titrants. For this purpose, 1 mg of the particles was diluted in 10 mL bi-distilled water. 
Thermogravimetric analyses (TGA) of the bulk extracted samples (approximately 10 mg) 
were recorded on a Netzsch STA 440 C TG/DSC. The measurements proceeded at a heating 
rate of 10 °C/min up to 900 °C in a stream of synthetic air of about 25 mL/min. Nitrogen 
sorption measurements were performed on a Quantachrome Instrument NOVA 4000e at -
196 °C. Sample outgassing was performed for 12 hours at a vacuum of 10 mTorr at 60 °C. 
Pore size and pore volume were calculated by a NLDFT equilibrium model of N2 on silica, 
based on the desorption branch of the isotherms. In order to remove the contribution of the 
interparticle textural porosity, pore volumes were calculated only up to a pore size of 8 nm. A 
BET model was applied in the range of 0.05 – 0.20 p/p0 to evaluate the specific surface area. 
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Infrared spectra of dried sample powder were recorded on a ThermoScientific Nicolet iN10 
IR-microscope in reflexion-absorption mode with a liquid-N2 cooled MCT-A detector. Raman 
spectroscopy measurements were performed on a confocal LabRAM HR UV/VIS (HORIBA 
Jobin Yvon) Raman microscope (Olympus BX 41) with a SYMPHONY CCD detection 
system. Measurements were performed with a laser power of 10 mW at a wavelength of 
633 nm (HeNe laser). Dried sample powder was directly measured on a coverslip. UV/VIS 
measurements were performed on a Perkin Elmer Lambda 1050 spectrophotometer equipped 
with a deuterium arc lamp (UV region) and a tungsten filament (visible range). The detector 
was an InGaAs integrating sphere. Fluorescence spectra were recorded on a PTI 
spectrofluorometer equipped with a xenon short arc lamp (UXL-75XE USHIO) and a 
photomultiplier detection system (model 810/814). The measurements were performed in 
HBSS buffer solution at 37 °C to simulate human body temperature. For time-based release 
experiments of fluorescein a custom made container consisting of a Teflon tube, a dialysis 
membrane (ROTH Visking type 8/32, MWCO 14,000 g/mol) and a fluorescence cuvette was 
used. The excitation wavelength was set to λ = 495 nm for fluorescein-loaded MSNs. 
Emission scans (505 – 650 nm) were performed every 5 min. All slits were adjusted to 
1.0 mm, bandwidth 8 nm). 
Cell Culture. HeLa cells were grown in  ulbecco’s modified Eagle’s medium ( MEM):F12 
(1:1) (Invitrogen) with Glutamax I medium supplemented with 10 % fetal bovine serum 
(FBS) at 37 °C in a 5 % CO2 humidified atmosphere. The cells were seeded on collagen A-
coated LabTek chambered cover glass (Nunc). For live cell imaging the cells were seeded 24 
or 48 h before measuring, at a cell density of 2x10
4
 or 1x10
4
 cells/cm
2
. 
In vitro Cargo Release. Cells were incubated 7 – 24 h prior to the measurements at 37 °C 
under a 5% CO2 humidified atmosphere. Shortly before imaging, the medium was replaced by 
CO2-independent medium (Invitrogen). During the measurements all cells were kept on a 
heated microscope stage at 37 °C. The subsequent imaging was performed as described in the 
spinning disk confocal microscopy section. 
Endosomal compartment staining. To stain the early/late endosome or the lysosome with 
GFP, commercially available CellLight© staining from Invitrogen was used (CellLight© 
Early Endosome-GFP, Late Endosome-GFP, and Lysosome-GFP, BacMam 2.0). The cells 
were simultaneously incubated with MSNs and the BacMam 2.0 reagent. The concentration 
of the labeling reagent was chosen with 25 particles per cell (PCP) of the BacMam 2.0 reagent 
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(cf. staining protocol
[25]
). For incubation, the cells stayed at 37 °C under 5% CO2 humidified 
atmosphere for 21 – 24 h till the measurement. 
Spinning disc confocal microscopy. Confocal microscopy for live-cell imaging was 
performed on a setup based on the Zeiss Cell Observer SD utilizing a Yokogawa spinning 
disk unit CSU-X1. The system was equipped with a 1.40 NA 100x Plan apochromat oil 
immersion objective from Zeiss. For all experiments the exposure time was 0.1 s and z-stacks 
were recorded. GFP was imaged with approximately 0.48 W/mm
2
 of 488 nm excitation light. 
Atto 633 was excited with 11 mW/mm
2
 of 639 nm and DAPI with 0.16 W/mm
2
 of 405 nm. In 
the excitation path a quad-edge dichroic beamsplitter (FF410/504/582/669-Di01-25x36, 
Semrock) was used. For two color detection of GFP or DAPI and Atto 633, a dichroic mirror 
(560 nm, Semrock) and band-pass filters 525/50 and 690/60 (both Semrock) were used in the 
detection path. Separate images for each fluorescence channel were acquired using two 
separate electron multiplier charge coupled device (EMCCD) cameras 
(PhotometricsEvolve
TM
). 
7.5 Appendix 
 
Figure 7.11: Small-angle X-ray diffraction pattern of MSN-SH (black) and MSN-phSA (red). 
7.5. Appendix  
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Figure 7.12: Raman spectroscopy data of functionalized MSNs. MSN-SH (black) and MSN-phSA (red). 
For clarity reasons, the spectra are shifted along the y-axis by 0.1 units. Measurements were performed at 
an excitation wavelength of 633 nm. 
 
Figure 7.13: Calibration curves of fluorescein at pH 7.4 (HBSS buffer, black curve) and pH 5.5 (CAP 
buffer, red curve) 
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8 Targeted Drug Delivery in Cancer Cells with Red-Light Photoactivated 
Mesoporous Silica Nanoparticles 
This chapter is based on the following publication: 
Stephan Mackowiak, Alexandra Schmidt, Veronika Weiss, Christian Argyo, Constantin von 
Schirnding, Thomas Bein, and Christoph Bräuchle, Nano Letters, 2013, 13, 2576 – 2583. 
 
 
8.1 Introduction 
The delivery of large amounts of cancer therapeutics specifically into the cytosol of cancer 
cells still faces significant challenges. Promising approaches in the field of drug delivery 
encompass the utilization of various types of nanoparticles such as polyplexes,
[1-3]
 
dendrimers,
[4-6]
 gold nanoparticles,
[7]
 and colloidal mesoporous silica nanoparticles (MSNs).
[8-
10]
 Each of these systems has its inherent advantages and disadvantages. Usually, they are 
either optimized for specific uptake by cancer cells, amount of cargo delivered, release of 
cargo into the cytosol, or ease of synthesis of the system itself. However, often they do not 
perform well in all of these required areas. Notably, release of the drug from the endosome 
poses a significant hurdle on the way toward drug delivery with high efficacy. Here, we will 
present a system that provides solutions for all of these aspects. In particular, a 
photoactivatable drug delivery system based on core−shell colloidal MSNs will be employed, 
which allows exact spatial and temporal control of the release of the cargo from both the 
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MSNs and the endosome.
[11-12]
 Core−shell MSNs are more suitable than regular MSNs for 
this task because they can have different functionalizations in the core and the shell. This 
allows us to optimize the core functionalization, for example, for cargo uptake or covalent 
binding of the cargo to the core by disulfide bridges.
[13]
 Moreover, the surface 
functionalization can be chosen to implement various gating mechanisms, such as 
surrounding the MSNs with a lipid bilayer to enclose the cargo in it.
[11, 14]
 Previously, our 
groups published a photoactivatable drug delivery system performing some of the above-
mentioned tasks.
[14]
 The current system is improved in three key areas. The used 
photosensitizer (PS) will be activated by red light instead of blue light; the synthesis is 
significantly simplified, and targeting ligands have now been added to the system. The 
function of the photosensitizer is to solve the problem of endosomal entrapment. Other 
approaches addressing this issue such as taking advantage of the proton sponge effect,
[15-16]
 
employing fusogenic or endosomolytic peptides,
[17-20]
 and others have been used.
[21-22]
 There, 
the endosomal escape occurs at a less defined time point and for all particles regardless of 
their location in healthy or cancerous cells. In contrast, the photoactivation approach offers a 
solution for both of these shortcomings by initiating the cargo release through an external 
stimulus in the form of a laser beam. The laser beam can be directed into the cancer tissue and 
activated at the right time point. The activation of the photosensitizer with red light instead of 
blue light reduces the phototoxicity and significantly increases the depth of tissue 
penetration,
[23]
 which will be crucial when activation in vivo is required as shown by the 
Kataoka group.
[24]
 In comparison to regular photochemical internalization and other 
photoactivatable systems our system exhibits specific uptake by cancer cells due to the 
presence of targeting ligands. Schlossbauer et al.
[14]
 presented MSNs with photosensitizers 
that allowed free choice and controlled release of the cargo. However, the issue of the 
targeting capability of the system was not addressed. In the current approach, we covalently 
link the photosensitizer molecule (PS) to the MSN surface and encapsulate the MSNs with a 
supported lipid bilayer (SLB) to retain the drug. This allows for choosing a drug different 
from the PS and implementing a gating mechanism as well. Most cancer cells have specific 
receptors overexpressed on their surface. These receptors are only present in small 
concentrations or not at all on the surface of healthy cells. Ideally, a drug delivery system can 
be easily modified to make it specific for multiple cancer cell types. Here we introduce the 
choice between two targeting ligands to our MSNs, namely, folic acid (FA) as an example of 
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a small molecule ligand and epidermal growth factor (EGF) as an example for a protein 
ligand. Both ligands are relevant for cancer cell targeting. For this purpose, targeting ligands 
(TL) are inserted into the SLB by diffusion to achieve specific uptake of the drug delivery 
vehicle by cancer cells. In the following, we will first discuss the synthesis and characteristics 
of our drug delivery system. Subsequently, live cell microscopy studies will be presented to 
evaluate the functionality of the employed targeting ligands and the release of the cargo from 
the MSNs by photoactivation. 
8.2  Results and Discussion 
Synthesis and Characterization. The core−shell MSNs were synthesi ed via a sol−gel 
method using tetraethyl orthosilicate (TEOS) as a silica source and CTAC as a pore 
template.
[12]
 The MSN core was functionalized with thiol groups and the surface with cyano 
groups. The cyano groups were hydrolyzed at elevated temperatures under acidic medium to 
result in carboxy groups exclusively at the external silica particle surface. A next step was the 
covalent binding of the PS to the MSNs. We note that a direct attachment of the AlPcS2a 
resulted in a significantly reduced pore accessibility and particle aggregation (data not 
shown). Introduction of a spacer helped to retain pore access and colloidal stability. Here, 
bifunctional PEG linkers were attached to the outer surface of MSNs via the EDC amidation 
synthesis route; they additionally offer a site for further functionalization. This strategy can be 
further utilized for covalent binding of PS molecules, targeting ligands or other biocompatible 
moieties. Previous studies have shown that coating of MSNs with hydrophilic polymers, 
including PEG, improves biocompatibility and colloidal stability of the drug delivery vehicles 
in aqueous media.
[25]
 However, the length of the integrated PEG linker should not be too long 
because otherwise the formation of the SLB around the nanoparticle can be difficult. Scheme 
8.1 depicts the complete synthesis strategy resulting in multifunctional mesoporous silica 
nanocarriers for a red-light photoactivated targeted drug release into cancer cells. 
8.2. Results and Discussion  
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Scheme 8.1. Synthesis pathway of core (Green) shell (Red) MSNs with covalently linked AlPcS2a (red star) 
via PEG linker (black chain) and surrounded by DOPC/DOTAP supported lipid bilayer with targeting 
ligand (green star, TL). Before the formation of the SLB, the MSN core is loaded with a cargo (yellow), in 
our case calcein or a rhodamine derivative. Drawing is not to scale. 
The transmission electron microscope (TEM) image of the MSNs (species I in Scheme 8.1) 
shows spherical particles with a mean diameter of 70 nm (Figure 8.1a). The mesoporous 
channel structure radiating from the particle center is apparent in the image. From dynamic 
light scattering (DLS) and nitrogen sorption experiments a mean particle size of 69 nm and a 
mean pore size of 5.2 nm was determined (black squares in Figure 8.1b and c). 
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Figure 8.1: (a) TEM image showing bare MSNs (I). The scale bar is 20 nm. (b) Particle sizes of species 
I−VI in Scheme 1 obtained by DLS measurements. All curves, except of species I (black curve, 
MSN_SHin_CNout), are shifted by a value of 30 along the y-axis for clarity. (c) Pore size distributions of 
species I−IV. The exact values of the maxima are given in Table 1. Data are shifted by a value of 0.3 along 
the y-axis for clarity. Species I (black curve) represent MSN_SHin_CNout, species II (red curve) are 
MSN_SHin_COOHout, species III (green curve) are MSN_SHin_PEGd8NH2, species IV (blue curve) are 
MSN_SHin_PEGd8-AlPcS2aout, species VI (cyan curve) are DOPC/DOTAP-
SLB@MSN_CARGOin_PEGd8-AlPcS2aout. 
The nitrogen sorption isotherms of the samples MSN_SHin_CNout (I, black squares), 
MSN_SHin_COOHout (II, red circles), MSN_SHin_PEGd8NH2out (III, green up triangles), and 
MSN_SHin_PEGd8-AlPcS2aout (IV, blue inverted triangles) can be seen in Figure 8.2, 
exhibiting a typical type IV isotherms for mesoporous materials. 
 
Figure 8.2: Nitrogen sorption isotherms for the samples MSN_SHin_CNout (black squares), 
MSN_SHin_COOHout (red circles), MSN_SHin_PEGd8NH2out(green up triangles) and MSN_SHin_PEGd8-
AlPcS2a (blue down triangles). For clarity reasons curves for MSN_SHin_COOHout, 
MSN_SHin_PEGd8NH2out, and MSN_SHin_PEGd8-AlPcS2aout are shifted along the y-axis by a value of 500 
each. 
  
8.2. Results and Discussion  
 
170 
 
The Brunauer-Emmett-Teller (BET) surface areas for each sample are calculated from the 
corresponding nitrogen sorption isotherm in the range p/p0 = 0.05 – 0.2 and are summarized 
in Table 8.1. All samples feature a high specific surface area typical for our MSNs. We 
assume that the reduced BET surface area in the sample MSN_SHin_COOHout (II) in 
comparison with MSN_SHin_CNout(I) comes from the more condensed silica network and 
pore shrinkage resulting from the hydrolysis of the cyano-moiety in hydrochloric acid. The 
decrease of the specific surface area in the sample MSN_SHin_PEGd8NH2out (III) can be 
explained by the addition of non-porous PEG and the blocking of some pores by frozen PEG-
linker in the surface layer of the MSNs. 
Table 8.1: Particle size, specific BET surface area, pore size and relative mass loss derived from Figure. 
8.1b, Figure. 8.2 and Figure 8.4. 
Sample 
Particle size 
[nm] 
BET surface 
area [m²/g] 
Pore size 
[nm] 
Relative mass loss 
[%] 
MSN_SHin_CNout 69 934 5.2 17 
MSN_SHin_COOHout 125 746 5.1 12 
MSN_SHin_PEGd8NH2out 98 615 5.6 18 
MSN_SHin_PEGd8-AlPcS2aout 294 918 5.5 31 
DOPC/DOTAP_SLB@MSN 160 n.a. n.a n.a 
 
This effect is relatively small due to the short length of the flexible spacer. In contrast, the 
BET surface area of the sample MSN_SHin_PEGd8-AlPcS2aout is with 918 m
2
/g significantly 
higher than the BET surface area for MSN_SHin_COOHout(II) and MSN_SHin_PEGd8NH2out 
(III). We suppose that this effect comes from interstitial pore volume occurring upon 
attachment of AlPcS2a onto the particle shell. Considering that phthalocyanines are large, 
sterically hindered molecules that lack the flexibility of a PEG-linker, a covalent attachment 
of them to the MSN surface will result in voids at liquid nitrogen temperatures. The pore size 
distributions derived from NLDFT calculations are given in Figure 4c and are summarized in 
Table 8.1. The pore size changes little upon PEGylation and photosensitizer attachment, 
indicating that the mesopores are still accessible for guest molecules. Furthermore, it proves 
the selective functionalization of the particle shell. 
To promote endosomal escape and subsequent delivery of the cargo into the cytosol, we 
employ a photoactivation approach. Herefore, a red-light sensitive photosensitizer, aluminum 
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phthalocyanine disulfonate (AlPcS2a), is covalently linked to the surface of the MSNs via an 
octamer PEG linker. The PEG linker is functionalized with amino groups on both ends. In the 
first reaction step, the surface cyano groups of the MSNs (I) are hydrolyzed to carboxyl 
groups (II), and subsequently the PEG linker is attached to the MSN surface via EDC 
amidation (III). The 
13
C solid state NMR (ssNMR) shows the successful implementation of 
these three steps (Figure 8.4a). The resonance of the carboxyl group appears at 180 ppm upon 
hydrolysis of the cyano groups (red trace in Figure 8.4a). Following EDC amidation, the 
carboxyl group disappears, and the C−O and CH2 resonances, both from the PEG linker, 
appear at 70 and 42 ppm, respectively (green trace in Figure 8.4a). The other resonances 
originate from the functionalized silanes of the MSNs. The different surface 
functionalizations, including the attachment of the PEG linker, are apparent in the final 
relative mass levels of the thermogravimetric analysis (TGA) curves as well (Figure 8.4b and 
Table 8.1). Species III with the PEG linker has a significantly greater mass loss than species I 
and II. The slightly lower mass loss of species II in comparison to species I originates from a 
more stable silica network that is formed during the 3 h heating in HCl, where the cyano is 
converted to carboxylic acid groups. The more stable silica network is apparent from the 
reduced BET surface area, as measured by N2 sorption experiments, as well. Subsequently, 
AlPcS2a is attached to the free remaining amino group of the PEG linker by linking the PEG-
NH2 group with one of the two sulfonate groups of AlPcS2a (IV). The successful attachment 
of AlPcS2a is inferred from the IR spectrum. The CH2 stretching vibrations from the organic 
functionality (mercaptopropyl- and cyanopropyl) are visible between 2800 cm
-1
 and 2850 cm
-
1
. Furthermore, several peaks at 2900 cm
-1
 (C-H stretching vibrations) and at 1400 cm
-1
 (C-H 
bending vibrations) are visible. The intensity of these vibrations decreases after the 
carboxylation of the cyanide groups. Further condensation of the silica framework was 
achieved through the hydrolysis of the cyano-moiety and therefore the content of ethoxy 
groups was reduced. The cyanide vibration at 2253 cm
-1
 for the species I disappears 
completely after hydrolysis while the new -COOH vibration at 1707 cm
-1
 
(MSN_SHin_COOHout) arises. After PEGylation by EDC amidation the C=O stretching 
vibration mode is moved to higher vibrational energies (1616 cm
-1
) resulting from the newly 
formed amide bond. Also the N-H bending vibrations appear at 1530 cm
-1
. The band between 
1300 cm
-1
 and 900 cm
-1
 can be attributed to silica framework vibrations and is visible in all 
spectra. The peak at 1332 cm
-1
 represents the asymmetric stretching of the -SO2 group in 
AlPcS2a. The peak arising at 904 cm
-1
 in the spectra of MSN_SHin_PEGd8-AlPcS2aout can be 
assigned to the stretching vibration of the newly formed N-S bond between the terminal 
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amino-group of the PEG-linker and AlPcS2a. The two peaks at 743 cm
-1
 and 720 cm
-1
 
correspond to the non-planar deformation vibrations of the C–H bonds of benzene rings. 
 
Figure 8.3: IR spectra of MSN_SHin_CNout (black), MSN_SHin_COOHout (red),MSN_SHin_PEGd8NH2out 
(green) and MSN_SHin_PEGd8-AlPcS2aout (blue). For clarity reasons curves were shifted along the y-axis 
by a value of 0.8 each. 
Thermogravimetric analysis shows a high mass loss for species IV which is comparably large 
due to the high molecular mass of AlPcS2a. In particular, the ratio of the mass loss going from 
species III to IV and from species II to III is 2. This can be related to the molecular mass ratio 
of the PS and the PEG, which is 2 as well. 
 
Figure 8.4: (a) Solid state 
13
C NMR spectra of species I−III. It shows the successful conversion of the 
surface cyano groups to carboxyl groups and the subsequent linkage of the PEG8 linker to the MSN shell. 
Spectra for MSN_SHin_COOHout (red) and MSN_SHin_PEGd8NH2out (green) are shifted by a value of 2 × 
106 each for clarity reasons. (b) Thermogravimetric analysis of species I−IV. The relative mass losses are 
given in Table 1. 
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The cyanopropyl groups of the sample MSN_SHin_CNout (I, black squares) are uncharged at 
high or low pH values, resulting in a zeta potential curve that is similar to the one of 
unfunctionalized MSNs. The successful attachment of NH2-PEGd8-NH2 to the sample 
MSN_SHin_COOHout results in a higher zeta potential value due to protonation of the amino 
groups at low pH values (green). The sample MSN_SHin_PEGd8_AlPcS2aout (I ) couldn’t be 
measured because the laser wavelength of 633 nm leads to an excitation of the 
photosensitizer, resulting in oxygen production with bubble formation on the electrode. 
Shorter measurement times did not lead to sufficient results. 
 
Figure 8.5: Zeta potential measurements of the samples MSN_SHin_CNout (black squares), 
MSN_SHin_COOHout (red circles), MSN_SHin_PEGd8NH2out (green up triangles). 
Cargo loading and release. To utilize the above multifunctional nanoparticles as drug 
delivery vehicles, a cargo was loaded into the MSN pores, and the entire nanoparticle was 
enclosed by a supported lipid bilayer to prevent premature release of the cargo from the MSN 
core. The cargo was loaded into the MSNs by incubating them in a concentrated solution of 
the cargo overnight. In our system different types of cargo can be loaded. Here we show two 
examples, calcein and a rhodamine derivative. After the loading of the cargo the SLB is 
formed around the nanoparticle via the solvent exchange method as published by Cauda et 
al.
[11]
 The SLB consists of a lipid mixture of 70 vol% of 1,2-dioleoyl-snglycero-3-
phosphocholine (DOPC) and 30 vol% of 1,2- dioleoyl-3-trimethylammonium-propane 
(DOTAP). The DLS data (Figure 8.1b) show that the modifications of the MSN surface, the 
attachment of the PEG linker, the linking of the photosensitizer, and the formation of the 
70 vol% DOPC/30 vol% DOTAP shell (SLB) result in colloidal systems with slightly varying 
8.2. Results and Discussion  
 
174 
 
hydrodynamic particle sizes (Figure 8.1b and Table 8.1, respectively). In particular, it appears 
that the presence of carboxyl- or sulfonyl groups, either directly on the MSN surface or on the 
AlPcS2a, results in an increase of the effective particle size. In contrast, the presence of PEG 
molecules on the MSN surface as well as the presence of the SLB results in a decrease of the 
effective particle size. In both cases, the origin of the size decrease can be attributed to the 
weaker interactions between the particles caused by steric or electrostatic stabilization. The 
accessible pore size as obtained by nitrogen sorption measurements is barely affected by the 
various surface modifications, as expected for particles that feature true core−shell spatially 
distributed functionalities (Figure 8.1c). The permeability of the SLB and the opening of the 
SLB by photoactivation were examined in situ with a cuvette, containing a semipermeable 
membrane.
[26]
 Figure 8.6 shows the release of cargo, either calcein (blue triangles) or a 
rhodamine derivative (  ) (black squares), from the MSN−PS−SL  ( I). 
 
Figure 8.6: Release kinetics of calcein (solid blue triangle) and a rhodamine derivative (RD, solid black 
squares) before and after photoactivation at 3 h with light of λ = 639 nm and 0.55 mW/mm
2
 for 1 min of 
MSN-PS-SLB measured in situ. Only after photoactivation a significant amount of cargo is released, 
demonstrating the impermeability of the SLB before. Analogously, the SLB can be opened by addition of 
triton to the MSN solution after a 3 h time period. For both calcein (open blue triangles) and the RD (open 
black squares) the release by triton is slower as compared to the opening of the SLB by photoactivation. 
The amount of released cargo over a 3 h time period before opening the SLB is minimal, 
demonstrating the integrity of the SLB. After 3 h in the cuvette the SLB was opened either by 
photoactivation or triton addition. To open the SLB through photoactivation the MSN-PS-
SLB particles were exposed to 639 nm light with a power density of 0.55 mW/mm
2
 for 1 min, 
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resulting in an activation of the photosensitizer and singlet oxygen production. The singlet 
oxygen reacts with the double bonds of the DOPC and opens the SLB. This is apparent from 
the strong increase of fluorescence starting after 3 h, originating from the release of the cargo 
from the MSN core. Alternatively, the SLB can be opened by triton addition. A strong 
increase of fluorescence for calcein (open blue triangles) and RD (open black squares) is 
apparent. However, the SLB opening via photoactivation seems to be more efficient, judging 
from the release rate of the cargos after induced SLB opening. 
Targeting. Besides the prevention of premature release of the cargo from the MSN core, the 
SLB offers the opportunity to add various targeting ligands to our nanoparticle system. In the 
following section, we will discuss how our MSN-PS-SLB system can be modified with two 
different targeting ligands, namely, folic acid (FA) and epidermal growth factor (EGF). The 
efficient modification of our drug delivery system with various targeting ligands as the final 
step in the synthesis allows for tuning of our multifunctional nanoparticles for a wide range of 
cell types without constructing a completely new system for each cell type.The system 
presented above offers this opportunity because the MSN-PS-SLB (VI) is only modified at the 
very end of the synthesis for a specific targeting ligand (TL). The basic building block for 
adding the targeting ligand to the MSN-PS-SLB (VI) is a DSPE-PEG2000-TL conjugate 
molecule. This building block is inserted into the SLB by incubating the MSN-PS-SLB (VI) 
with DSPE-PEG2000-TL at 37 °C for 3 h (FA) and 12 h (EGF), respectively. In the studies 
presented here, we chose FA and EGF as targeting ligands because their receptors are 
commonly overexpressed on a wide range of cancer cells.
[27-28]
 FA receptors are 
overexpressed on various cell lines such as HeLa cells and KB cells,
[27]
 and the EGF receptor 
is abundant on HuH7 cells, for example.
[29]
 The functionality of the targeting ligands on our 
nanoparticle system was evaluated by performing competition experiments and by evaluating 
the MSN-PS-SLB-TL (VII) uptake with live cell confocal fluorescence microscopy. 
In a competition experiment the MSN-PS-SLB-TL (VII) are incubated with cells that were 
either previously incubated with free targeting ligand or not. Preincubation of cells with free 
targeting ligand will block the specific receptors on the cell surface. Consequently, uptake of 
the MSN-PS-SLB-TL (VII) should only happen unspecific and therefore is expected to take 
much longer than receptor-mediated endocytosis. To evaluate the functionality of the FA 
ligand, KB cells were used. In the experiments shown in Figure 8.7a the cells were 
preincubated with FA for 2 h at 37 °C before the MSN-PS-SLB-FA (VII) particles were 
added to the cells and incubated for 3 h at 37 °C. Recording z-stacks of the cells with a 
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spinning disk confocal fluorescence microscope allows us to indicate MSNs inside or outside 
the cell. A typical cut through the cell is shown in Figure 8.7. 
 
Figure 8.7: Unspecific and receptor-mediated endocytosis of MSN-PS-SLB particles with folic acid ligand 
(MSN-PS-SLB-FA) by KB cells and MSN-PS-SLB particles with EGF ligand (MSN-PS-SLB-EGF) by 
HuH7 cells with GFP tagged tubulins (HuH7tub), respectively. (a) Incubation of MSN-PS-SLB-FA 
particles with FA preincubated KB cells for 3 h at 37 °C. (b) Incubation of MSN-PS-SLB-FA particles 
with KB cells, not FA preincubated, for 3 h at 37 °C. (c) Internalization of MSN-PS-SLB-EGF particles by 
HuH7tub with EGF preincubated and (d) non pre-incubated HuH7tub cells. The KB cell membrane is 
shown in green and the particles in red. For HuH7tub the GFP tagged tubulins are shown in green and 
the particles in red. Images were taken with live KB cells and HuH7tub cells. The scale bar is 10 μm. 
It shows that in KB cells only a few individual particles are present inside the cell (Figure 
8.7a), whereas full stacks emphasize the quasi absence of nanoparticles inside the cell, 
independent of the chosen focal plane. In contrast, incubation of MSN-PS-SLB-FA (VII) with 
KB cells that were not preincubated with FA before resulted in significant uptake of particles 
(Figure 8.7b). The nanoparticles appear in the single representative z-slice as well as in the 
full stack, through the entire height of the cell. This clearly demonstrates that the particles are 
taken up by receptor-mediated endocytosis and that unspecific uptake of the particles by KB 
cells is small after 3 h incubation time. To utilize EGF as another targeting ligand beside folic 
acid, we synthesized a lipid-EGF construct, where the EGF (50 µg) is covalently attached to 
the lipid DSPE-PEG2000-maleimide (Scheme 8.2). In a first step, the N-terminus of the 
targeting peptide was modified via the Traut’s reagent (2-Iminothiolane, 2 equiv., 16 nmol) in 
an aqueous solution by stirring for 1 h at room temperature. This resulted in a terminal thiol 
group which can be used for further functionalization. Subsequently, the modified EGF was 
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covalently attached to the lipid DSPE-PEG2000-maleimide (3.5 µL of a 10 mg/mL 60/40 
H2O/EtOH v%). The final DSPE-PEG2000-EGF construct can be further utilized to use as 
targeting ligand on the nanoparticle as described below. 
 
Scheme 8.2: Chemical modification of the EGF targeting ligand via the Traut’s reagent (2-iminothiolane) 
to achieve thiolation of the N-termius of EGF. In a second step the lipid DSPEPEG2000-maleimide 
covalently binds to the modified EGF. 
Similar to the FA experiments, we performed competition experiments with the EGF ligand. 
Experiments were performed with HuH7 cells, which are known to overexpress the EGF 
receptor.
[29]
 Figure 8.7c shows that in the case of preincubation of HuH7 cells with EGF 
almost no MSN-PS-SLB-EGF (VII) particles are endocytosed by the HuH7 cells after 3 h. In 
contrast, a significant number of the particles is present inside the cells when the cells were 
not preincubated with EGF (Figure 8.7d). Again typical slices of the z-stacks are shown in 
Figure 8.7c,d. The above results demonstrate that our MSN-PS-SLB nanoparticles can be 
modified efficiently to meet the specific requirements of various cancer types and to ensure a 
specific receptor-mediated uptake. In addition, in the two cell types discussed here the 
unspecific uptake of the MSNs is very small after 3 h. Both are important factors for 
successful drug delivery vehicles in order to prevent damage of healthy cells by cancer 
therapeutics. Furthermore, the targeting ligand is introduced after the completion of the 
synthesis of the actual nanoparticle system. This offers more flexibility to separately 
synthesize both the nanoparticle system and the DSPE-PEG2000-TL because possible 
incompatible reaction conditions can be avoided. This allows for selecting the synthesis 
strategies for both components more freely, which is considered a significant advantage for 
the incorporation of fragile peptides into these systems. Besides the specific uptake of the 
drug delivery vehicle by cancer cells, it is of key importance for efficient drug delivery to 
release the drug into the cytosol, and ideally to do so with spatial and temporal control. In the 
following, we will show that our system provides the means to achieve this. 
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In vitro cargo release by photoactivation. One of the main challenges for drug delivery with 
high efficacy is to overcome the endosomal entrapment in order to release the drug into the 
cytosol. A photoactivation approach provides both of these capabilities. In the studies where 
MSNs and photosensitizers were used, the photosensitizer was either loaded as a cargo into 
MSNs
[30]
 or covalently attached to them.
[14]
 The covalent attachment of the photosensitizer is 
advantageous compared to loading it into the MSN pores. The ratio of MSNs to 
photosensitizer is more easily controlled, the loading capacity of the MSNs can be completely 
used for the drug, and a spatial separation between drug and photosensitizer exists. This could 
be important considering that the singlet oxygen, produced by photoactivation of the 
photosensitizer, will most likely damage the drug when not spatially separated from it. In 
previous work from our group,
[14]
 the photosensitizer had to be excited by blue light, which 
cannot penetrate the tissue very deeply.
[23]
 Here we have improved this system by using a 
different photosensitizer, namely, AlPcS2a. First, it is photoactivatable with red light, and 
thereby the phototoxicity caused by light activation with blue light is reduced. Additionally, 
the potential depth of tissue penetration of the activation laser is increased by a factor of about 
5. The latter feature will become important if this drug delivery system is tested in vivo. 
Nishiyama et al. demonstrated this by using AlPcS2a for a transfection of the conjunctival 
tissue in rat eyes.
[24]
 Finally, AlPcS2a can be more easily attached to the MSN surface than 
the previously used photosensitizer because a sulfonate group can be directly linked to an 
amino group. To verify that the drug delivery mechanism works in vitro, we incubated MSN-
Calcein-PS-SLB-FA nanoparticles for 3 h with HeLa cells. In comparison to the incubation 
with free calcein, the incubation of the nanoparticles containing calcein as a cargo produces a 
significantly higher calcein concentration inside the cell (Figure 8.8a). 
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Figure 8.8: Fluorescence microscopy of MSN-PS-SLB-FA nanoparticles loaded with calcein inside HeLa 
cells, after an incubation time of 16 h. (a−c) Calcein (green) and AlPcS2a (red) are colocalized (yellow) 
prior to photoactivation. (d) Intensity profile along the white line in the merged image for both. (e−h) 
1 min, (i−l) 5 min, and (m−p) 10 min after photoactivation. The scale bar is 10 μm. 
The uptake of free calcein by KB cells is negligible. This demonstrates that our drug delivery 
system can be used to efficiently transport membrane impermeable cargos into the cell. 
Before photoactivation, calcein and the photosensitizer are colocalized (yellow color in Figure 
8.8c) and exhibit a dot-like pattern, indicating that calcein and the MSN-PS-SLB-FA particles 
are still inside the endosomes (Figure 8.8a−c). This demonstrates that the escape from the 
endosome does not happen automatically and that a mechanism is required to overcome this 
key challenge in the field of drug delivery. To induce the opening of the SLB coat around the 
MSNs and the following endosomal escape in a cascaded manner, we activated the integrated 
photosensitizer AlPcS2a with 1.2 W/mm
2
 of 639 nm light for 1 min, at similar conditions as 
those used for the in situ experiment in Figure 8.6. As a result, 1 min after activation an 
increase of the green fluorescence caused by calcein through the entire cell and in particular in 
the nucleus can be observed (Figure 8.8e and h). In contrast, no change of the red 
fluorescence pattern originating from the photosensitizer is observed; only a small decrease in 
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fluorescence can be seen due to photobleaching during the photoactivation step. This trend 
continues over time as is apparent from the images taken at 5 min (Figure 8.8i−k) and at 
10 min (Figure 8.8m−o) after photoactivation. In the merged image after 1, 5, and 10 min 
(Figure 8.8g, k, and o), the presence of the green signal becomes dominant, indicative of a 
lower colocalization between calcein and photosensitizer due to the spreading of calcein in the 
cell. The green fluorescence is observed in particular inside the cell nucleus. This time-series 
of images shows that photoactivation can open the SLB and the endosome via an activation 
cascade, resulting in the release of calcein into the cytosol. While the green fluorescence from 
calcein is present through the entire cytosol after photoactivation (Figure 8.8e, i, and m), the 
dot-like pattern of the red fluorescence, caused by the PS on the MSNs, does not change 
(Figure 8.8f, j, and h). This shows that, in contrast to calcein, the MSNs do not escape from 
the endosomes. The reason for this behavior is unknown but has been observed before.
[30]
 
However, we note that free PS in endosomes does spread after photoactivation, and it is 
therefore not believed to cause much damage to the cell. The destruction of cells through 
photosensitizers is also discussed in the literature, and if the photosensitizer is not located 
close to the cell membrane it cannot cause necrosis.
[31]
 The induction of apoptosis is 
dependent on the cell line, the overall light dose, the localization, the type of photosensitizer, 
concentration of the photosensitizer, and many more parameters, and therefore it should be 
subject of continuing intensive studies. However, for the intensities in the range of 
0.12−1.2 W/mm
2
, which were used in this work, the system works without observable 
damage. Furthermore, the lifetime of singlet oxygen is relatively short (around 2 × 10
−7
 s
[32]
). 
We emphasize that the cargo is located in the channels of the MSNs, whereas the 
photosensitizer is clearly separated from the pores via a PEG linker and located at the outside 
of the MSNs. Consequently the singlet oxygen cannot destroy much of the cargo or of the cell 
membrane during the activation, as it cannot diffuse inside the pores or too close toward the 
cell environment in this short time. In addition to calcein, our multifunctional system can be 
loaded with various cargos (not shown here). As a result, our system provides a means to 
spatially control the release of cargo by applying laser light at specific areas, in particular the 
cancer tissue. This spatial control is available in addition to the ligand based targeting ability 
of our particles and should further reduce unintentional exposure of healthy cells to cancer 
therapeutics. Therefore, the selectivity of drug release should be enhanced in comparison to 
the cases where only the proton sponge effect or fusogenic/endosomolytic peptides are used. 
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8.3 Conclusions 
In summary, we have developed a drug delivery system based on mesoporous silica 
nanoparticles that addresses some of the key issues in the field of drug delivery. These 
involve high selectivity and drug delivery with high efficacy. Furthermore, a combination of 
the high loading capacity of MSNs, the supported lipid bilayer for controlled release, the 
addition of targeting ligands, and overcoming of endosomal entrapment by photoactivation 
makes this system a potent drug delivery vehicle. Employing fluorescence microscopy, we 
were able to demonstrate the selective uptake of our nanoparticles by various cancer cell lines 
and the release of different cargos in vitro. Furthermore, we have demonstrated that the red-
light-based photoactivation approach has many advantages compared to other approaches 
used in the field. In particular, by covalently linking the PS to the MSN surface and using a 
PS that can be excited by red light, negative side effects of the PS can be minimized, and 
activation of the PS in vivo is feasible. Moreover, photoactivation for cargo release enhances 
the spatial selectivity of where the drug is released as compared to using targeting ligands 
only. With this new system we have created a platform for drug delivery based on MSNs that 
is flexible regarding the loaded type of drug as well as regarding the employed targeting 
ligand (implying the desired cell type for drug delivery). We anticipate that the integration of 
all these strategies into one multifunctional drug delivery vehicle as well as the efficient 
synthesis and modification of the nanoparticles for multiple cell types will hold promise for 
wide-ranging applications, especially in cancer therapy. 
8.4 Experimental 
Chemicals. Tetraethyl orthosilicate (TEOS, Fluka, >99%), (3-mercaptopropyl)-
triethoxysilane (MPTES, Gelest, 95%), (3-cyanopropyl)-triethoxysilane (CN-TES, ABCR, 
98%), cetyltrimethylammonium chloride (CTAC, Fluka, 25 wt% in H2O), triethanolamine 
(TEA, Aldrich, 98%), ammonium fluoride (NH4F, Sigma, >98%), α,ω-bis-amino octa 
(ethylene glycol) (NH2-PEGd8-NH2, Iris Biotech), Al(III) phthalocyanine chloride disulfonic 
acid (AlPcS2a, Frontier Scientific), ammonium nitrate (Sigma, 99%), conc. hydrochloric acid 
(Aldrich, >95%, 37 wt%), 1,3,5-triisopropylbenzene (TiPB, Fluka, 96%), sulfo-N-
hydroxysuccinimide (sulfo-NHS, Aldrich, 98%), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC, Sigma, 97%), calcein (CAL, Sigma), dimethyl sulfoxide (DMSO, 
Sigma, >99.5%), ethanol (EtOH, Aldrich, >99.5%), 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC, Avanti Polar Lipids), 1,2-distearoyl-sn-glycero-3-
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phosphoethanolamine-N-[folate(polyethylene glycol)-2000] (ammonium salt) (DSPE-
PEG2000-FA, Avanti Polar Lipids), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[maleimide(polyethylene glycol)-2000] (ammonium salt) (DSPE-PEG2000-maleimide, Avanti 
Polar Lipids), 2-Iminothiolane hydrochloride (Traut’s reagent, Sigma-Aldrich), 5(6)-Carboxy-
X-rhodamine (RD, Sigma), Wheat germ agglutinin (WGA) Alexa Fluor 488 conjugate 
(Invitrogen), epidermal growth factor (EGF, PeproTech, >98%), Folic acid (FA, Sigma, 
>97%). All chemicals were used as received without further purification. Doubly distilled 
water from a Millipore system (Milli-Q Academic A10) was used for all synthesis and 
purification steps. 
Synthesis of core-shell MSNs. Bi-functional core-shell colloidal mesoporous silica 
nanoparticles were synthesized according to a slightly modified published method.
[12, 33]
 A 
mixture of TEOS (1.63 g, 9.22 mmol), MPTES (112 mg, 0.48 mmol) and TEA (14.3 g, 
95.6 mmol) was heated under static conditions at 90 °C for 20 min in a polypropylene reactor. 
Then a solution of CTAC (25 wt% in water, 2.41 mL, 1.83 mmol), NH4F (100 mg, 
2.70 mmol) and TiPB (2.54 g, 12.4 mmol) in water (21.7 g, 1.21 mol) was preheated to 60 °C 
and added quickly. The reaction mixture was stirred vigorously (1000 rpm) at room 
temperature for 20 minutes. Subsequently TEOS (138.2 mg, 0.922 mmol) was added in four 
equal increments every three minutes. This step was followed by 30 minutes of stirring at 
room temperature. For the shell functionalization a mixture of TEOS (19.3 mg, 92.5 μmol) 
and CN-TES (21.4 mg, 92.5 μmol) was added to the reaction. The resulting mixture was then 
allowed to stir at room temperature for 12 h. After the addition of 100 mL ethanol, the MSNs 
were collected by centrifugation, redispersed in 100 mL of ethanol and extracted according to 
the procedure described below.  
Extraction of MSNs. Extraction of the surfactant was performed by heating 250 mg of MSN 
for 45 minutes under reflux at 90 °C in a solution containing 2 g ammonium nitrate in 100 mL 
ethanol. This extraction step was performed twice. The template-free MSNs were separated 
by centrifugation and washed with ethanol after each extraction step. MSN_SHin_CNout were 
obtained as colloidal suspension in EtOH. 
Hydrolysis of MSNs containing cyano groups. 250 mg of MSN_SHin_CNout in EtOH were 
collected by centrifugation and washed with H2O once. The particles were re-dispersed in 
10 mL H2O and 30 mL hydrochloric acid (37 wt%) was added carefully. The reaction mixture 
was heated to reflux for 3 h. After cooling down, 20 mL H2O were added and the synthesis 
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was stirred at room temperature overnight. The resulting colloidal suspension of 
MSN_SHin_COOHout was diluted further with 100 mL H2O, collected by centrifugation, and 
redispersed in 100 mL of water. This washing step was repeated twice with both water and 
ethanol. MSN_SHin_COOHout were obtained as an ethanolic suspension. 
PEGylation of MSNs. An ethanolic suspension containing 20 mg of MSN_SHin_COOHout 
was centrifuged and redispersed in 60 mL of water. This washing step was repeated twice. 
EDC (0.85 µl, 4.6 µmol, 1.2 eq) was added at room temperature to a diluted suspension of 
MSN_SHin_COOHout in 40 mL of water. The reaction mixture was stirred for 5 min before 
sulfo-NHS (1 mg, 4.6 µmol, 1.2 eq) was added. A second solution, containing bi-functional 
NH2-PEGd8-NH2 (7.05 mg, 19.2 µmol, 5 eq.) dissolved in 2 mL water was prepared. The 
EDC-activated MSN_SHin_COOHout were added dropwise to the PEG containing solution. 
Afterwards, the pH was adjusted with two drops of hydrochloric acid (37 wt%) to a value 
pH < 7 and the reaction mixture was stirred for 12 h at ambient temperature. In order to 
remove the excess of the PEG-linker, the reaction mixture was washed five times with 30 mL 
of water to remove unbound PEG. All washing steps were followed by centrifugation. Finally, 
the sample MSN_SHin_PEGd8NH2out was re-dispersed in 10 mL ethanol. 
Attachment of PS. 1 mg of MSN_SHin_PEGd8NH2out in ethanolic solution was centrifuged 
and resuspended in a 500 µL water/DMSO mixture (2:1). Subsequently, 40 µL of an AlPCS2a 
stock solution (2 mg in 1 mL DMSO) were added to the MSNs. The reaction mixture was 
stirred in the dark at room temperature for 72 h. The resulting MSN_SHin_PEGd8-AlPcS2aout 
were extensively washed by centrifugation with water/DMSO (1:1) in order to remove excess 
photosensitizer. In order to remove DMSO from the mesopores the sample was washed three 
times with water after no free PS could be detected. The colloidal solution of sample 
MSN_SHin_PEGd8-AlPcS2aout was used for further experiments immediately. 
Cargo loading. 0.5 mg of the sample MSN_SHin_PEGd8-AlPcS2aout in ethanol were 
centrifuged and redispersed in 1 mL water. This washing step was repeated twice. Then, the 
suspension was centrifuged again and redispersed in 500 µL calcein in water (1 mM stock 
solution in water) or RD (1 mM stock solution in water), respectively. The mixture was stirred 
over night in the dark yielding the sample MSN_CARGOin_PEGd8-AlPcS2aout. 
SLB formation. 0.5 mg of MSN_CARGOin_PEGd8-AlPcS2aout in 1 mL dye solution were 
centrifuged (14000 rpm, 4 min) and the supernatant discarded. Afterwards, a mixture of 
70 µL DOPC and 30 µL DOTAP (each 2.5 mg/mL in 60:40 H2O:EtOH) were added to the 
resulting pellet, mixed extensively, and sonicated for 10 s. To form the supported lipid bilayer 
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around the MSNs via solvent exchange method, 700 µL of water were added. The resulting 
suspension was mixed and sonicated for 10 s, yielding 
DOPC/DOTAP@MSN_CARGOin_PEGd8-AlPcS2aout. 
TL incorporation. 0.5 mg of DOPC/DOTAP@MSN_CARGOin_PEGd8-AlPcS2aout in 800 µl 
water were incubated with 6 µL of DSPE-PEG2000-TL for 3 h (for DSPE-PEG2000-Folate) and 
12 h respectively (for DSPEPEG2000-EGF) at 37 °C. The resulting sample 
DOPC/DOTAP@MSN_CARGOin_PEGd8-AlPcS2aout-TL was used without further 
purification for confocal microscopy studies. 
Cargo release experiments. Fluorescence time-based release experiments were recorded on a 
PTI fluorescence system featuring a PTI 814 photomultiplier detector and a PTI A1010B 
Xenon arclamp driven by a PTI LPS-220B lamp power supply. For temperature settings, a 
Quantum Northwest TC 125 sample holder was used. Our previously described custom-made 
release cuvette system was used for all experiments.
[26]
 All samples were measured at a 
temperature of 37 °C with slits of 2/2/2/2. For RD an excitation wavelength of 575 nm was 
used (emission maximum at 597 nm), whereas calcein was excited with 495 nm and with an 
emission maximum at 516 nm. Results are given in Figure 6. For all experiments, 0.5 mg of 
DOPC/DOTAP@MSN_CARGOin_PEGd8-AlPcS2aout was used. 200 µL of the particle 
suspension was filled into the reservoir cap sealed with a dialysis membrane (Molecular 
weight cut-off 14000 g/mol) allowing released dye molecules to pass into the fluorescence 
cuvette. In order to monitor the release of adsorbed dyes upon membrane rupture with singlet 
oxygen, the sample was excited with 0,56 W/mm
2
 of 633 nm light for 1 minute prior the 
measurement. For triton mediated release, 5 µL of a 1 mM stock solution of TritonX100 was 
added to the particle solution. 
Characterization. All samples were investigated with a FEI Titan 80-300 operating at 
300 kV with a high-angle annular dark field detector. A droplet of the diluted MSN solution 
in ethanol absolute was dried on a carbon-coated copper grid. Nitrogen sorption 
measurements were performed on a Quantachrome Instruments NOVA 4000e. All four 
samples (15 mg each) were heated to 393 K for 12 h in vacuum (10 mTorr) to outgas the 
samples before nitrogen sorption was measured at 77 K. For calculations of pore sizes and 
volumes a non-local density functional theory (NLDFT) equilibrium model of nitrogen on 
silica was used. Dynamic light scattering (DLS) measurements were performed on a Malvern 
Zetasizer-Nano instrument equipped with a 4 mW He-Ne laser (633 nm) and an avalanche 
 
185 
 
photodiode. The hydrodynamic radius of the particles was determined by dynamic light 
scattering in ethanolic suspension. For this purpose, 100 µL of an ethanolic suspension of 
MSN particles (ca. 10 mg/mL) was diluted with 3 mL of ethanol prior to the measurement. 
Zeta potential measurements of the samples were performed on a Malvern Zetasizer-Nano 
instrument equipped with a 4 mW He-Ne laser (633 nm) and an avalanche photodiode. For 
determination of the zeta potential curves, two drops of the ethanolic MSN suspension (~ 
3 %wt.) was mixed with 1 mL commercial Hydrion Buffer solution of the appropriate pH 
prior to measurement. IR measurements were performed on a Bruker Equinox 55 
FTIR/FTNIR Spectrometer in absorbance mode (spectra were background substracted). 
Thermogravimetric analysis of the bulk samples MSN_SHin_CNout, MSN_SHin_COOHout, 
MSN_SHin_PEGd8NH2out and MSN_SHin_PEGd8-AlPcS2aout was performed on a Netzsch 
STA 440 C TG/DSC with a heating rate of 10 K/min in a stream of synthetic air of about 
25 mL/min. The mass was normalized to 100% at 133.8 °C for all samples. Cross-polarized 
13
C solid-state NMR (ssNMR) measurements were performed on a Bruker DSX Avance500 
FT spectrometer in a 4 mm ZrO2 rotor. The spinning rate was 10 kHz and a total number of 
up to 8000 scans were recorded. 
Cell culture. KB cells were grown in folic acid deficient Roswell Park Memorial Institute 
1640 medium (RPMI 1640, Invitrogen) supplemented with 10% FCS at 37 °C in a 5% CO2 
humidified atmosphere. The cells were seeded on ibidiTreat µ-Slide (IBIDI). HuH7 cells were 
grown in  ulbecco’s modified Eagle’s medium ( MEM):F12 (1:1) (Invitrogen) medium 
supplemented with 10% fetal bovineserum (FBS) at 37 °C in a 5% CO2 humidified 
atmosphere. To reduce autofluorescence of the cells, the medium was changed to 
DMEM:F12(Invitrogen) supplemented with 10% B-27 two days before seeding. The cells 
were seeded on collagen A-coated LabTek chambered cover glass (Nunc). HeLa cells were 
grown in  ulbecco’s modified Eagle’s medium ( MEM):F12 (1:1) (Invitrogen) with 
Glutamax I medium supplemented with 10% fetal bovineserum (FBS) at 37 °C in a 5% CO2 
humidified atmosphere. The cells were seeded on collagen A-coated LabTek chambered 
cover glass (Nunc). For live cell imaging the cells were seeded 24 or 48 h before measuring, 
at a cell density of 2x104 or 1x104 cells/cm
2
. 
Uptake studies. To evaluate the functionality of the folic acid ligand, KB cells were 
incubated with nanoparticles for 3 h at 37 °C under a 5% CO2 humidified atmosphere. In the 
case of live cell imaging the cell membrane was stained afterwards by adding 4 µL of 
1 mg/mL wheat germ agglutinin Alexa Fluor 488 or 633 conjugate (WGA488, WGA633, 
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Invitrogen) to 400 µL of cell medium. After 1 min, the cell medium was removed, the cells 
were washed twice with cell medium, and imaged immediately. In the case of fixed cells the 
cells were washed three times after the 3 h incubation time with PBS (Invitrogen). Afterwards 
200 μL of 4% paraformaldehyde (PF , Science Service) were added for 15 minutes.  fter 
removing PFA the cells were washed three times with PBS and stained by adding 4 µL of 
1 mg/mL WGA 488 to 400 μL of P S.  fter 1 min the cell medium was removed, the cells 
were washed twice with PBS and imaged. In control experiments, the FA receptors on the KB 
surface were blocked by pre-incubation of the cells with 3 mM folic acid (Sigma) for 2 h at 
37 °C under a 5% CO2 humidified atmosphere, before particle were added. In the case of 
EGF, HuH7 cells with GFP tagged tubulin were used in addition to staining the cell 
membrane. In the case of HuH7 tubulin the cell medium was exchanged with CO2-
independent medium (Invitrogen) and imaged immediately after incubation with cells. After 
incubation with nanoparticles, the cell medium was exchanged with CO2-independent 
medium (Invitrogen) and imaged immediately. The wildtype HuH7 cells were treated 
equivalent to the live cell imaging of the KB cells. For the control experiments, EGF receptors 
on the HuH7 surface were saturated by pre-incubating the cells with 0.2 µM EGF (PeproTech, 
>98%) for 2 h at 37 °C under a 5% CO2 humidified atmosphere, before particle addition. 
Cargo release experiments. Cells were incubated 16 – 22 h prior to the measurements at 
37 °C under a 5% CO2 humidified atmosphere. Shortly before imaging, the medium was 
replaced by CO2-independent medium (Invitrogen). During the measurements all cells were 
kept on a heated microscope stage at 37 °C. The photosensitizer AlPcS2a was activated by 
1.2 W/mm
2
 of 639 nm light for 1 min. The subsequent imaging was performed as described in 
the Spinning disk confocal microscopy section. 
Spinning disc confocal microscopy. Confocal microscopy for live-cell imaging was 
performed on a setup based on the Zeiss Cell Observer SD utilizing a Yokogawa spinning 
disk unit CSU-X1. The system was equipped with a 1.40 NA 100x Plan apochromat oil 
immersion objective from Zeiss. For all experiments the exposure time was 0.1 s and the 
frame rate varied between 3 frames/s and 1 frame/30s, depending on the specific requirements 
of the experiment. Calcein and WGA488 were imaged with approximately 0.4 W/mm
2
 of 
488 nm excitation light. The rhodamine derivative (RD) was excited with 1.2 W/mm
2
 of 
561 nm light. AlPcS2a was excited with 0.12 W/mm
2
 of 639 nm for imaging and for 
photoactivation with 1.2 W/mm
2
. In the excitation path a quad-edge dichroic beamsplitter 
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(FF410/504/582/669-Di01-25x36, Semrock) was used. For two color detection of calcein and 
AlPcS2a and accordingly WGA 488 and AlPcS2a, a dichroic mirror (660 nm, Semrock) and 
band-pass filters 525/50 and 690/60 (both Semrock) were used in the detection path. In case 
of RD a band-pass filter 629/60 (Semrock) was used. Separate images for each fluorescence 
channel were acquired using two separate electron multiplier charge coupled devices 
(EMCCD) cameras (PhotometricsEvolveTM). 
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9 Investigation of the Endosomal Escape via the Proton Sponge Effect 
with Dendron-Functionalized Mesoporous Silica Nanoparticles 
This chapter is based on work in cooperation with: 
Veronika Weiss, Stephan Mackowiak, Tim Gatzenmeier, Christoph Bräuchle, and Thomas 
Bein. 
 
 
9.1 Introduction 
Nano-sized drug delivery systems such as multifunctional mesoporous silica nanoparticles 
(MSNs) encounter many challenges on their way towards selectively reaching their desired 
target and efficiently release their cargos at the desired location. In particular, endosomal 
entrapment is a major obstacle for efficient drug and cargo delivery, faced by MSNs and other 
nanocarrier systems that are internalized by cells via endocytosis.
[1-3]
 Especially for non-
membrane permeable or immobilized cargo molecules, the nanocarriers need to enter the 
cytosol for an efficient delivery to the targeted cell compartments, such as nucleus, 
mitochondria or the microtubule network. Several strategies have already been described to 
address the demanding task of endosomal escape, including pore formation, membrane 
fusion, photoactivated endosomal membrane rupture, and the proton sponge effect.
[4-7]
 
Recently, the issue of endosomal entrapment has been addressed in a joint project of the 
groups of Bräuchle, Bein and coworkers showing no efficient cytosolic delivery of the cargo 
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cysteine after endocytosis from multifunctional MSNs designed for a redox-driven disulfide 
cleavage-based drug release system.
[1]
 In order to overcome this barrier, photo-induced 
endosomal release via excitation of co-incubated photosensitizer molecules was employed, 
causing rupture of the endosomal membrane upon singlet oxygen generation. Compared to the 
photoactivation pathway needing an external stimulus to cause endosomal escape, the proton 
sponge effect could be an alternative promising “automatic” strategy for endosomal release of 
the nanocarriers. The mechanism of the proton sponge effect follows an intrinsic osmotic 
swelling caused by the buffering capacity of modified nanocarriers and finally results in 
rupture of the endosomal membrane.
[8]
 The intracellular trafficking of endosomal vesicles to 
become late endosomes or endolysosomes leads to an acidification of the endosomal 
compartment by proton pumps (H
+
-ATPase) causing a decrease of the internal pH value from 
7.4 to 5.5.
[9]
 Investigation of diverse cationic lipids and polymers such as poly 
(ethyleneimine) (PEI) showed their substantial buffering capacity below the physiological 
pH.
[10-11]
 After endocytosis, such polymers or particles act like a proton trap preventing a drop 
in pH.
[12]
 The buffering capacity of these species leads to a continuous inflow of protons 
driven by the proton pumps, coupled with a passive influx of chloride anions to maintain 
electrical neutrality within the compartment. Subsequently, osmotic swelling and ultimately 
rupture of the endosomal membrane is caused by the substantial increase of the ionic 
concentration within the endosome. Several cationic polymers with high buffering capacities 
have been examined as potential proton sponges, whereupon poly(amidoamine) (PAMAM) 
dendron structures have attracted great interest due to their high amino group content, simple 
and variable synthesis as well as biomimetic structure.
[13-16]
 Dendrons represent a structural 
component of a parent dendrimer structure that are highly ordered, monodisperse, three-
dimensional, tree-like polymers comprising specific size and shape characteristics.
[17]
 Due to 
their high positive surface charge at physiological pH, PAMAM dendrimers also form stable 
complexes with DNA. In vivo experiments demonstrated that the use of high PAMAM 
dendrimer generations (G7-10) as transfection agent for DNA is highly efficient.
[18-19]
 The 
resulting transfection was explicitly attributed to an activated proton sponge mechanism. 
Experiments on PAMAM-coating of carbon nanotubes further indicate that PAMAM 
structures are beneficial for cellular uptake and provide a reduction of cytotoxicity of carbon 
nanotubes.
[20]
 Lin and co-workers investigated a gene transfection nanocarrier system based 
on MCM-41-type mesoporous silica nanospheres containing covalently attached second 
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generation (G2) PAMAM dendrimers.
[21]
 An intracellular delivery of plasmid-DNA 
complexed by the PAMAM dendrimers could be observed. In recent years, MSNs have been 
intensively utilized as drug delivery vehicles, due to their excellent material features such as 
good biocompatibility, large capacity of its mesoporous system and efficient attachment of 
organic surface functionalization or targeting ligands.
[22-27]
 
In the present work, we have established newly designed multifunctional core-shell MSNs 
coated with poly(amidoamine) (PAMAM) dendron structures on the outer surface which 
feature a high buffering capacity, acting as a pH-dependent intrinsic endosomal escape 
mechanism via the proton sponge effect. Covalent binding sites (mercapto groups) located 
exclusively inside the mesopores can form disulfide bridges for immobilization for cargo 
molecules. Subsequently, this nanocarrier system offers controlled cargo release upon redox-
driven cleavage of disulfide bridges when entering the reductive milieu of the cytosol. Further 
attachment of the targeting ligand folate at the outer dendron periphery of the nanocarriers 
provide specific receptor-mediated cellular uptake. The targeting efficiency of folate 
molecules has been extensively investigated by many research groups.
[28-30]
 Folate specifically 
binds to the folate receptor FR-α, which is overexpressed on many cancer cell lines, including 
HeLa and KB cells, while only minimally present in healthy tissue.
[5, 31-32]
 Our nanocarrier 
system can be modified at the very last synthesis stage with various ligands for specific 
targeting of cancer cells. It is anticipated that the combination of all these important 
requirements for an efficient drug delivery makes the mesoporous silica nanocarriers a 
promising platform for specific cancer therapy. 
9.2 Results and Discussion 
The synthesis of PAMAM dendron-coated MSNs was carried out in three steps. First, 
propargyl-PAMAM dendrons were obtained in three different generations (D1, D2, and D3) 
by iterative steps of Michael additions and amidations following a previously described 
procedure.
[33]
 The synthetic route comprising alternating use of the reagents methyl acrylate 
and 1,2-ethylenediamine for a stepwise creation of increasing PAMAM dendron generations 
is shown in Figure 9.1. 
9.2. Results and Discussion  
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Figure 9.1: Synthesis of propargyl-PAMAM dendrons (D0.5 – D3). Reagents and reaction conditions: a) 
methyl acrylate (large excess), MeOH, 0 → 25 °C, 48 h and b) 1,2-ethylenediamine (large excess), MeOH, 
0 → 25 °C, 48 h. 
For a convergent synthesis route to covalently attach the PAMAM dendrons at the external 
MSN surface, a PAMAM dendron silane precursor was synthesized in a second step. Three 
PAMAM dendron silanes were synthesized by performing a Huisgen click reaction to attach 
azidopropyl trimethoxysilane to the propargyl-PAMAM dendrons. According to a previous 
report,
[34]
 the azidopropyl trimethoxysilane was synthesized and subsequently reacted with 
alkyne-PAMAM dendrons to gain triazole-linked PAMAM moieties by using azide-alkyne 
click chemistry. Successful conversion was observed by IR spectroscopy (cf. Appendix 9.5). 
In a last step, this silane linker was used in a delayed co-condensation approach to create core-
shell functionalized MSNs via a sol-gel process, as described previously.
[23, 25]
 In brief, 
tetraethyl orthosilicate (TEOS) was used as a silica source and cetyltrimethylammonium 
chloride (CTAC) as template. The silica framework formation was catalyzed by the base 
triethanolamine (TEA), which also served as a structure directing agent to result in colloidal 
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silica nanoparticles. Specifically, three different bifunctional MSNs (MSN-SHIN-Dn OUT, 
n = 1-3) equipped with different dendron generations (D1, D2 and D3) on the external surface 
were prepared via a delayed co-condensation approach. The MSNs consisted of a thiol-
functionalized particle core, and additionally PAMAM dendrons were exclusively present on 
the outer particle surface. For all resulting MSN samples, the nitrogen sorption measurements 
showed type IV isotherms indicating a mesoporous structure of the nanoparticles with typical 
inflection points at about 0.3 p/p0 (Figure 9.2a). 
 
Figure 9.2: a) Nitrogen sorption isotherms and b) DFT pore size distributions of functionalized MSNs. 
MSN-SHIN-N3 OUT (black), MSN-D1 (red), MSN-D2 (green), and MSN-D3 (blue). 
At higher partial pressures (about 0.9 p/p0) a second hysteresis loop arose for all samples, 
which we attribute to interparticle textural porosity. For the reference sample MSN-SHIN-
N3 OUT a relatively high BET surface area and pore volume was observed (data summarized in 
Table 9.1). For all PAMAM dendron-coated MSNs these structural parameters decreased 
depending on the size of the dendrons. This effect was partially due to the increasing sample 
mass by addition of the non-porous organic polymer. Furthermore, large PAMAM dendron 
generations might have caused clogging of some pore entrances towards to access of nitrogen 
molecules at the low measurement temperatures (-196 °C). A slight average pore constriction 
could also be observed, which correlates with the size of the attached PAMAM structures. 
This decrease could be due to the reduction of the pore mouth diameters partially covered by 
frozen organic PAMAM moieties. Nevertheless, PAMAM dendron-coated MSNs still 
exhibited a large accessible mesoporous structure offering enough space for the incorporation 
of cargo molecules. 
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Table 9.1: Structural parameter of functionalized MSNs. 
Sample BET surface area (m²/g) Pore volume
a
 (m³/g) DFT pore size
b
 (nm) 
MSN-SH
IN
-N
3 OUT
 1190 0.74 2.9 – 4.4 
MSN-D1 823 0.42 2.5 – 3.9 
MSN-D2 718 0.39 2.6 – 4.1 
MSN-D3 497 0.24 2.2 – 3.8 
a
Pore volume is calculated up to a pore size of 8 nm to remove the contribution of interparticle porosity.  
b
DFT pore size refers to FWHM of the corresponding pore size distribution. 
Transmission electron microscopy shows spherically shaped nanoparticles with sizes of about 
70 nm in diameter for PAMAM dendron-coated MSNs (Figure 9.3c, MSN-D3). A worm-like 
porous structure consisting of radially grown mesoporous channels was present for all 
samples. Additionally, dynamic light scattering (DLS) measurements were performed to 
determine particle sizes for all samples; the particle size distributions are shown in Figure 
9.3a. All samples featured narrow size distributions with an average particle size of about 
122 nm. The size difference between TEM and DLS data is attributed to a tendency for weak 
agglomeration in solution. Summarizing, the above data confirm the formation of well-
defined mesoporous nanoparticles with good colloidal stability in aqueous solution. 
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Figure 9.3: a) Dynamic light scattering (DLS) measurements, b) zeta potential measurements, c) 
transmission electron micrograph, and d) IR spectroscopy of functionalized MSNs. MSN-SHIN-N3 OUT 
(black), MSN-D1 (red), MSN-D2 (green), MSN-D3 (blue), and MSN-SHIN-NH2 OUT (brown). The TEM 
image shows MSN-D3. For clarity reasons, the IR spectra are shifted along the y-axis by 0.2 units. 
Zeta potential measurements showed drastic changes in the surface charge of PAMAM 
dendron-coated MSNs (Figure 9.3b). At acidic pH values, highly positive surface charges 
were observed for all three samples containing PAMAM dendrons at the outer particle 
surface. A zeta potential of about +60 mV at pH 2 was obtained for the sample MSN-D3 
consisting of the largest PAMAM generation. This sample exhibited the highest amino group 
content leading to a highly positively charged particle surface. The samples MSN-D1 and 
MSN-D2 showed slightly smaller zeta potential values (about +50 mV at pH 2). Both samples 
showed an almost identical zeta potential curve in acidic milieu. This suggests that the content 
of accessible amino groups on the periphery of both particle types was nearly identical. It is 
reasonable to expect a higher density of 1
st
 generation PAMAM dendrons on the external 
particle surface compared to the more bulky 2
nd
 generation due to steric hindrance of the 
9.2. Results and Discussion  
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larger molecules. Nevertheless, the PAMAM dendron-coated MSNs showed a significant 
difference of the zeta potential values compared to the reference sample MSN-SHIN-N3 OUT. 
Here, the isoelectric point (IEP) was close to pH 2 which resulted in a negatively charged 
particle surface over the pH range measured. Furthermore, MSNs functionalized with 
aminopropyl groups (MSN-SHIN-NH2 OUT) featured only slightly positive surface charge with 
an IEP of about 4.2. The IEPs for the PAMAM-derived particles were significantly shifted to 
higher pH values (about 6.7). These highly positively charged particle surfaces in acidic 
milieu gave evidence for a high proton acceptor density of the polymer shells resulting in a 
high buffering capacity. For further investigation of the buffering capacity of PAMAM 
dendron-coated MSNs, all samples were titrated against an aqueous solution of NaOH 
(0.01 M). As depicted in Figure 9.4, PAMAM-derived samples featured a significant increase 
in the required volume of NaOH solution to be neutralized (pH 7). This suggested a high 
tendency for proton uptake, and a stepwise increase in buffering capacity was observed for 
higher PAMAM dendron generations. MSN-D3 provided great potential to act like a proton 
sponge showing optimal buffering effect at around pH 6 which perfectly fits the endosomal 
acidification range. In general, a high buffering capacity in the physiological range (pH 5 – 7) 
is desirable to enable endosomal release via the proton sponge mechanism. For PAMAM 
dendrimer or dendron structures, the buffering capacity is mainly provided by the tertiary 
amino groups.
[13, 35]
  
 
Figure 9.4: Titration data of functionalized MSNs. MSN-SHIN-N3 OUT (black), MSN-D1 (red), MSN-D2 
(green), and MSN-D3 (blue). Quantitative data are given in the experimental part. 
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CHN elemental analysis provided quantitative information about the degree of organic 
functionalization of the modified MSNs. The data are shown in Table 9.2 (aminopropyl 
functionalized MSNs (MSN-SHIN-NH2 OUT) have been used as a reference). The nitrogen 
content (wt% N) of the samples correlates with the amount of PAMAM functionalization A 
stepwise increase in nitrogen content for samples with increasing PAMAM generations was 
observed. Furthermore, the measured values for all PAMAM dendron coated MSNs were 
significantly higher compared to the reference samples MSN-SHIN-N3 OUT and MSN-SHIN-
NH2 OUT. These high nitrogen contents are the basis for a high protonation level in acidic 
milieu. 
 
Table 9.2.: CHN elemental analysis data for functionalized MSNs. 
Sample MSN-SHIN-N3 OUT MSN-D1 MSN-D2 MSN-D3 
MSN-SHIN-
NH2 OUT 
wt% N 0.860 1.42 2.09 2.47 0.350 
Organic functional groups present on the MSNs were examined with IR spectroscopy (Figure 
9.3, for full range IR spectra see also Appendix 9.5). All samples featured typical bands of the 
silica framework appearing at 1240 – 1050 cm
-1
 (asymmetric stretching vibration of Si-O-Si), 
and at 964 and 796 cm
-1
 (asymmetric bending and stretching vibration of Si-OH). The 
reference sample MSN-SHIN-N3 OUT showed a characteristic signal at 2111 cm
-1
, which was 
related to the azide vibration mode (asymmetric stretching vibration of –N=N
+
=N
-
). 
Additionally, a band at 1629 cm
-1
 indicated the bending modes of physisorbed water. This 
band was present in all spectra but was partially covered by other, more intensive bands for 
the PAMAM dendron-coated particles. The nanoparticles MSN-D1, MSN-D2 and MSN-D3 
showed two additional bands at 1644 cm
-1
 (C=O stretching vibration) and 1554 cm
-1
 (N-H 
deformation and C-N stretching vibration) which were attributed to the amide bonds of the 
PAMAM dendron moieties. An increase in intensity of these signals was observed with 
increasing PAMAM dendron generations indicating increasing amounts of functional groups 
within the samples. Further characterization of the attached functional groups was performed 
by 
13
C solid state NMR spectroscopy (Figure 9.5). MSN-SHIN-N3 OUT showed distinct signals 
for the propyl chains of the mercaptopropyl- and azidopropyl-moieties (which have been 
incorporated into the silica framework during the co-condensation approach) at 53 ppm (a, -
CH2-N3), 27 ppm (b, -CH2-SH), 22 ppm (c, CH2-CH2-CH2-), and 10 ppm (d, Si-CH2-). 
9.2. Results and Discussion  
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Additional peaks of high intensity at 58 ppm (e, O-CH2-CH3) and 15 ppm (f, O-CH2-CH3) 
were present in all samples and were attributed to surface-bound ethoxy groups resulting from 
the extraction steps in ethanolic solution. PAMAM dendron functionalized MSNs featured 
characteristic peaks for the amide groups of the PAMAM dendrons at 173 ppm (g, C=O). 
Furthermore, weak signals at 144 ppm (h) and 125 ppm (i) were observed, these are attributed 
to the two carbon atoms in the triazole ring, thus providing evidence for a successful click 
reaction of the PAMAM dendron silane precursor. Several strong signals in the range between 
60 to 10 ppm correspond to different types of methylene groups belonging to the PAMAM 
moieties (52 and 40 ppm (k and l, N-CH2-R), 21 and 10 ppm (m and n, R-CH2-R)). 
 
Figure 9.5: 
13
C solid state NMR spectra of functionalized MSNs. a) MSN-SHIN-N3 OUT (black), b) MSN-D1 
(red), c) MSN-D2 (green), and d) MSN-D3 (blue). a refers to -CH2-N3 (53 ppm), b to -CH2-SH (27 ppm), c 
to CH2-CH2-CH2- (22 ppm), d to Si-CH2- (10 ppm), e to O-CH2-CH3 (58 ppm), f to O-CH2-CH3 (15 ppm), g 
to C=O (173 ppm), h and i to carbon atoms of the triazole ring (144 and 125 ppm, respectively), k and l to 
N-CH2-R) (52 and 40 ppm, respectively), and m and n to R-CH2-R (21 and 10 ppm, respectively). 
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From all the above results, we conclude a successful synthesis of core-shell functionalized 
MSNs with different generations of PAMAM dendrons (D1, D2 and D3) via the delayed co-
condensation approach. The PAMAM moieties are exclusively located at the external particle 
surface resulting in an organic polymer coating of MSNs featuring high buffering capacity. 
The sample MSN-D3 showed optimal properties and is expected to have great potential for 
generating the proton sponge effect. Hence, in the following we exclusively investigated the 
MSN-D3 particles for cargo release, cell uptake and cell targeting experiments. 
To prove a stimuli-responsive cargo release behavior of the PAMAM dendron-coated MSNs, 
we performed time-based release experiments of the fluorescent model drug 5(6)-carboxy-X-
rhodamine (ROX). The thiol-functionalization of the particle core offers the possibility to 
covalently attach cargo molecules to the internal pore surface via disulfide bridges. In a 
reductive milieu (simulation of the cytosol), disulfide bridges can be cleaved causing a release 
of the cargo molecules from the mesopores. A derivative of the fluorescent dye ROX 
(containing the thiol-reactive group methanethiosulfonate, MTS) was covalently attached to 
the particle core in a one-step synthesis at mild conditions (1 h, room temperature, dark). The 
presence of non-bound dye was excluded due to extensive washing steps before the release 
experiments. A custom-made two-compartment release set-up was used to perform the in vial 
release experiments (Figure 9.6), as previously described.
[26]
 
 
Figure 9.6: Redox-responsive release kinetics of 5(6)-carboxy-X-rhodamine (MTS-ROX) before (black) 
and after (red) addition of dithiothreitol (DTT) to simulate the reductive milieu of the cytosol. Before 
medium change, MSN-D3 shows no premature release of the fluorescent cargo molecules which are 
attached to the mesopores via disulfide bridges. Only in reductive milieu a significant increase in 
fluorescence intensity can be observed, demonstrating a redox-responsive release behavior of the MTS-
ROX due to cleavage of the disulfide bridges. 
9.2. Results and Discussion  
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The PAMAM dendron-functionalized MSNs with immobilized MTS-ROX in the mesopores 
showed no cargo release in (non-reducing) aqueous solution within the first hour. Only upon 
addition of a reducing agent (dithiothreitol, DTT), a drastic increase in fluorescence intensity 
was observed. This demonstrates the redox-responsive cleavage of the disulfide bridges, 
followed by the release of the fluorescent model drug from the pore system. The redox-
responsive behavior shown here offers great potential for a specific cargo release once the 
mesoporous silica nanocarriers have escaped from the endosomes and entered the cytosol of 
the targeted cell. 
We investigated the potential of PAMAM dendron-coated MSNs to achieve endosomal 
escape via the proton sponge effect by performing in vitro cell experiments. Fluorescent live-
cell imaging with high-resolution spinning-disk confocal microscopy is a versatile technique 
to examine the cellular uptake of nanocarriers and the intracellular cargo release. In a first 
experiment, a derivative of the anticancer drug colchicine was covalently attached to the 
internal pore surface of MSNs bearing thiol groups in the particle core. Thus, colchicine 
molecules with the thiol-reactive group methanethiosulfonate (MTS) formed disulfide 
bridges. After endocytosis, the loaded nanocarriers need access to the reductive cytosol which 
provides the appropriate redox potential to cause cleavage of the covalent linkage and 
successful cargo release. The understanding of cellular redox compartmentalization is still 
limited and leads to a controversial discussion of the redox potential of the endosomal 
environment in the literature.
[36]
 FRET experiments with disulfide-bridged folate-dye 
conjugates showed a time-dependent reduction of the fluorescence signal after cellular uptake 
to KB cells, suggesting to some extend a reductive milieu in the endosomes.
[37]
 In contrast, 
Austin et al. showed that the pathway of endocytosis for antibody-drug conjugates containing 
disulfide bridges to breast carcinoma cells (SKBr3) provides a oxidizing environment and 
hence no significant disulfide cleavage could be observed.
[38]
 Since the acidic milieu of 
lysosomes and late endosomes is not favorable for reducing agents such as glutathione (GSH), 
endolysosomal content could be mainly degraded by means of thiol reductases.
[39]
 These 
enzymes are able to cleave disulfide bridges of free drug conjugates, but are too large to 
access the porous system of MSNs. Therefore, we expect that our nanocarrier system provides 
efficient cargo release only after endosomal rupture when the particles are freely distributed in 
the cytosol. 
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The intracellular release of the cell membrane-permeable anticancer drug colchicine causes 
inhibition of the microtubuli polymerization due to irreversible binding to tubulins.
[40]
 
However, the depolymerization of the microtubules, which are basic structural components of 
the cellular cytoskeleton, still proceeds thus ultimately leading to cell death. MTS-modified 
colchicine was immobilized at the inner mesoporous surface of the PAMAM dendron-coated 
silica nanoparticles, and subsequently these loaded drug delivery vehicles were incubated 
with tubulin-GFP-transfected KB cells. In Figure 9.7a, the fluorescently-labeled microtubule 
network (green) of untreated KB cells is depicted for comparison. Already after 2 h of particle 
incubation (MSNs have been additionally labeled with Atto 633, red), endocytosis occurred to 
a high degree (Figure 9.7b). Importantly, the microtubule network seemed to be still intact, 
suggesting that no release of colchicine had occurred at this time point. After 7 h of 
incubation, a partial destruction of the microtubule network could be observed (Figure 9.7c). 
After 22 h of incubation, cell death finally occurred which was indicated by the disappearance 
of the tubulin structure, a blurred green fluorescence signal and a rounded shape of the cells. 
We note that KB cell incubation with unloaded PAMAM dendron-coated MSNs showed no 
cytotoxic effects. The alternative uptake of free colchicine into the cells could be excluded: 
Reference experiments with the sample supernatant after particle separation by centrifugation 
showing no effect on the microtubule network for 22 h (cf. Appendix 9.5). 
 
Figure 9.7: Fluorescence microscopy of a,e) KB cells with GFP tagged tubulins (green). The cells were 
incubated with MSN-D3 loaded with immobilized colchicine (MTS-Col) in the mesopores and labeled with 
Atto 633 (red) for b,f) 2 h, c,g) 7 h and g,h) 22 h. e-h) Zoom in on representative microtubule structures. A 
time-dependent destruction of the tubulin network can be observed, finally causing cell death. The scale 
bars represent 10 µm. 
9.2. Results and Discussion  
 
202 
 
This destruction of the cytoskeleton due to MSN-delivered colchicine has been observed by 
our groups before. Cauda et al. could show efficient cell death triggered by colchicine after 
endocytosis of the drug-loaded MSN nanocarriers sealed with a supported lipid bilayer.
[24]
 
Despite the observed enhanced therapeutic effect compared to free drug molecules, concerns 
about premature leakage from the lipid bilayer-coated nanocarriers may arise since colchicine 
features membrane permeability. Thus, immobilization of the drug molecules to the internal 
mesoporous surface via stimuli-responsive cleavable linkers (e.g. disulfide bridges) as shown 
in the present work promises further improvement of spatially-controlled cargo release. The 
cell experiments discussed above demonstrate time-dependent intracellular release of 
immobilized colchicine from the mesoporous drug delivery vehicles. We anticipate that the 
natural acidification of the endosomal compartment initiated the proton sponge effect with our 
particles. The high buffering capacity of the PAMAM dendrons caused high internal osmotic 
pressure subsequently leading to rupture of the endosomal membrane and access to the 
cytosol. Reducing agents present in the cytosol were able to cleave the disulfide bridges and 
colchicine was efficiently released. 
We further investigated the in vitro release of 4’,6-diamidino-2-phenylindole (DAPI) on HeLa 
cancer cells. DAPI preferentially stains the nuclei of cells. The intercalation to dsDNA leads 
to a significantly enhanced fluorescent signal that can be detected by fluorescence live-cell 
imaging microscopy (20-fold increase).
[41-42]
 PAMAM dendron-coated MSNs were immersed 
in a solution containing an in situ synthesized DAPI derivative with thiol-reactive 
methanethiosulfonate groups, which was subsequently covalently attached to the mercapto-
functionalized mesopores of the silica nanoparticles (sample MSN-D3-MTS-DAPI). These 
covalent disulfide bridges should be cleaved only once the expected proton sponge effect has 
achieved endosomal escape and the nanocarriers have reached the reductive milieu of the 
cytosol. HeLa cells were incubated with MSN-D3-MTS-DAPI for 5, 10 and 22 h. Figure 9.8 
shows an efficient cellular uptake behavior of the nanoparticles labeled with Atto 633 (red) 
already after 5 h. Moreover, only weak staining of the nuclei (blue) was observed at this time 
point. In contrast, free DAPI molecules are able to permeate through the cell membrane 
causing efficient nuclei staining already within a few minutes (1-5 min), as described by 
standard nucleus staining protocols.
[43]
 Reference experiments with the sample supernatant 
after particle separation by centrifugation showed only a marginal staining of the nuclei, 
which proves that only a small amount of free dye molecules was present in the particle 
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solution. Therefore, we conclude that the DAPI was released from the intracellular MSNs 
upon cleavage of the disulfide anchors. Over the entire time range a successive increase in 
fluorescence intensity of the DAPI-stained nuclei could be observed. We attribute this time-
dependent release behavior of DAPI to the relatively slow process of the proton sponge effect 
which was caused by the PAMAM dendron content of our nanocarriers. Consequently, 
endosomal escape was provided for an efficient cytosolic delivery of the cargo molecules. 
Similar observations for a delayed cargo release were made in our group for pH-responsive 
capping systems (cf. chapter 7 and PhD thesis of Stefan Niedermayer).
[44]
 Acidification of the 
endosomal compartment is realized while trafficking along the tubulin network towards the 
nucleus. This process takes several hours, which can explain the fairly slow release of the 
DAPI cargo from the PAMAM dendron-containing multifunctional nanocarriers. 
 
Figure 9.8: Fluorescence microscopy of HeLa cells incubated with MSN-D3 nanoparticles loaded with 
immobilized DAPI (MTS-DAPI, blue) inside the mesopores and labeled with Atto 633 (red) after a) 5 h, b) 
10 h and c) 22 h incubation with the cells. The nuclei are indicated with dashed circles. Time-dependent 
nuclei staining can be observed suggesting triggered release of the cargo molecules from the nanocarriers 
after endosomal escape via the proton sponge effect and access to the cytosol. The scale bar represents 
10 µm. 
For further monitoring of the proton-sponge induced cargo delivery, bare MSNs without 
dendron functionalization on the external surface were loaded with DAPI (MSN-NH2-MTS-
DAPI) for reference experiments. These nanoparticles only present amino groups at the 
external surface. We monitored their release behavior in comparison to the sample MSN-D3-
MTS-DAPI and its solution after particle separation (by centrifugation), denoted as 
supernatant (for fluorescence microscopy images refer to Appendix 9.5). HeLa cells were 
incubated with the samples for a total time period of 61 h.  
The fluorescence intensity of DAPI-stained nuclei as a function of the incubation time has 
been investigated for all three samples (MSN-D3-MTS-DAPI, MSN-NH2-MTS-DAPI, and 
supernatant of MSN-D3-MTS-DAPI). The experimental findings are summarized in 
9.2. Results and Discussion  
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Figure 9.9. The nuclei areas were selected as distinct regions of interest (ROI) and the 
fluorescence intensity was evaluated at different time points for all samples. Sample MSN-
D3-MTS-DAPI revealed a significant increase in fluorescence intensity over time, as 
discussed above (cf. Figure 9.8). This proves an efficient DAPI delivery into the cells shown 
by fluorescent nuclei staining. The supernatant of sample MSN-D3-MTS-DAPI exhibited no 
temporal increase of fluorescence intensity proving that only a very small amount of free dye 
was present in the solution, which was already completely incorporated into the nuclei after 
5 h (first data point). As a result, DAPI needs to be released from the mesopores of the 
dendron-coated silica nanoparticles in order to achieve efficient nuclei staining. 
Strikingly, the fluorescence intensity for the reference sample MSN-NH2-MTS-DAPI also 
remained constant at a marginal level comparable to the supernatant of sample MSN-D3-
MTS-DAPI. Almost no nuclei staining could be observed for sample MSN-NH2-MTS-DAPI, 
indicating that negligible amounts of DAPI were released from these nanocarriers. This 
comparison demonstrates that the PAMAM dendron functionality of our drug delivery 
vehicles is of key importance to achieve successful cargo delivery to cancer cells. 
 
Figure 9.9: Nuclei staining kinetics of the DAPI delivery to HeLa cells from MSN-D3-MTS-DAPI (black), 
MSN-NH2-MTS-DAPI (blue), and the supernatant (red) of the MSN-D3-MTS-DAPI solution (after 
particle separation). The fluorescence intensity of distinct regions of interest (stained nuclei) was 
evaluated after different time points of sample incubation. Data represent average fluorescence intensity ± 
standard deviation (the fluorescence intensities of 44 – 104 nuclei were determined for one data point).  A 
time-dependent increase of fluorescence intensity can be observed for MSN-D3-MTS-DAPI, 
demonstrating an efficient DAPI release from the nanocarriers. In contrast, the fluorescence intensity 
remains constant at a marginal level for the reference samples. This shows that negligible DAPI release 
occurred for MSN-NH2-MTS-DAPI and that almost no free DAPI molecules had been present in the 
particle solution (supernatant). 
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Taken together, these in vitro release experiments with different cell lines and different cargo 
molecules incorporated into the mesoporous system of PAMAM dendron-coated silica 
nanoparticles clearly show an efficient endosomal escape followed by intracellular delivery 
caused by the proton sponge effect. 
Targeting. Another key feature of an effective drug delivery vehicle is specific targeting of 
the desired tissue, mainly cancer cells. Many cancer cell lines were found to overexpress 
diverse cell membrane receptors due to increased metabolic activity. In contrast, healthy 
tissue features only small concentrations of such receptors on the cell membrane surface. A 
preferential targeting of cancer cells can be achieved by exploiting a receptor-mediated 
cellular uptake of the nanocarriers. Targeting ligands such as folic acid can be attached to the 
periphery of the PAMAM dendron-coated MSNs. The covalently bound FA moieties are 
intended to interact with the folic acid receptor FR-α, resulting in a fast and specific 
endocytosis.
[5, 28]
 Amino-group terminated PAMAM dendrons offer the possibility to 
covalently attach folate via a short bifunctional PEG-linker. Atto 633-labeled MSNs equipped 
with the folate targeting ligand were incubated for 5 h with KB cells to investigate receptor-
mediated endocytosis. In Figure 9.10 membrane-stained KB cells (WGA 488, green) are 
depicted. Two cellular uptake experiments were performed simultaneously. On the one hand, 
KB cells were pre-treated with free folate to achieve full saturation and blocking of the cell 
receptors before particle incubation. Here, unspecific cell uptake could be observed only to a 
small degree (Figure 9.10b); this is commonly expected to take much longer than receptor-
mediated endocytosis. The particle location (inside or outside the cell) can be determined by 
evaluating cellular z-stacks with a spinning disk confocal fluorescence microscope.  
A significantly higher efficiency of particle internalization into the cells occurred for KB cells 
without pretreatment with free targeting ligands (Figure 9.10a). Here, the fast cellular uptake 
is attributed to the receptor-mediated endocytosis of MSNs with folate (MSN-D3-FA) which 
can also be seen in the orthogonal views. 
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Figure 9.10: a) Receptor-mediated and b) unspecific endocytosis of MSN-D3 with targeting ligand folate 
(MSN-D3-FA, red) by KB cells (membrane staining, green). A specific receptor-mediated cell uptake can 
be observed for MSN-D3-FA with KB cells (not FA-preincubated) after 5 h incubation at 37 °C (a). 
Incubation of MSN-D3-FA with FA-preincubated KB cells for 5 h at 37 °C shows only unspecific cellular 
uptake (b). The scale bar represents 10 µm. 
9.3 Conclusion 
In summary, the synthesis of PAMAM dendron-coated MSNs combines advantageous 
structural parameters such as high loading capacity and tunable functionality with the high 
capacity of PAMAM dendrons for proton absorption. The novel synthesis strategy, based on 
creating PAMAM dendron silane precursors that were used in a delayed co-condensation 
approach, resulted in core-shell functionalized MSNs containing PAMAM dendron moieties 
exclusively at the external particle surface. We show that these multifunctional mesoporous 
silica nanocarriers provide triggered and efficient release of the fluorescent dye DAPI and the 
anticancer drug colchicine to cancer cells, which is induced by the high buffering capacity of 
the external PAMAM dendron shell causing the proton sponge effect. As a result, our drug 
delivery vehicles provide an intrinsic endosomal escape pathway for efficient intracellular 
release of immobilized cargo molecules. This technique prevents endosomal entrapment of 
the nanocarriers and can also provide access for impermeable cargos to the cytosol or to other 
targeted cell compartments. Furthermore, the nanoparticles offer optional attachment of 
various cargos inside their mesopores via disulfide bridges, and binding of different targeting 
ligands to their outer periphery. These multifunctional MSNs are viewed as a general and 
powerful platform for controlled drug delivery in various biomedical applications, in 
particular for cancer therapy. 
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9.4 Experimental 
Materials. Propargylamine (Aldrich, 98 %), N,N-diisopropylethylamine (DIPEA, Sigma-
Aldrich, ≥ 99 %), copper(I) iodide (Aldrich, 99.999 %), (3-aminopropyl) triethoxysilane 
(APTES, Aldrich, 99%), tetraethyl orthosilicate (TEOS, Fluka, > 98 %), triethanolamine 
(TEA, Aldrich, 98 %), cetyltrimethylammonium chloride (CTAC, Fluka, 25 % in H2O), (3-
mercaptopropyl) trimethoxysilane (MPTMS, Gelest, 95 %), methanethiosulfonate 5(6)-
carboxy-X-rhodamine (MTS-ROX, Biotium), colchicine methanethiosulfonate (MTS-Col, 
Santa Cruz Biotechnology), 4,6-diamidino-2-phenylindole dihydrochloride (DAPI, Sigma 
Aldrich), folic acid (FA, Sigma), Atto 633 maleimide (ATTO-TEC), 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC, Fluka, 97 %), N-
hydroxysulfosuccinimide (sulfo-NHS, Sigma Aldrich, >98.5 %), poly (ethylene glycol) 
bisamine (PEG2000-bisNH2, MW2000, Sigma Aldrich), N-succinimidyl oxycarbonylethyl 
methanethiosulfonate (NHS-3-MTS, Santa Cruz Biotechnology) and oxalic acid were used as 
received. Methyl acrylate (Aldrich, 99 %) and 1,2-ethylenediamine (Aldrich, 99.5 %) were 
freshly distilled prior to use. Ethanol (EtOH, absolute), N,N-dimethyl formamide (DMF, 
Sigma Aldrich, anhydrous) and methanol (MeOH, anhydrous, Sigma) were used as solvents 
without further purification. Bidistilled water was obtained from a Millipore system (Milli-Q 
Academic A10). (3-Azidopropyl)trimethoxy silane (AzTMS) was freshly prepared as 
previously reported.
[45]
 
Synthesis of propargyl-PAMAM dendrons. Starting with propargylamine, the synthesis of 
PAMAM dendrons employs a Michael addition with methyl acrylate and amidation with 1,2-
ethylendiamine in an alternating fashion. The methodology was developed by Lee et al..
[33]
 
General procedure for Michael addition. A solution of the amino-terminal compound in 
anhydrous methanol (80 mL) was added drop-wise to a stirred solution of freshly distilled 
methyl acrylate in methanol over a period of about 1 h at 0 °C. The resulting solution was 
allowed to warm up to room temperature and stirred for 48 h. The reaction progress was 
monitored by NMR spectroscopy and stopped when the N-H signal had disappeared. Solvent 
and methyl acrylate were removed in vacuo, traces of methyl acrylate were removed by 
redissolving the residue in methanol and repeated removal of the solvent. Drying under high 
vacuum gave the desired pure product as orange viscous oil. 
General procedure for amidation. A solution of the ester-terminal compound in methanol 
(80 mL) was added drop-wise to a stirred solution of freshly distilled 1,2-ethylendiamine in 
methanol over a period of approx. 1 h at 0 °C. The resulting solution was allowed to warm up 
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to room temperature and stirred for 48 h. The reaction was monitored by NMR spectroscopy 
and stopped when no methyl ester signal could be detected anymore. Solvent was removed in 
vacuo, the excess of 1,2-ethylendiamine was removed successively by adding 100 mL of an 
azeotropic toluene/methanol mixture (9:1) and removal of the volatiles in vacuo. This 
procedure needed to be repeated four to six times with a final pressure after removal of 
< 10 mbar. Remaining toluene was removed by azeotropic distillation using methanol. Drying 
under high vacuum gave the desired pure product as orange viscous oil. 
Dendron D0.5 Starting material: Propargylamine (1.50 g, 1.74 mL, 27.2 mmol, 1 eq.); 
Reagents: methyl acrylate (17.0 g, 17.9 mL, 197 mmol, 7.3 eq.) in 20 mL methanol; Yield: 
5.74 g (25.3 mmol, 93 %); IR (film): 3280, 2956, 2840, 1741, 1641, 1542, 1437, 1203, 1175, 
1056 cm
-1
; 
1
H NMR (270 MHz, CDCl3) d = 3.60 (s, 6H, OMe), 3.35 (d, 
4
J = 2.3 Hz, 2H, N-
CH2-C≡CH), 2.77 (t, J = 7.0 Hz, 4H, N-CH2-CH2), 2.39 (t, J = 7.1 Hz, 4H, N-CH2-CH2-CO), 
2.14 (t, J = 2.3 Hz, 1H, CH2-C≡C-H); 
13
C NMR (68 MHz, CDCl3) d = 172.84 (C=O), 78.22 
(CH2-C≡CH), 73.47 (CH2-C≡CH), 51.77 (NH2-CH2-CH2), 49.13 (OMe), 42.10 (N-CH2-
C≡CH), 33.09 (N-CH2-CH2-CO) (NMR spectra are shown in Appendix 9.5); HRMS (ESI) 
calculated for C11H17NO4 ([M+H]
+
) 228.1236, found 228.1229. 
Dendron D1 Starting material: D0.5 (4.90 g, 21.6 mmol, 1 eq.); Reagents: 1,2-
ethylendiamine (111 g, 100 mL, 1.85 mol, 86 eq.) in 30 mL methanol; Yield: 6.23 g 
(21.2 mmol, 98 %); IR (film): 3281, 3062, 2933, 2826, 1639, 1543, 1456, 1356, 1250, 1195, 
935 cm
-1
; 
1
H NMR (400 MHz, CDCl3) d = 7.31 (s, 2H, NHCO), 3.37 (d, 
4
J = 2.4 Hz, 2H, N-
CH2-C≡CH), 3.23 (dt, J = 6.0 Hz, 4.0 Hz, 4H, CONHCH2-CH2), 2.78 (t, J = 6.0 Hz, 4H, N-
CH2-CH2), 2.76 (t, J = 5.6 Hz, 4H, N-CH2-CH2) 2.33 (t, J = 6.1 Hz, 4H, N-CH2-CH2-CONH), 
2.19 (t, J = 2.4 Hz, 1H, CH2-C≡C-H), 1.67 (br s, 4H, NH2); 
13
C NMR (68 MHz, CDCl3) d = 
172.51 (C=O), 77.83 (CH2-C≡CH), 73.85 (CH2-C≡CH), 49.72 (N-CH2-CH2-CO), 42.22 
(CONH-CH2-CH2), 41.80 (N-CH2-C≡CH), 41.61 (NH2-CH2-CH2), 34.23 (N-CH2-CH2-CO) 
(NMR spectra are shown in Appendix 9.5); HRMS (ESI) calculated for C13H25N5O2 ([M+H]
+
) 
284.2087, found 284.2081. 
Dendron D1.5 Starting material: D1 (5.78 g, 20.4 mmol, 1 eq.); Reagents: methyl acrylate 
(28.5 g, 30.0 mL, 331 mmol, 16 eq.) in 40 mL methanol; Yield: 12.3 g (19.6 mmol, 96 %); IR 
(film): 3284, 2951, 2841, 1732, 1653, 1540, 1436, 1361, 1260, 1177, 841 cm
-1
; 
1
H NMR 
(400 MHz, CDCl3) d = 7.07 (s, 2H, NHCO), 3.63 (s, 12H, OMe), 3.42 (d, 
4
J = 2.3 Hz, 2H, N-
CH2-C≡CH), 3.25 (dt, J = 6.0 Hz, 4.0 Hz, 4H, CONH-CH2-CH2), 2.81 (t, J = 6.6 Hz, 4H, N-
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CH2-CH2), 2.72 (t, J = 6.7 Hz, 8H, N-CH2-CH2-COOMe), 2.50 (t, J = 5.0 Hz, 4H, N-CH2-
CH2), 2.39 (t, J = 6.6 Hz, 8H, N-CH2-CH2-COOMe), 2.34 (t, J = 6.5 Hz, 4H, N-CH2-CH2-
CONH), 2.16 (t, J = 2.2 Hz, 1H, CH2-C≡C-H); 
13
C NMR (68 MHz, CDCl3) d = 172.91 
(C=O), 171.81 (C=O), 77.86 (CH2-C≡CH), 73.42 (CH2-C≡CH), 52.82, 51.49, 49.27, 49.16, 
41.00, 36.97, 33.70, 32.60 (NMR spectra are shown in Appendix 9.5); HRMS (ESI) 
calculated for C29H49N5O10 ([M+H]
+
) 628.3558, found 628.3546. 
Dendron D2 Starting material: D1.5 (10.5 g, 16.7 mmol, 1 eq.); Reagents: 1,2-
ethylendiamine (111 g, 100 mL, 1.85 mol, 110 eq.) in 20 mL methanol; Yield: 12.1 g 
(16.4 mmol, 98 %); IR (film): 3280, 2930, 2819, 1637, 1545, 1362, 1249, 1126, 933 cm
-1
; 
1
H NMR (400 MHz, CDCl3) d = 7.90 (s, 2H, NHCO), 7.68 (s, 4H, NHCO), 3.38 (d, 
4
J = 
2.3 Hz, 2H, N-CH2, 3.25-3.15 (m, 12H), 2.78-2.73 (m, 12H), 2.67 (t, J = 6.0 Hz, 8H), 2.46 (t, 
J = 5.8 Hz, 4H), 2.34-2.25 (m, 12H), 2.19 (t, J = 2.0 Hz, 1H, CH2-C≡C-H), 1.98 (br s, 8H, 
NH2); 
13
C NMR (68 MHz, CDCl3) d = 172.90 (C=O), 172.24 (C=O), 77.66 (CH2-C≡CH), 
73.66 (CH2-C≡CH), 52.71, 49.67, 49.17, 44.48, 41.93, 41.24, 37.65, 34.15, 33.63 (NMR 
spectra are shown in Appendix 9.5); HRMS (ESI) calculated for C33H65N13O6 ([M+H]
+
) 
740.5259, found 740.5249. 
Dendron D2.5 Starting material: D2 (6.7 g, 10.4 mmol, 1 eq.); Reagents: methyl acrylate 
(85.5 g, 90.0 mL, 0.99 mol, 96 eq.) in 30 mL methanol; Yield: 14.5 g (10.2 mmol, 98 %); IR 
(film): 3295, 2953, 2822, 1731, 1646, 1539, 1436, 1358, 1259, 1174, 844 cm
-1
; 
1
H NMR 
(270 MHz, CDCl3) d = 7.64 (s, 2H, NHCO), 7.01 (s, 4H, NHCO), 3.55 (s, 24H, OMe), 3.35 
(d, 
4
J = 2.0 Hz, 2H, N-CH2-C≡CH), 3.22-3.12 (m, 12H), 2.74-2.60 (m, 28H), 2.50-2.40 (m, 
12H), 2.36-2.20 (m, 28H), 2.12 (t, J = 2.0 Hz, 1H, CH2-C≡C-H); 
13
C NMR (68 MHz, CDCl3) 
d = 172.99 (C=O), 172.89 (C=O), 172.30 (C=O), 78.01 (CH2-C≡CH), 73.51 (CH2-C≡CH), 
52.90, 52.49, 51.59, 49.87, 49.71, 49.22, 40.96, 37.37, 37.14, 33.83, 32.57 (NMR spectra are 
shown in Appendix 9.5); HRMS (ESI) calculated for C65H113N13O22 ([M+H]
+
) 1428.8201, 
found 1428.8189. 
Dendron D3 Starting material: D2.5 (6.42 g, 4.50 mmol, 1 eq.); Reagents: 1,2-
ethylendiamine (122 g, 110 mL, 2.0 mol, 452 eq.) in 10 mL methanol; Yield: 6.5 g 
(3.91 mmol, 87 %); IR (film): 3271, 3074, 2933, 2863, 1636, 1540, 1436, 1359, 1197, 1127, 
935 cm
-1
; 
1
H NMR (270 MHz, CDCl3) d = 7.98 (s, 2H, NHCO), 7.77 (s, 4H, NHCO), 7.57 (s, 
8H, NHCO), 3.39 (d, 
4
J = 2.0 Hz, 2H, N-CH2-C≡CH), 3.29-3.11 (m, 32H), 2.79-2.72 (m, 
24H), 2.70-2.64 (m, 12H), 2.63-2.56 (m, 12H), 2.51-2.42 (m, 8H), 2.38-2.21 (m, 24H), 2.12 
(t, J = 2.0 Hz, 1H, CH2-C≡C-H), 1.65 (br s, 16H, NH2); 
13
C NMR (68 MHz, CDCl3) d = 
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173.37 (C=O), 173.15 (C=O), 172.82 (C=O), 77.43 (CH2-C≡CH), 72.69 (CH2-C≡CH), 53.05, 
52.66, 52.17, 50.75, 50.25, 46.46, 45.01, 42.49, 42.32, 41.66, 37.86, 34.51, 34.13 (NMR 
spectra are shown in Appendix 9.5); HRMS (ESI) calculated for C73H145N29O14 ([M+H]
+
) 
1653.1604, found 1653.1595. 
Synthesis of PAMAM Silanes. Huisgen azide-alkyne 1,3-dipolar cycloaddition with amino-
terminated propargyl-PAMAM dendrons and AzTMS was performed based on a similar 
reaction of AzTMS with an alkyne compound reported by Lim et al..
[46]
 
General procedure. The amino-terminated propargyl-PAMAM dendron D1, D2, or D3 (1 eq.) 
was dissolved in a suspension of molecular sieves (3 Å) in anhydrous methanol (15 mL) and 
DIPEA (2 eq.). The resulting suspension was degassed afterwards. Under an atmosphere of 
nitrogen, copper(I) iodide (10 mol%), as catalyst, and AzTMS (0.25 eq.) were added. The 
reaction was stirred for 24 h at room temperature and subsequently filtered using a syringe 
filter. After exposure to air the solution turned purple-blue very quickly. The solvent was 
removed in vacuo; drying of the crude product at high vacuum yielded a blue gum which was 
used without further purification. 
S1 Starting material: D1 (134 mg, 0.471 mmol); Reagents: AzTMS (24.2 mg, 24.2 mL, 
0.118 mmol), DIPEA (122 mg, 164 mL, 0.942 mmol), CuI (9.50 mg, 0.050 mmol); Crude 
product: 204 mg containing 47.6 mg (0.106 mmol) of S1. 
S2 Starting material: D2 (1.48 g, 2.00 mmol); Reagents: AzTMS (103 mg, 103 mL, 
0.500 mmol), DIPEA (517 mg, 697 mL, 4.00 mmol), CuI (38.1 mg, 200 mmol); Crude 
product: 1.38 g containing 425 mg (0.45 mmol) of S2. 
S3 Starting material: D3 (3.31 g, 2.00 mmol); Reagents: AzTMS (103 mg, 103 mL, 
0.500 mmol), DIPEA (517 mg, 697 mL, 4.00 mmol), CuI (38.1 mg, 0.200 mmol); Crude 
product: 3.5 g containing 836 mg (0.45 mmol) of S3. 
Synthesis of dendron-functionalized MSNs (MSN-SHIN-Dn OUT, n = 1-3). Colloidal 
mesoporous silica nanoparticles (MSN-SHIN-Dn OUT, n = 1-3) were prepared according to a 
synthesis procedure published by Cauda et al..
[23]
 The amount of functionalized silane was 
calculated to be 1% of total silica. A mixture of TEA (14.3 g, 95.6 mmol), TEOS (1.56 g, 
7.48 mmol) and MPTMS (92.3 mg, 87.3 mL, 0.47 mmol) was heated for 20 min at 90 °C 
without stirring in a polypropylene reactor. Afterwards, a preheated (to 60 °C) mixture of 
CTAC (2.41 mL, 7.29 mmol) and H2O (21.7 g, 1.21 mol) was added to the first solution and 
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stirred for 20 min at room temperature. Then, every 3 min 37.2 µL TEOS (34.6 mg) was 
added to the stirring suspension, four times in total. The reaction was stirred for further 
30 min. After this time, a mixture of TEOS (19.2 mg, 92.2 µmol) and functionalized 
trialkoxysilane (RTMS: AzTMS, S1, S2, or S3) (92.2 µmol) was added. In the case of the 
PAMAM silanes S1-3, the amount of crude product to be used for particle functionalization 
was calculated from the mass fraction of the silane in the crude product (the yield of S1, S2 
and S3 was estimated at 90 %; 0.106 mmol for S1; 0.45 mmol for S2 and S3). Furthermore, 
the mixture of TEOS and PAMAM silane was dissolved in a solution of 2 mL methanol and 
1 mL water briefly before the addition to the reaction mixture. The reaction was stirred at 
room temperature over night. The suspension was diluted 1:1 with absolute ethanol, the 
colloidal MSNs were separated by centrifugation (19,000 rpm, 43,146 rcf, 20 min) and 
redispersed in absolute ethanol. The subsequent template extraction was performed by heating 
the samples under reflux at 90 °C (oil bath) for 45 min in a solution of ammonium nitrate 
(2 wt% in ethanol) followed by 45 min under reflux at 90 °C in a solution of 10 mL conc. HCl 
(37 %) in 90 mL ethanol. The extracted MSNs were collected by centrifugation after each 
extraction step and finally washed with 100 mL absolute ethanol. The resulting MSNs were 
stored in an ethanol/water solution (2:1). 
Cargo loading. MSN-D3 (1 mg) was incubated for 2 h at room temperature in the dark with 
MTS-ROX (5 µL, 5 mg/mL in DMF), MTS-Col (50 µL, 5 mg/mL in DMF), or MTS-DAPI 
for a one-step covalent attachment of the cargo molecules to the internal surface of the 
mesopores via disulfide bridges. MTS-DAPI was prepared in-situ by mixing DAPI (10 µL, 
5 mg/mL in DMF) and NHS-3-MTS (100 µg) in an aqueous solution for 1 h at room 
temperature in the dark. This reaction mixture was subsequently added to MSN-D3. The 
particles were washed five times (centrifugation, 4 min, 14,000 rpm, 16,837 rcf) with water 
and were finally redispersed in 1 mL H2O. 
MSN labeling. MSN-D3 (0.5 mg) were mixed with Atto 633 maleimide (1 µL, 2 mg/mL in 
DMF). After 2 h of stirring at room temperature in the dark the labeled particles were washed 
three times with water by subsequent centrifugation (4 min, 14,000 rpm, 16,837 rcf) and 
redispersed in H2O. 
Attachment of the targeting ligand folate. Oxalic acid, EDC, and sulfoNHS (each 5 mg) 
were successively added to an aqueous dispersion of MSN-D3 (0.5 mg) and the resulting 
reaction mixture was stirred at room temperature in the dark for another 2 h. Subsequently, 
the particles were washed three times (centrifugation, 4 min, 14,000 rpm, 16,837 rcf) and 
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redispersed in 300 µL H2O. The PEG linker was attached via EDC amidation. EDC, 
sulfoNHS and PEG2000-bisNH2 (each 5 mg) were consecutively added to the particle 
dispersion and stirred for another 2 h at room temperature in the dark. The particles were 
washed three times by centrifugation (4 min, 14.000 rpm) and redispersed in 100 µL water. 
Then 400 µL of a folate stock solution (0.75 µM in H2O), EDC (5 mg), and sulfoNHS (5 mg) 
were added. The reaction mixture was stirred over night at room temperature in the dark. 
After washing the particle three times with water (centrifugation, 4 min, 14,000 rpm, 
16,837 rcf) the MSN-D3-FA sample was finally redispersed in 1 mL H2O. 
Characterization. NMR spectra were recorded on a Jeol Eclipse 270 (
1
H: 270 MHz,
13
C: 
67.9 MHz), a Jeol Eclipse 400 (
1
H: 400 MHz,
13
C: 101 MHz) NMR or a Jeol 500 Eclipse 
spectrometer (
1
H: 500.16 MHz,
13
C: 125.77 MHz). 
13
C solid-state NMR measurements were 
performed on a Bruker DSX Avance500 FT spectrometer in a 4 mm ZrO2 rotor (100 mg 
sample) at a frequency of 10 kHz (
13
C{
1
H} cross polarization, pulse sequence program 
CPRAMP). IR spectra were recorded on a Bruker Equinox 55. The dried powder of the silica 
nanoparticles (1.5 mg) was mixed with KBr (200 mg) to produce pressed, transparent pellets 
to be measured in absorbance mode. For background measurements a neat KBr pellet 
(200 mg) was used. IR spectra of the organic compounds were recorded in the attenuated total 
reflectance (ATR) mode on the same device or on a Perkin-Elmer FT-IR Spektrum BXII 
spectrometer with Schmith Dura SampIIR II ATR-Unit. Mass spectra were measured on a 
Thermo Finnigan LTQ FT with IonMax (ion source with ESI head). Elementary analysis was 
performed on a Vario EL or Vario micro cube CHN analyzer detecting carbon, nitrogen, 
hydrogen and sulfur. The dried powder of the silica nanoparticles was pyrolized at 1150 °C in 
an oxygen-enriched He-atmosphere. The resulting gases were detected by thermal 
conductivity measurements. Acid-base titrations were performed on a Metrohm 905 Titrando 
potentiometric titrator combined with the software tiamo. The titration method met the 
following parameters: monotonic equivalence point titration (MET); stirring speed 5; 
measurement value drift 20.0 mV/min; min. delay 0 s; max. delay 300 s; volume increment 
0.025 mL; dosing speed maximal; stop value pH 10.2. The samples were prepared as follows: 
A volume containing 13.7 mg particles from the suspensions was added to 30.0 mL H2O. The 
starting pH was set to 3.000 using HCl (0.1 M) and NaOH (0.01 M) from the dosing unit. The 
samples were titrated against NaOH (0.01 M). TGA measurements of the bulk extracted 
samples (about 10 mg of dried powder) were performed on a Netzsch STA 440 Jupiter 
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thermobalance (heating rate of 10 K/min in a stream of synthetic air of about 25 mL/min). 
XRD patterns were collected at small angles on a Bruker D8 Discover with Ni-filtered Cu-Kα 
radiation and a position sensitive detector (Vantec) and in the range of 10 – 45 ° on a Stoe 
Stadi P powder diffractometer equipped with an image plate detector system, in transmission 
geometry, with Cu-Kα radiation. Nitrogen sorption measurements were performed on a 
Quantachrome Instruments NOVA 4000e at -196 °C. Sample out-gassing was performed at 
120 °C for 12 h at a pressure of 10 mTorr. Pore size and pore volume were calculated using a 
NLDFT equilibrium model of N2 on silica, based on the desorption branch of the isotherm. 
The BET model was used in the range of 0.05 – 0.20 p/p0 to estimate the specific surface area. 
DLS and zeta potential measurements were performed on a Malvern Zetasizer-Nano 
instrument equipped with a 4 mW He-Ne laser (633 nm) and avalanche photodiode detector. 
DLS measurements were directly recorded on aqueous colloidal suspension at a constant 
concentration for all sample solutions of 1 mg/mL. For determination of the zeta potential 
profiles, one to three drops of the ethanolic particle suspension (ca. 3 wt%) was mixed with 
1 mL of commercial Hydrion Buffer solution of the appropriate pH prior to measurement. 
H ckel’s approximation was used for interpretation. For TEM (using a Titan 80–300 kV 
microscope operating at 300 kV), samples were prepared by dispersing MSNs (1 mg) in 4 mL 
absolute ethanol, by means of an ultrasonic bath, and drying a drop of the resulting diluted 
suspension on a carbon-coated copper grid. 
Cell culture. KB cells were grown in folic acid deficient Roswell Park Memorial Institute 
1640 medium (RPMI 1640, Invitrogen) supplemented with 10 % fetal bovine serum (FBS) at 
37 °C in a 5 % CO2 humidified atmosphere. The cells were seeded on ibidiTreat µ-Slide 
(IBIDI). HeLa cells were grown in  ulbecco’s modified Eagle’s medium ( MEM):F12 (1:1) 
(Invitrogen) with Glutamax I medium supplemented with 10 % FBS at 37 °C in a 5 % CO2 
humidified atmosphere. The cells were seeded on collagen A-coated LabTek chambered 
cover glass (Nunc). For live cell imaging the cells were seeded 24 or 48 h before measuring, 
at a cell density of 2x10
4
 or 1x10
4
 cells/cm
2
. 
In vitro cargo release. Cells were incubated 5 – 48 h prior to the measurements at 37 °C 
under a 5% CO2 humidified atmosphere. Shortly before imaging, the medium was replaced by 
CO2-independent medium (Invitrogen). During the measurements all cells were kept on a 
heated microscope stage at 37 °C. The subsequent imaging was performed as described in the 
Spinning disk confocal microscopy section. 
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Nuclei staining kinetics with DAPI. HeLa cells were measured 5, 11, 24, 33, 49, and 61 h 
after incubation with the samples MSN-D3-MTS-DAPI, MSN-NH2-MTS-DAPI and the 
supernatant of MSN-D3-MTS-DAPI (after particle separation). Each time point was measured 
with an independently incubated set of cells. In order to evaluate the fluorescence of the 
nucleoli, the z-stack position was set exclusively in the region of the nuclei. The integrated 
intensity of a distinct region of interest (ROI) around the nuclei was determined (44 – 104 
nuclei for each data point) and divided by the area of the ROI. Thus, the average integrated 
density per nuclei area (± standard deviation, represented by error bars) could be plotted 
dependent on incubation time. The relatively large error bars are assumed to result from a 
different particle uptake behavior for each cell. The number of particles internalized by the 
cells was not taken into account. 
Cell targeting. To evaluate the functionality of the folic acid ligand, KB cells were incubated 
with nanoparticles for 5 h at 37 °C under a 5 % CO2 humidified atmosphere. The cell 
membrane was stained shortly before the measurement by adding 4 µL of 1 mg/mL wheat 
germ agglutinin Alexa Fluor 488 conjugate (WGA488, Invitrogen) to 400 µL of cell medium. 
After 1 min, the cell medium was removed, the cells were washed twice with cell medium, 
and imaged immediately. In control experiments, the FA receptors on the KB surface were 
blocked by pre-incubation of the cells with 3 mM folic acid (Sigma) for 2 h at 37 °C under a 
5% CO2 humidified atmosphere, before particles were added. 
Spinning disc confocal microscopy. Confocal microscopy for live-cell imaging was 
performed on a setup based on the Zeiss Cell Observer SD utilizing a Yokogawa spinning 
disk unit CSU-X1. The system was equipped either with a 1.40 NA 100x or a 1.40 NA 63x 
Plan apochromat oil immersion objective from Zeiss. For all experiments the exposure time 
was 0.1 s and z-stacks were recorded. WGA488 was imaged with approximately 0.14 W/mm
2
 
and GFP with 6.6 W/mm
2
 of 488 nm excitation light. Atto 633 was excited with 11 mW/mm
2
 
of 639 nm and DAPI with 0.16 W/mm
2
 of 405 nm excitation light. In the excitation path a 
quad-edge dichroic beamsplitter (FF410/504/582/669-Di01-25x36, Semrock) was used. For 
two color detection of WGA488, GFP, or DAPI and Atto 633, a dichroic mirror (560 nm, 
Semrock) and band-pass filters 525/50 and 690/60 (both Semrock) were used in the detection 
path. Separate images for each fluorescence channel were acquired using two separate 
electron multiplier charge coupled device (EMCCD) cameras (PhotometricsEvolve
TM
). 
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9.5 Appendix 
 
Figure 9.11: 
1
H and 
13
C NMR spectrum of propargyl-dendron D0.5. 
9.5. Appendix  
 
216 
 
 
Figure 9.12: 
1
H and 
13
C NMR spectrum of propargyl-dendron D1. 
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Figure 9.13: 
1
H and 
13
C NMR spectrum of propargyl-dendron D1.5. 
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Figure 9.14: 
1
H and 
13
C NMR spectrum of propargyl-dendron D2. 
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Figure 9.15: 
1
H and 
13
C NMR spectrum of propargyl-dendron D2.5. 
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Figure 9.16: 
1
H and 
13
C NMR spectrum of propargyl-dendron D3. 
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Figure 9.17: IR spectroscopy data of a) AzTMS, b) dendron-silane S1, c) dendron-silane S2, and d) 
dendron-silane S3. 
 
Figure 9.18: IR spectroscopy data of functionalized MSNs. 
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Figure 9.19: Fluorescence microscopy of KB cells with GFP tagged tubulins (green). a/c) The cells were 
incubated with MSN-D3 loaded with immobilized colchicine (MTS-Col) in the mesopores and labelled 
with Atto 633 (red) after 22 h incubation on the cells. b/d) Cells were incubated with sample supernatant 
(after particle separation by centrifugation) for 22 h. c/d) Zoom in on representative microtubule 
structures. A destruction of the tubulin network was only observed for particle-incubated cells. The scale 
bars represent 10 µm. 
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Figure 9.20: Fluorescence microscopy of HeLa cells incubated with MSN-D3-MTS-DAPI (a, b, c), MSN-
NH2-MTS-DAPI (d, e, f), and the supernatant of MSN-D3-MTS-DAPI (g, h, i). The nanoparticles were 
loaded with covalently attached DAPI (MTS-DAPI, blue) and labeled with Atto 633 (red). The cells were 
incubated with the samples for 5 h (a, d, g), 24 h (b, e, h) and 61 h (c, f, i). The nuclei are indicated with 
dashed circles. A time-dependent nuclei staining can be observed for MSN-D3-MTS-DAPI, suggesting 
triggered release of the cargo molecules from the nanocarriers after endosomal escape via the proton 
sponge effect and access to the cytosol. For MSN-NH2-MTS-DAPI and the supernatant incubation almost 
no nucleic staining can be detected, which implies that no DAPI has been released from the particles or 
has been present in the solution, respectively. The scale bars represent 10 µm. 
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10 Conclusions and Outlook 
The focus of the present work was the synthesis and characterization of tailor-made 
multifunctional mesoporous silica nanoparticles (MSNs) for advanced drug delivery 
applications. The customized, stimuli-responsive nanovehicles developed in this work meet 
various prerequisites for controlled cargo delivery regarding targeted cancer diagnosis and 
therapy. 
In a first project (Chapter 3), the effects of high-boiling organic solvents such as TOPO, TOA 
and squalene on colloidal MSNs have been studied. A liquid-phase “calcination” of MSNs at 
elevated temperatures (275 and 400 °C) led to a higher degree of silica condensation and 
simultaneously to template extraction. The retention of the colloidal nature of the 
nanoparticles and the prevention of non-reversible aggregation during the calcination process 
are important advantageous of this newly developed method. It is anticipated that a higher 
degree of condensation and the resulting stability provide improved characteristics for 
biomedical applications such as stable drug delivery vehicles. 
In Chapter 4, the integration of a superparamagnetic core to the silica host material offers the 
possibility of specific targeted delivery to cancer tissue by applying an external magnetic 
field. We created a new synthesis strategy to obtain multifunctional nanocomposites with a 
magnetic core and different functional mesoporous silica shells. An inner pore 
functionalization provides control over attachment, diffusion and release of cargo molecules 
such as chemotherapeutics. Integrated functional groups at the external particle surface enable 
the attachment of labels, protecting layers, and targeting ligands. Multifunctional magnetic 
MSNs provide a promising platform for spatially-controlled drug delivery and may improve 
in vivo investigations of biodistribution and accumulation via magnetic resonance imaging 
(MRI). Future experiments will have to demonstrate a magnetically driven targeted drug 
delivery in organisms. 
Biocompatibility and hemocompatibility are important requirements for blood-stream 
injectable drug nanocarriers. The covalent attachment of heparin on the external surface of 
MSNs showed efficient anticoagulant properties for such multifunctional nanocarriers in 
blood-clotting tests (Chapter 5). The covalently bound heparin still showed significant activity 
serving as a cofactor for the anticoagulant serine protease inhibitor antithrombin. These 
results imply a long-term stability of heparin-functionalized MSNs injected into the blood 
10. Conclusions and Outlook  
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stream. Furthermore, in the future these novel nanomaterials could be used as anticoagulant 
coatings for stents with integrated drug release options. 
A stimuli-responsive controlled cargo release can be achieved by judicious modification of 
the nanocarriers with bulky gatekeepers. In Chapter 6, an enzyme-responsive cargo release 
mechanism by linkage of avidin via short peptide sequences is described. These peptide 
linkers are selectively cleaved by the enzyme MMP-9 that is known to be overexpressed in 
cancer tissue. To the best of our knowledge we report for the first time on avidin-coated 
MSNs showing specific in vitro release of the anticancer drug cisplatin to lung cancer cells. 
Additionally, a combination treatment with cisplatin and the proteasome inhibitor bortezomib 
led to an improved performance of the MSNs for cancer treatment. Thus, the effective dose of 
the chemotherapeutic agent could be reduced, which can lead to a further reduction of side-
effects. Future work will address in vivo biodistribution studies in lung tissue and in vivo 
therapeutic studies in mouse models, intended to prove the applicability of our system in 
organisms. 
In a different project (Chapter 7), a novel pH-responsive capping system based on 
sulfonamide-linked carbonic anhydrase (CA) enzyme has been successfully developed. CA 
enzymes act here as bulky gatekeepers and have been found to efficiently block the 
mesoporous system of silica nanoparticles, thus preventing premature cargo release. A time-
dependent release of the model drug DAPI was observed in in vitro studies on HeLa cancer 
cells with fluorescent live-cell imaging. These results can be attributed to the acidification of 
the endosomal compartment, initiating the pH-responsive release. Future experiments will 
allow the introduction of functional groups with bio-orthogonal reactivity by a precise genetic 
modification of the enzymes. Thus, the multifunctional MSNs may enable the attachment of 
targeting ligands for specific receptor-mediated cellular uptake and targeted drug delivery to 
cancer cells. 
In this thesis, two different strategies for a successful endosomal escape of mesoporous silica 
nanocarriers have been developed. In Chapter 8, a photoinduced rupture of the endosomal 
membrane was achieved with immobilized photosensitizers. We describe the development of 
multifunctional drug delivery vehicles based on mesoporous silica nanoparticles equipped 
with a red-light sensitive photosensitizer, encapsulated by a supported lipid bilayer (SLB), 
and functionalized with different targeting ligands. We anticipate that these multifunctional 
drug delivery vehicles are a promising platform to achieve spatially and temporally controlled 
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drug release. Future work aims at the employment of near-infrared or two-photon excitation 
schemes for light-activated cargo release, which would be favorable for the enhancement of 
tissue penetration in in vivo applications.  
In another project (Chapter 9), PAMAM dendron-coated MSNs that exhibit high buffering 
capacity were successfully synthesized. We were able to demonstrate endosomal escape from 
these nanocarriers via the proton sponge effect and controlled release of immobilized cargo 
molecules (the anticancer drug colchicine and the fluorescent dye DAPI), which had been 
covalently attached to the porous system via disulfide bridges. Additionally, a specific cell 
uptake was achieved by modification with targeting ligands. This newly designed 
multifunctional nanocarrier system based on PAMAM dendron-coated MSNs provides 
autonomous cargo delivery into cancer cells since it responds to internal cellular triggers, 
namely changes in pH and in redox-potential, respectively. 
In summary, specially designed mesoporous silica nanoparticles with release-on-demand 
properties offer promising prospects as precisely controllable and efficient drug delivery 
vehicles. Our MSNs combine advantageous properties of different materials in one 
multifunctional device for theranostic treatment and bioimaging in biomedical applications 
such as cancer therapy. It is hoped that precise dosing of chemotherapeutics at the desired 
locations in cancer tissue could be achieved with the family of mesoporous carrier systems, 
thus significantly reducing side effects. In the present work, general drug delivery platforms 
based on multifunctional MSNs have been established, which will be investigated as 
promising candidates in future in vivo applications. 
Multifunctional MSNs are not only bearers of drugs but maybe also bearers of hope. 
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